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Abstract
In 2019, the EPMA celebrated its 10th anniversary at the 5th World Congress in Pilsen, Czech Republic. The history of the
International Professional Network dedicated to Predictive, Preventive and Personalised Medicine (PPPM / 3PM) is rich in
achievements. Facing the coronavirus COVID-19 pandemic it is getting evident globally that the predictive approach, targeted
prevention and personalisation of medical services is the optimal paradigm in healthcare demonstrating the high potential to save
lives and to benefit the society as a whole. The EPMA World Congress Supplement 2020 highlights advances in 3P medicine.
Introduction
European Association for Predictive, Preventive and Personalised
Medicine has been created in 2009. In 2011 the historical 1st
EPMAWorld Congress took place in Bonn, Germany.
In 2019, the EPMA celebrated its 10th anniversary at the 5th
World Congress in Pilsen, Czech Republic. The decade-old
professional history of the EPMA is rich in achievements.
Herewith we briefly highlight some of them.
Geographic distribution of the 3PM-relevant expertise under
the EPMA-umbrella started with approximately 20 countries in
2009; currently, the EPMA is represented in 54 countries
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worldwide who actively promote 3PM concepts in bio/medical
sciences and practical medicine strongly benefiting patients and
healthcare systems.
The first issue of the EPMA Journal, Springer Nature, was
released in March 2010. In 2018, the journal received its first
IF 3.9; in 2020, it reached 4.901. Nowadays the EPMA J. is a
highly recognised international forum for 3P medicine oper-
ating in a hybrid subscription/open access modus. Scopus
CiteScore 2019 of the EPMA J. is 7.7, https://www.scopus.
com/sourceid/19700201201?origin=sourceInfo&zone=
refpointrank#tabs=1, thereby Scopus ranks the EPMA J.
amongst the top 3% in the category “Health Policy”, due to
highly requested and well-cited strategic papers created by
multi-professional groups of EPMA experts such as
– General report & recommendations in predictive, pre-
ventive and personalised medicine 2012: white paper of
the European association for predictive, preventive and
personalised medicine. https://doi.org/10.1186/1878-
5085-3-14.
– Medicine in the early twenty-first century: paradigm and
anticipation – EPMA position paper 2016. https://doi.
org/10.1186/s13167-016-0072-4.
SCImago top-ranks the EPMA J. in all three categories,
namely “Health policy”, “Medical Biochemistry” and “Drug
discovery”:
ht tps: / /www.scimagojr .com/journalsearch.php?q=
19700201201&tip=sid
In 2018, Springer Nature awarded the below-mentioned arti-
cle the status of an “article with a potential to change the
wor l d” i n t he ca t ego ry “Med ic ine and Pub l i c
Health”, https://www.springernature.com/gp/researchers/
campaigns/change-the-world/medicine-public-health
– Pregnancy Associated Breast Cancer: The Risky Status
Quo and New Concepts of Predictive Medicine. EPMA J.
2018, https://doi.org/10.1007/s13167-018-0129-7.
“Advances in Predictive, Preventive and Personalised
Medicine” is a very successful EPMA/Springer Nature book
series which educates both professionals and the general pop-
ulation in 3P medicine. Since 2012, 12 book volumes have
been released dedicated to a whole spectrum of PPPM related
aspects such as digital health, information technology frame-
work, application of artificial intelligence in healthcare, drug
delivery systems, liquid biopsy and multi-level diagnostics,
amongst others.
“Horizon 2020” is the main European Scientific Programme
which EPMA experts have contributed to with 3PM-related
protocols as well as with the top-expertise provided by
Representatives and Members of the association involved in
the evaluation panels.
EPMA AWARD for EXCELLENCE in BIOMEDICAL
SCIENCES was created in 2017, and the 1st EPMA award
was given to Prof. Dr. Josef Flammer, University of Basel, for
phenotyping of the “Flammer Syndrome”, which the EPMA
international jury panel valued as being of great clinical utility.
“Young professionals in PPPM” Award was created by
the EPMA in 2015. At the international workshops
linked to the biannual EPMA World Congresses, the
presentations made by young professionals get evalu-
ated by an international jury panel. The best presen-
tations and smart 3PM concepts receive awards that
effectively promote the careers of young professionals
in innovative bio/medical fields.
EPMA World Congress 2019 in Pilsen, Czech Republic
attracted 3PM experts from 35 countries. The congress was
dedicated to innovation in a broad spectrum of bio/medical
fields with a specific focus on the concepts of predictive di-
agnostics, targeted prevention and personalisation of medi-
cal services in “Cancer” , “Metabolic Disorders” ,
“Cardiovascular Disease”, “Neurological, Neurodegenerative
and Neuropsychiatric Disorders”, “Inflammatory Disorders”,
“Dentistry”, “Biobanking and Screening Programmes”,
“Multi-omics” , “Microbiome, Immune-, Pre- and
Probiotics”, and “Innovative Technologies”, among others.
Further, there were several new topics presented at the con-
gress: among others these were “Implementation of 3PM
Concepts in Plastic Surgery”, “Application of Artificial
Intelligence in Medicine – 3PM strategies” and “Medical
Use of Cannabis”. The latter topic was discussed in the EU
Parliament in 2019, and the EPMA position has been eluci-




Oral and poster presentations provided valuable infor-
mation regarding pilot projects towards personalised
healthcare (e.g. awarded by ICPerMed), individualised
patient profiles, multi-level biomarker panels, patient
stratification, creation and application of innovative IT-
tools, ethical issues, doctor-patient collaboration, optimal
structure and organisation of the modern hospital
ambitioned to practically implement the paradigm
change from reactive to predictive, preventive and
personalised medicine.
World First 3P Medical Unit
In March 2020, the historically first worldwide unit
dedicated to Predictive, Preventive and Personalised
(3P) Medicine led by Secretary-General of the EPMA,
Prof. Dr. Olga Golubnitschaja, was created in Germany
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3PM vision and strategies
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Introduction
Many people do not realize they already have adopted wear-
able devices for medical monitoring—smartwatches. Typical
stories of smartwatches providing life-saving diagnostic infor-
mation include the following: (1) A smartwatch alarming all
night regarding abnormal heartrate alerted the wearer to seek
medical attention for what proved to be atrial fibrillation [1];
(2) A hiker—lost as nightfall approached—stumbled and fell
on difficult terrain. Unbeknownst to the hiker, the fall trig-
gered his smartwatch to automatically call the emergency
phone number (911 in the USA), thereby avoiding what could
have been a tragic outcome. Smartphones, with accelerometer
and GPS capabilities, have apps for people with epilepsy who
may require emergency medical assistance [2].
Medical monitoring has not always been so painless, persis-
tent, and unobtrusive. Atrial fibrillation required attaching
electrodes to the skin with a conductive gel, in turn connected
to a device—possibly portable, but certainly obtrusive.
Monitoring of blood glucose by diabetic patients required re-
peated finger-sticks—painful, intermittent, and obtrusive.
Phases of Biofluid Monitoring
Diagnostic techniques for biofluids, e.g., blood, urine, saliva,
and cerebrospinal fluid (CSF), have evolved over the past
several decades (Fig. 1) [3]. The first phase—extending
from the twentieth century to the present—entails
obtaining a sample from the patient (an invasive procedure
for blood and CSF) and sending it to a laboratory for analysis.
Results are not available for hours to days for samples obtain-
ed from outpatients, and minutes to hours for inpatients.
The second phase began about two decades ago with point-of-
care (POC) monitoring, where the laboratory comes to the
patient (i.e., to the recently obtained sample) rather than
transporting the sample to the laboratory.
The third phase, more recently available, consists of wearable
devices. This is the epitome of POCmonitoring since the patient
and the device are inseparable. Smartwatches can do this for
pulse and blood pressure, patches applied to the skin for contin-
uous blood glucose monitoring. The patches, e.g., for glucose
monitoring, typically monitor the analyte concentration in inter-
stitial fluid (ISF), which closely parallels blood glucose [3–7].
The line between the third and fourth phases—wearable and
implantable devices—is blurred. Part of this is due to expan-
sion of the fluids monitoring from blood (or ISF) to sweat,
saliva, and tears.Mostwould call amouthguard tomonitor saliva
a wearable device—but what about a “smart” contact lens to
monitor tears? Truly implantable devices (e.g., inserted subcuta-
neously by aminor surgical procedure) canmonitor analytes such
as glucose for months (potentially longer) rather than the days to
a week or so of most patches [8].
Power to the Patient—Digitizing Biofluid Monitoring
During the sample-to-lab and POC phases, urine was the ideal
biofluid—non-invasively obtained and relatively easily
transported. Blood required an invasive procedure, a needlestick.
Sweat and tears were not easily obtained in a manner guarantee-
ing uniformity, and saliva could vary greatly depending on time
of sampling (e.g., after a drink or a meal).
Wearable devices have transformed those problems into one
consisting of a tissue-device interface (TDI) challenge.
Fig. 1 The four technological waves of biochemical monitoring. (reference [3],
with permission)
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Continuous biofluid monitoring is a reality: sampling urine,
blood, or other biofluids continuously was not practical pre-
viously outside a hospital setting (with an indwelling catheter
for urine or blood or even CSF). A second problem in phases
one and two was obtaining continuous diagnostic information
from the biofluid.
The smartphone and smartwatches plus machine learning and
artificial intelligence (AI) have allowed not only continuous
biofluid monitoring but also continuous, real-time interpreta-
tion of that monitoring information in a precise and personal-
ized manner—“digital biomarkers” [9]. This can answer the
question:
“What does this biofluid monitoring value mean for this par-
ticular patient at this precise moment?”
Once answered, that information can guide real-time, precise,
personalized treatment, e.g., continuous feedback-guided (or
closed-loop) insulin release in diabetes. The patient, if desired,
can have control over when the biofluid monitoring informa-
tion is gathered or processed or transmitted, e.g., to a
databank. The patient can remove the patch or the smartwatch,
or turn off the smartphone containing the app transferring the
data.
Blood, Sweat, Tears, and Saliva
Although the primary target has been a wearable monitor of
blood glucose for diabetic patients, other biological signals
that can be measured through the skin include chemicals (be-
yond glucose—potassium, chloride, lactate), electrical (elec-
trocardiogram (ECG), electroencephalogram (EEG), electro-
myogram (EMG)), and physical (temperature, pressure, light,
sound) [3–7]. Additionally, non- or minimally invasive mon-
itoring has included measures ranging from respiratory rate to
joint movement to gait [5, 9–11]. This review is primarily
limited to the TDI for biofluids.
Wearable skin patches depend on knowledge of the
structure of human skin [3, 6, 7]. “Smart” skin exhibits
many technological advances, as illustrated in Fig. 2
[7]. Skin patches usually monitor ISF concentrations of the
chemical of interest, relatively straightforward for ISF glucose
(as a surrogate for blood glucose). Sweat, however, poses a
different problem, since sweat is not continuously available
for monitoring. In the typical skin patch for sweat, the patch
incorporates an electrode to deliver a cholinergic agent such as
carbachol into the skin for st imulat ion of sweat
(iontophoresis) [3, 6].
Fig. 2 Recent research trends in smart skin from four viewpoints. First, the structures of smart skins are advancing from stretchable to
ultra-thin to breathable sensors, resulting in enhancement of biocompatibility and reduced burden of sensor attachment. Second, multi-
modality is expanding from electrical to physical to chemical sensors. Third, more advanced functions such as stimulation, drug delivery,
and displays are being incorporated, in addition to sensing functions. Fourth, novel materials such as self-healing conductors, intrinsically
stretchable semiconductors, and photoactive materials are being developed. (reference [7], with permission)
S4
EPMA Journal (2020) 11(Suppl 1):S1–S133
Monitoring tears is challenging: (1) the rate of tearing is not
uniform; (2) the device must be acceptable to the patient.
Tear-based biofluid sensors include smart contact lenses and
devices placed in the lower eyelid (Fig. 3A) [4, 6].
Saliva is readily available but suffers from analyte variability
(e.g., temperature and concentration) resulting from the pres-
ence of liquids of varying temperatures over time in the oral
cavity (hot vs cold drinks) [6]. Patient acceptance of a device
in the oral cavity—given that some saliva biofluid sensors are
mouthguards or otherwise bulky/obtrusive—is another issue
(Fig. 3B) [6].
 
Fig. 3A Tear-based biosensors. a Contact lens sensor previously under development by Google and Novartis to measure tear glucose concentration.
Prototype platform contained integrated electronics for sensor response processing and wireless transmission. b Multifunctional wearable
smart sensor system incorporated onto a contact lens for monitoring both glucose in tears and intraocular pressure using enzyme-
functionalized graphene-silver nanowire hybrid nanostructures. c A wireless glucose sensor incorporated into a contact lens platform
with wireless power transfer circuitry and display pixels for a fully integrated and transparent platform that does not hinder vision. d
Wearable contact lens tear glucose biosensor applied to an artificial eye, with schematic representation of smartphone-based quantifica-
tion of glucose levels through reflection of incident light by the photonic microstructure within the lens. The smart contact lens system
integrated with a glucose sensitive hydrogel monitors changing glucose concentrations in vitro without complicated fabrication procedures
and allows rapid response time for continuous measurements. e NovioSense electrochemical tear glucose sensor. A small spring-like
sensing device is designed to be placed within the conjunctival fornix for continuous access to tear glucose. (reference [6], with
permission)
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Sometimes It Takes Guts to Monitor
Confirmation of ingestion of prescribed medications, particu-
larly in unreliable patients (e.g., dementia), is another biosens-
ing challenge. One solution is the “smart pill”—a capsule
containing a microsensor that is swallowed, monitoring
whether the medication is present in the stomach [4]. The
“smart pill” communicates with a skin patch, which not only
documents that the pill was swallowed (and when) but also (if
desired) blood pressure, pH, and temperature.
For continuous monitoring, a sensor can be stationed in the
gut (most likely the stomach). Such monitoring could include
medication ingestion, pH, controlled drug delivery, and imag-
ing of the gut lining. An ingestible sensor that is self-
powered by stomach acid in contact with zinc and cop-
per electrodes on the sensor surface is being developed
[12]. Another ingestible capsule under development uses
a microneedle that inserts into the stomach wall to de-
liver a drug (e.g., insulin) [13].
 
Fig. 3B Saliva-based biosensors. a Mouthguard-based wearable salivary uric acid biosensing platform with integrated wireless electronics and
analysis of salivary uric acid concentrations. b Mouthguard-based sensor for glucose monitoring in saliva with on-body application
and analysis of increasing glucose concentrations. c On-body depiction and cross-sectional configuration of radio frequency trilayer
tooth-mounted sensor for wireless monitoring of food consumption. This dielectric sensor fabricated with biocompatible materials is
capable of being mounted onto tooth enamel to detect foods and fluids during ingestion when functionalized with analyte-sensitive
layers. Projected uses were for detection of sugars, alcohol, salinity, pH, and temperature. d Operational principles and electronics
configuration of a wireless, user-comfortable sensing platform for long-range oral monitoring of sodium intake during hypertension
management. (reference [6], with permission)
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Wear Your Heart on Your Sleeve; Wear Your Brain on
Your Hat
The topic of brain biomonitoring—from EEG to next-
generation brain-machine interfaces (BMIs)—is be-
yond the scope of this article but has been recently
reviewed [14]. An area of concern regarding brain
biomonitoring is direct-to-consumer (DTC) marketing
of devices that are of undocumented value or possible
risk [15–17]. Brain biomonitoring information obtain-
ed through DTC marketing raises questions of both
personal privacy and ultimate use of such data by
marketers. Increasing DTC availability of brain elec-
trical stimulation (e.g., via a skullcap), notably trans-
cranial direct current, alternating current, and random
noise stimulation techniques, raises questions of safe-
ty [15]. Ethical considerations regarding DTC brain
biomonitoring and biostimulating remain unresolved
[15–17].
Conclusions and Expert Recommendations
The field of wearable and implantable biosensors is evolving
so rapidly that no review truly reflects the “state-of-the-art.”
Advances in the TDI and AI promise that such devices will
not only enhance diagnostic capabilities but also provide a
wealth of information for improved treatments.
Specific recommendations:
1. Incorporating the latest technology into biosensors—from
nanotechniques to microfluidics—is essential. A
smartphone from ten years ago would be unacceptable
in the consumer marketplace; outdated diagnostic tech-
niques in medicine are similarly unwarranted.
2. Similarly, the latest AI is necessary to analyze the huge
amounts of data that wearable and implantable biosensors
provide.
3. The consumer/patient must be involved in device devel-
opment from the outset. What may appear wonderful in
the lab or the boardroom may prove a failure in the mar-
ketplace and social media. Consumer/patient acceptance
(CPA) is crucial for widespread adoption.
4. Flexibility is key. Some patients may prefer a patch for
continuous glucose monitoring, others a smart contact
lens, and others an implanted device (requiring a minor
procedure for implantation but not frequent replacement).
What works in a high-income country such as Belgium
may not work in a low-income country such as Burkina
Faso.
5. Legislation and safeguards regarding the huge amounts of
personal medical data generated by wearable and implant-
able biosensors is essential, since data collection and stor-
age systems can be hacked. This is especially crucial with
regard to biomodulating devices, e.g., cardiac pace-
makers, brain stimulation, and controlled drug delivery
systems.
6. Given the vulnerability to hacking, wearable and implant-
able biosensors require the same caution as other wide-
spread threats to population health, e.g., toxins (both liq-
uid and aerosol), biological warfare agents, and radiation.
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Background
In the past few years, extraordinary developments in the field
of next generation sequencing (NGS) technologies, such as
whole genome sequencing (WGS), have made it possible for
clinicians to have access to a huge amount of biological infor-
mation which could potentially explain complex genetic diag-
noses, genetic predisposition to severe diseases, reproductive
risks and inappropriate responses to certain medications.
These advances herald a new era of predictive preventive per-
sonalized medicine (PPPM), although incorporation into clin-
ical practice has proved to be challenging [1]. “NAGEN
1000” is a Spanish regional pilot study to implement recent
advances of cutting edge genomic research technology into
real clinical practice.
Goal, materials and methods
NAGEN 1000’s main goal is the implementation of the whole
genome sequencing (WGS) derived information as a clinical
tool for the development of PPPM in the Public Health Service.
A scientific implementation approach was used to identify and
categorize both the local barriers and facilitators to accelerate
the incorporat ion of translat ional genomics into
healthcare (see Fig. 1).
Fig. 1. Local barriers for genomic medicine implementation in Navarra (NAGEN 1000 project)
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Key Actions for this implementation:
1. Subjects: NAGEN1000 is recruiting 1000 patients, and their
relatives, affected with one condition from a list of nearly
200 rare diseases (RD). Albeit rare, joint RD’s prevalence is
high (2–7%), with a very high social impact, wide multidis-
ciplinary medical coverage, and a high rate of identifiable
genetic causes. These featuresmake it possible to involve the
medical community, raise population awareness and offer
good support to evidence-based medicine practice. The rate
of 1 genome per 500 inhabitants facilitates a wide participa-
tion from patients and health professionals.
2. Results and incidental findings: Pertinent findings
explaining the referral condition, secondary findings on
personal and reproductive risks of severe inherited dis-
eases, and pharmacogenomic variants determining drugs
dose and toxicity are reported, based on patient’s choice,
providing the necessary evidence of the effectiveness of
medical interventions based on genomic medicine. New
genetic counselling interventions, variant validation and
reporting pathways have been put in place for the best
provision of services.
3. Electronic health record (EHR) adaptation: The existing
EHR has been modified to host a newly designed recruit-
ment tool which enables and guides the identification and
immediate referral of patients from any point in the
Navarre health system network. An additional develop-
ment also makes it possible that clinically actionable ge-
nomic results are available for participants’ doctors with
all other clinical information across the system.
4. Clinical research: A number of new exciting genomic
results, potentially providing new insights into the genetic
basis of RDs, and additional information on population
genomics, are being produced by NAGEN 1000, offering
exceptional material to support new research. It is a main
goal of the Project to ensure an adequate data harmoniza-
tion, which enables data sharing for research under an
appropriate regulatory and legal framework.
5. Optimized use of pre-existing public infrastructures: In
order to overcome the lack of local facilities, NAGEN
1000 externalizes WGS sequencing services to CNAG-
CRG, the Spanish world leader public centre for genomic
analysis. Bioinformatic analysis also relies primarily on
CNAG-CRG through the RD-Connect Genome-
Phenome Analysis Platform which was deployed for the
project to store, analyse and interpret the genomic, data
making use of the phenotypes encoded with the Human
Phenotype Ontology (HPO), and the experts from the
Bioinformatics Platform of the Rare Diseases Spanish
network (CIBERer) through the Interactive Variant
Analysis (IVA) tool based on the genome browser
Genome Maps, but expertise in this field has gradually
been transferred to the newly created local Translational
Bioinformatics Unit during the course of the Project.
6. ICT: New ICT solutions have been adopted for NAGEN
1000 allowing the storage and high performance manag-
ing of massive genomic data, through an innovative part-
nership with NASERTIC, a local company providing data
analysis infrastructures such as the new IBM POWER 9
processor, which build on cross-disciplinary collaboration
in research and development with the local industry.
7. ELSI: While genetic data protection is widely regulated for
clinical and research purposes, within the NAGEN 1000
project, the local Health Research Authority has specifically
resolved that the massive genomic information resulting
from WGS will also be part of the patient’s medical record,
and it will accordingly be protected and stored. In order to
enable the use of genomic data for research, the constitution
of a “Genomic Library” has been proposed, which would
accept specific research enquiries on anonymized genomic
sequences upon pertinent EC approval. This scenario re-
quires a new regulatory legal framework, which has also
been explored through a specific partnership with Avantia
400+ from the Pyramide group, a local consulting company
with wide experience in data protection.
Results
Key results to date:
1. Clinical and pre-clinical results: Around 700 patients have to
date followed through the above-outlined pathway, and 33%
of the families have now found the long-awaited genetic
cause for their previously unexplained condition and now
have hope of an improvement of their clinical care based on
these findings. Remarkably, 10% of these diagnoses were
attributed to genes previously unknown to cause a human
disease, or causing different phenotypes than those previous-
ly described (Fig. 2). Additionally, 2% of participants carried
genetic predispositions to severe diseases, 4% had reproduc-
tive risks and 100% had pharmacogenomic actionable vari-
ants influencing prescription (Table 1). Further, candidate
genomic variants potentially explaining patients’ diseases
have been identified in an additional 24% of participating
families, which provides an extended base for new collabo-
rative research projects. Interestingly, about 20 different
medical specialities have referred patients to NAGEN
1000, indicating a desirable multidisciplinary involvement
in this implementation initiative.
2. Healthcare workforce education and public empower-
ment: Monographic NAGEN 1000 symposiums, hospital
briefings, clinical sessions and face to face meetings have
been organized, opening the participation to all medical
professionals in the region. Moreover, the 18 designated
specialities “physician champions”, especially commis-
sioned to facilitate recruitment, help with the clinical
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interpretation of genomic variants, and to spread the word,
received 50 category 1 and 2 CME credits from a NAGEN
1000 tailored genomics education programme. Public in-
volvement has also been possible through a press confer-
ence, which was widely covered by national general and
medical press and social media, open conferences at the
“Science Week” and “Rare Diseases Day”, a specific
website www.nagen1000navarra.es, and communications
to national and international congresses.
3. Sustainability: After deducting marginal costs due to the
Translational Bioinformatics Unit establishment and ICT
infrastructures, the cost-effectiveness analysis (CEA) rec-
ognized a full running costs of €12,776 per RD diagnosis
(prior to familial cascade genetic testing and including duo
and trio studies costs when necessary) compared with
€18,300 average cost per diagnosis estimated for the
standard of care pathway [2]. Considering that cost-
benefit analysis (CBA) outperforms CEA for RD,
we conducted a survey of all participants which
showed that more than 50% of them would be will-
ing to pay more than €10,000 for the genomic in-
formation they received after their participation in
NAGEN 1000, regardless of whether their diagnosis
was ultimately achieved or not.
Conclusions and expected impacts
Genomics has become a major contributor to multiomics and
PPPM related approaches in management of major and fatal pa-
thologies such as cancer, diabetes and stroke [3–5]. NAGEN
1000 illustrates how translational research and innovation in the
field of genomics and PPPM is already delivering real benefits to
patients, and it was awarded as the Best Practice in Personalised
Medicine by ICPerMed in 2018. Significantly, it resulted in set-
ting the new Genomic Medicine Unit of Navarrabiomed and its
NAGEN strategy, which has now raised €6 million for 3 R&D
projects on PM over the past 4 years. NAGEN is an exemplar
practice for the Spanish Senate Initiative for a National Strategy
on Genomics and PM (2018), and has given rise to the launch of
the Navarra Government Strategy on Personalised Medicine an-
nounced in November 2019.
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Motivation to create the specialised dental section focused
on 3P Medicine
Dental disorders can cause a great number of pathophysiological
conditions such as acute and chronic infections and inflammatory
processes, voice and digestive disorders, otorhinolaryngologic
pathologies and cancer. Therefore, risk assessment, early diag-
nosed suboptimal dental health followed by cost-effective
targeted prevention and personalisation of medical services as
the concept of predictive, preventive and personalised (3P) med-
icine is beneficial for the quality of life of the patient, healthcare
economy and society at large. Owing to the evident lack of 3PM
programmes in the current management of dentistry, the ambi-
tion of the EPMA is to promote cross-sectional research and
practical implementation in the area. The specialised EPMAden-
tal section was created in 2012 towards the initiative of the
Departments of Oral and Maxillofacial surgery and Hospital
Dentistry, Voronezh State Medical University named after
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N.N. Burdenko, Russia supported by the the Dental College of
Georgia at Augusta University, USA. Since then, more than 20
national centres and international groups have joined the dental
section of the EPMA.
Multi-professional topics of the section
The dental EPMA-section has created a number of cross-
sectional and multi-lateral projects dedicated to the below-
listed topics, among others
– Risk assessment, predictive strategies and personalised
prevention [1]
– Stem cells and tooth regeneration [2]
– Psychologic aspects in dental practice [3,4]
– “Dry mouth” syndrome and related pathologies [5]
– Pathology-specific body fluid patterns and multi-level di-
agnostics [6]
– Innovative materials, technologies and approaches in
dental practice [7,8]
– Education [4,9,10]
The dental section under the EPMA leadership follows the
innovative concepts of 3P Medicine [11]. Regular updates of
scientific projects and practical implementation is performed
utilising the platform of biannual EPMA World Congresses
(Fig. 1) [12–14].
Outlook
Future projects promoted by the specialised section con-
sider several promising topics such as mild inflamma-
tion as the trigger of a cascade of pathologies,
microbiome research, application of nanoceria, valida-
tion of pathology specific biomarker patterns in body
fluids, amongst others.
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Background
The diabetes mellitus pandemic is a major challenge for public
health, healthcare systems and economies, due to the numer-
ous associated comorbidities [1].
The Republic of North Macedonia is estimated to have one of
the highest age-adjusted comparative diabetes prevalences in
Europe, mainly due to the estimated high prevalence of type 2
diabetes [2–4].
Several factors have been implicated in such a high prevalence of
type 2 diabetes in the country, and its steep rise in the past three
decades, including: (1) dietary and lifestyle habits similar to
Turkey, the country with the highest age-adjusted comparative
diabetes prevalence in Europe; (2) transition from planned to
market economy in the last decade of the past century, with sharp
rise of unemployment in middle-age populations, and associated
psycho-social effects; (3) very high smoking prevalence [3].
The fact that cardiovascular diseases (CVD) are the major
cause for morbidity and mortality in the country, and that
the majority of diabetes patients would be diagnosed or die from
CVD, as well as the fact that the Republic of NorthMacedonia is
categorized as a European country with a very high risk for
cardiovascular mortality, further aggravate the situation regarding
the very high national diabetes prevalence [3,5,6].
The National eHealth System (NeHS) was introduced in the
country on 1 July 2013, covering all citizens across primary,
secondary and tertiary healthcare levels [3]. Implementation
of the National eHealth System has been praised internation-
ally as a key platform for improving the performance of the
national healthcare system [7].
In order to manage the national diabetes burden, several
initiatives have been undertaken, such as integration of
diabetes care module in NeHS since 1 Jan 2015, and
formation of National Diabetes Committee according to
the Law on Healthcare since February 2015. In addition,
international guidelines have been adopted as national
guidelines for diabetes care and treatment, and were
published in the Official Journal of Republic of North
Macedonia, where laws and bylaws are published, fur-
ther emphasizing the importance attributed to diabetes
as a nationwide condition.
The National eHealth System module for diabetes care was
upgraded with possibility to record metabolic parameters,
such as glycemic control, weight, lipid profile, blood pressure
and diabetes complications, thus strengthening the role of
NeHS as a critical resource for monitoring of diabetes care
in the country.
Furthermore, NeHS has become essential platform for preven-
tive, predictive and personalized metabolic control in diabetes
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patients, covering the total population of Republic of North
Macedonia.
Taking into consideration that diabetes has been a huge
healthcare and socio-economic burden for the country, the
analysis of data on metabolic control parameters in diabetes
patients derived from NeHS would be of utmost importance.
Since there are no different targets for metabolic control in
adult type 1 and insulin treated type 2 diabetes patients, data
on metabolic parameters in insulin treated diabetes patients
derived from NeHS would be cumulatively analyzed and
reported.
The concept of preventive, predictive and personalized med-
icine (PPPM) has emerged as the focal point of efforts in
healthcare aimed at controlling the prevalence and manage-
ment of non-communicable chronic diseases, including diabe-
tes [8–11]. The management of diabetes and the critical role of
PPPM in modernization of healthcare have been acknowl-
edged as priorities by global and regional organizations and
health-related institutions such as the Organization of the
United Nations, the European Union and the National
Institutes of Health [8–11].
The possible predictive role of novel biomarkers in diabetic
complications, particularly nephropathy, has been reported,
with the possibility for predictive diagnosis and targeted pre-
ventive measures [12]. In addition, a nomogram for prediction
of 3-year personalized risk of type 2 diabetes mellitus based
on age, body mass index, fasting blood glucose, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol,
and triglycerides was developed; and suboptimal health status
was identified as an independent risk factor for type 2 diabetes
mellitus in a community-based cohort [13,14].
This would be the first study to evaluate the role of NeHS in
the Republic of NorthMacedonia as a platform for Preventive,
Predictive and Personalized Metabolic Control in diabetes pa-
tients, through analysis of metabolic parameters in insulin
treated diabetes patients.
Methods
The National eHealth System, covering the total population of
the country across all three healthcare levels, plans to use ICD-
10 (Tenth Revision of International Classification of Diseases)
to search for living patients with codes E10–E14 in their
Electronic Healthcare Records (EHR), who are on insulin treat-
ment and with any data for metabolic parameters in their EHR.
Since the entry of metabolic parameters in EHR is not man-
datory, the number and proportion of insulin treated diabetes
patients with any data for metabolic parameters out of all
insulin treated diabetes patients are to be identified (n, %),
with a cut-off date of 1 May 2017.
In addition, number and percentage of insulin treated diabetes
patients with HbA1c <7% (adequate glycemic control), 7–
7.9% (inadequate glycemic control) and ≥ 8% (poor glycemic
control) are to be identified, according to the current
Guidelines [15].
The number and percentage of insulin treated diabetes patients
with body mass index (BMI) <25 kg/m2 (normal weight pa-
tients), 25–29.9 kg/m2 (overweight patients) and ≥ 30 kg/m2
(obese patients) are to be identified.
Achievement of lipid profile targets is to be evaluated through
identification of number and percentage of insulin treated di-
abetes patients with recommended target values for total cho-
lesterol (TC), LDL cholesterol (LDL) and triglycerides (TG);
namely with TC <5 mmol/l. LDL < 2.6 mmol/l, and TG <
1.7 mmol/l, respectively.
Finally, the number and percentage of insulin treated diabetes
patients with systolic blood pressure (SBP) <140 mmHg (ad-
equate SBP) and with diastolic blood pressure (DBP)
<90 mmHg (adequate DBP) are to be identified.
Results
Previous publications with data derived from NeHS have re-
ported the total number of diagnosed diabetes patients in the
Republic of North Macedonia to be 84,568 (57.3% females),
with a mean age of diagnosed diabetes patients of 62.6 ±
12.5 years [4]. The national prevalence of diagnosed diabetes
cases in the total population was 4.0%, whereas it was 5.0%
20–79 years ago [4]. The recent International Diabetes
Federation (IDF) Diabetes Atlas estimated total diabetes
cases, including both diagnosed and undiagnosed, for the
country to be 175,100 (95% Confidence Interval (CI)
131,200–218,200), and 20–79 years ago it was 11.2% (95%
CI 8.4–13.9%) and diabetes age-adjusted comparative preva-
lence in population 20–79 years of 9.3% (95% CI 6.8–11.5%)
[2].
Furthermore, the IDF Diabetes Atlas has emphasized that the
estimation of total diabetes prevalence study in the Republic
of North Macedonia was done based on a study conducted
within the past five years, further strengthening the accuracy
of the estimation [2].
Previous publications with data derived from NeHS have re-
ported the total number of insulin treated diabetes patients in
the country to be 37,011 patients, or 43.8% of all diagnosed
diabetes patients [3].
As the entry of metabolic parameters in individual EHRs of
NeHS remains optional, it is expected that the majority of
insulin treated diabetes patients would have no data for a sin-
gle metabolic parameter. Of those who have, it would be in-
teresting to identify the results of national metabolic control,
taking into account the results from the GUIDANCE Study, a
retrospective analysis of EHRs of 7597 diabetes patients from
eight major European countries, that found the majority of
diabetes patients to be in inadequate or poor glycemic control,
with percentage of patients achieving target HbA1c <7% to be
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60% in Belgium (n = 1044), 65% in France (n = 1056), 49% in
Germany (n = 959), 53% in Ireland (n = 950), 36% in Italy
(n = 984), 71% in Netherlands (n = 1021), 57% in Sweden
(n = 550) and 39% in United Kingdom (n = 1033) [16].
Conclusions and Expert recommendations
This is the first study to analyse the metabolic control param-
eters in insulin treated diabetes patients from the Republic of
North Macedonia derived from the NeHS, covering the total
population of the country. Furthermore, it is the first study to
evaluate the significance of NeHS as a national platform for
preventive, predictive and personalized metabolic control in
diabetes patients.
The National eHealth System has been established as a plat-
form for predictive diabetes care, as it enables monitoring of
metabolic control parameters and the associated predicted car-
diovascular risk in diabetes patients, taking into consideration
that CVDs are the primary cause of morbidity and mortality in
diabetes patients.
The National eHealth System has also been established as a
platform for preventive diabetes care, since it enables moni-
toring of development of micro-vascular complications in di-
abetes patients, and through monitoring of glycemic control
and risk factors, it provides directions for focusing preventive
activities to avoid or delay diabetic complications.
Finally, the National eHealth System has served as a platform
for personalized diabetes care, since it enables personalized
diabetes care that is based on the glycemic control and con-
comitant conditions and treatments; NeHS data are available
to care-givers across the spectrum of healthcare levels (prima-
ry, secondary, tertiary), and there is a potential to add new
scientifically sound and approved biomarkers to NeHS nation-
wide at a patient level in the future, to further personalize
diabetes care.
It is expected that this first study of metabolic control in
insulin-treated diabetes patients derived from the NeHSwould
suggest a need for improvement of glycemic, weight, lipid and
blood pressure control. Monitoring of metabolic control pa-
rameters through NeHS is expected to confirm its value as a
platform for predictive, preventive and personalizedmetabolic
control in insulin treated diabetes patients at an individual
level for every citizen with diabetes in the country, thus con-
tributing to the overall, national metabolic control.
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Introduction
Strokes have serious health and social consequences
worldwide [1–3]. Education and lifestyle adjustment
are key tools for the successful prevention of many
civilization diseases. Furthermore, education has an
important role in the detection of clinical signs and
symptoms of illness and in choosing the right proce-
dure. Stroke is an ideal topic for education and pre-
vention [4–7], optimally in a young population be-
cause a “young stroke” is by no means a rare occur-
rence [8] and the long-term effect of preventive mea-
sures can pay off [1,9,10].
The aim of this project was to obtain information about the
sample’s previous awareness regarding strokes and learn
about the lifestyle and health status of a young popula-
tion sample and that of their family members.
Furthermore, we set out to educate a young community
sample about strokes.
Methods
Medical students who completed a neurology course and
passed special training on the topic of strokes were in charge
of giving special preventive lectures to high school students.
All activities were performed in school classes (each for 25–
32 students). After a short introduction and explanation of the
aim and purpose of the educational activity, the students were
asked to fill in an anonymous questionnaire online/a printed
questionnaire. The questionnaire consists of three parts: (a)
Their general knowledge regarding strokes (definition, princi-
ples, etiology, signs and symptoms, consequences, treatment
and prevention options) and how to react in case of a
suspected stroke (b) Personal health and lifestyle information,
(c) Questions regarding the students’ family members’ health.
A presentation on strokes and a discussion followed. The in-
formed students completed the first part of the questionnaire
and were then asked to take a quiz 14–21 days later.
Results
A total number of 16 sessions for 356 students (150 men, 206
women), age range 15–18 years of age, took place between
April and May 2019 in four different high schools in the West
Bohemia region. Results showed that only 33% of students
had previous knowledge on the topic of strokes and stroke
signs and symptoms, only 11% knew how to respond to a
suspected stroke and 31% of students knew one or more
stroke risk factors; 28% are cigarette smokers, 39% confirm
occasional alcohol consumption and 10% are frequent alcohol
drinkers; 47% of the females in the sample did not know the
relationship between smoking and hormonal contraception.
37% did not know or did not care about their glucose and lipid
metabolism. Improved knowledge of the topic of strokes was
detectable later in 81% students, 37% discussed it within their
family and 7% showed the presentation to their family mem-
bers. Of the students, 87% considered the education activity
beneficial, 7% had a neutral response to it and 5% perceived it
as a useless harassment. In addition, 74% agreed with the fact
that a healthy lifestyle is of importance, 18%were not sure and
only 8% of the students considered any measures and lifestyle
changes useless.
PPPM relevant conclusions
As far as predictive medicine is concerned, this activity en-
ables the identification of a risk group in a young population
(individual risk factors, inappropriate lifestyle, family risk and
burden). Primary prevention and providing information on
preventive measures are the main goals of this activity; espe-
cially to populations at risk. The realization of this educational
activity is of importance for encouraging lifestyle adjustments
among the young population and embodies the potential of
information trickling down to their family members. The
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principles of personalized medicine can be achieved with the
dissemination of knowledge and by educating the public
about strokes and the optimal measures to take in case of a
stroke [3]. This type of educational activity is not expensive, is
well feasible and could be used on young populations
worldwide.
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Introduction
In the early twenty-first century, high levels of urban-
ization and sub-optimal life-styles have strongly con-
tributed to epidemics of non-communicable diseases
(NCDs) [1–6]. Environment and lifestyle are decisive
factors in human health. According to WHO (2015),
“the epidemic of lifestyle diseases is a much greater
threat to public health than any other epidemic known
to humanity”.
The paradigm shift from reactive to predictive, pre-
ventive and personalized medicine (PPPM) in public
healthcare is evidence-based justified and effectively
promoted by the European Association for Predictive,
Prevent ive and Personal ised Medicine (EPMA,
Brussels) [7]. The Russian Project of the National
Technological Initiative follows the PPPM concepts
to effectively implement the paradigm change to
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improve heathcare services for the population and
healthcare economy [8].
Aims
To create a new model for hospitals to implement innovative
PPPM concepts and services – see Fig. 1.
Concepts, Challenges and Potential Solutions
At the stage of transition to PPP Medicine, Innovative Health
and Development Centers should become the Centers of
Attraction for the whole family.
We consider extending the list of Departments in the PPPM
Center to include healthcare architecture, salutogenic design
of interiors to cover research, education, creativity and other
solutions for health.
I. The Department of Research may propose preclinical pre-
dictive diagnosis with different tests for detection of men-
tal, physica and somatic health. The cardinal objective of
this Department is the development of approaches and
technologies for recognizing the so-called suboptimal
health conditions before disease appearance and the appli-
cation of scientifically based interventions countering
identified risks. Since the main goal of the PPPM Center
is to promote health and reduce disease burden, this
Department has to accumulate, analyze and validate data
on healthy people to provide big data analytics and create
the intervention platform with personalized preventive
programs for healthy lifestyle, healthy food, ergonomics
for professional longevity, etc.
The novel examination protocol includes: neuropsycho-
logical study for examination of cognitive, emotional sta-
tus, memory tests, stress factors; as well as clinical,
laboratory, instrumental and genetic tests to search for
the markers of early NCDs stages.
II. The Department of Education has to organize education
throughout life—from childhood to “silver age”: Master
classes and courses may cover the practical information
in personalized health management, in holistic medicine
with fundamental laws to support mental, physical and
spiritual health for creativity and professional realization.
This Department may present the conceptions of balance
and happiness and include healthy rooms with ergonomic
equipment.
III. The Department of art-therapy and communications
may include spaces for self-expression in paint, music
and dance therapy therapy for development of brain
plasticity.
IV. The Department of Traditional Medical Systems enables
enhancing the knowledge towards the disease preven-
tion and treatment. From a predictive and preventive
medicine point of view, Ethno-medicine provides a
unique expertise for recognizing the pre-clinical health
conditions before a clinical manifestation of severe
pathologies.
V. The Department of Creativity may propose solutions for
personalized fashion style.
VI. The Department of Physical Activity analyzes psycho-
logical and physical data to prescribe personalized phys-
ical programs to strengthen the systemic mechanisms
Fig. 1 Preliminary concepts of PPPM Center implementation at the stage of transition from reactive to predictive, preventive and personalized services
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for disease prevention and cognition improvement.
Different categories of individuals can receive scientifi-
cally based programs in the smart halls with functional
space for fitness and movement skills development.
VII. The Department of Healthy Food can organize master-
classes in cooking for healthy life, advocate healthy
nature food, dietetics for participants, according to in-
dividual constitution approach.
Conclusions and outlook
To achieve the paradigm change from reactive to preventive,
predictive and personalized medicine, it is essential to estab-
lish innovative PPPM Centers based on evidence-based sci-
entific achievements, multi-professional expertise, ICT solu-
tions and robust infrastructure strongly supported by adequate
budgets and supportive political decisions to create attractive
conditions and market opportunities for the healthcare indus-
try [9,10]. Involvement of the above-described Center as the
institutional member of the European Association for
Predictive, Preventive and Personalized Medicine (EPMA,
Brussels) is foreseen to develop a long-term European-
Russian collaboration within the multi-professional and inter-
national network and to effectively implement PPPM con-
cepts in the Russian Federation.
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Introduction
F.D. Roosevelt University Hospital with Policlinic
(FDRH) in Banská Bystrica, Slovakia [1] is one of the
largest hospitals in Slovakia, ISO 9001 certified, having
almost 1000 beds, approximately 2300 employees, and
providing medical services to as many as half a million
patients annually. The management team of the Hospital
permanently monitors the trends in the development of
the healthcare worldwide and creates its long-term de-
velopment strategy being familiar with the concept of
the predictive, preventive, and personalized medicine
(3PM), promoted by the European Association for
Predictive, Preventive and Personalised Medicine
(EPMA) since 2009 [2–10].
Working well in consensus with the 3PM concepts,
FDRH with the approval from the Ministry of Health
of the Slovak Republic, became an Institutional member
of the EPMA, following the general vision to accom-
plish the pioneering mission and bringing practical 3PM
aspects into daily practice that will benefit the patient
and healthcare as a whole in Slovakia. Keeping this in
mind, FDRH encourages medical facilities and organi-
zations in other regions of Slovakia to join our initiative
for better coordination of joint efforts in tight collabo-
ration with the international professional network led by
EPMA on a global scale.
Implementation of 3 PM concepts into daily practice in
steps
& The first step
Keeping in mind the complexity of the objectives,
FDRH decided, in the first step, to focus on significant-
ly extending the range of tests in our Clinical laboratory
complex that would provide the value added to the
spectrum of the routine tests [11]. FDRH expects to
equip the laboratory diagnostics with powerful analytical
technologies for clinical biochemistry, clinical microbi-
ology, and toxicology, such as high performance liquid
chromatography (HPLC), liquid chromatography coupled
to mass spectrometry (LCMS), gas chromatography/
mass spectrometry (GCMS), atomic absorption spec-
trometry (AAS), matrix-assisted laser desorption/ionization
mass spectrometry with time-of-flight detector (MALDI-
TOF), as well as other most recent analytical methods in
international collaboration with other EPMA Institutional
members. Furthermore, FDRH creates cooperation with na-
tional and regional partners who would provide analytical
services toward health relevant environmental factors [12].
The complementary services to related medical units in the
context of 3PM are also under consideration such as services
related to healthy nutrition, relax and sport in the mountains,
and wellness. To achieve this, we plan to gradually transform
one of our external hospital facility into a climatic spa. This
option creates a wide spectrum of opportunities for an inter-
national collaboration within the European Union and world-
wide [13].
& Follow-up step
In the next step we plan to significantly increase capacities in
medical imaging and in multi-level diagnostics [9, 10, 14],
thus expanding the overall predictive diagnostic potential of
the hospital.
& Essential step forward
The essential step forward is a continual education of the
patients and individuals interested in advanced healthcare
supporting their health status. This aspect has attracted partic-
ular attention due to the worldwide pandemic of COVID-19,
as declared by WHO on 11 March 2020 [15]. any medical
professional would disagree that having had the concept of
3PM been implemented in healthcare, including improved
health literacy, the current pandemic situation would have
been much easier to deal with and more effectively
managable.
The vision
The vision we have is to offer, in a supportive interna-
tional cooperation, the health-focused services in predic-
tive diagnostics, primary prevention and health-
enhancing services to the patients, through which a
wide spectrum of medical and other professionals would
take care of individual patients at either particular stages
of their diseases, or the clients who do not suffer of any
apparent health problems or individuals with suboptimal
health status [16] who are interested in an assessment of
their health in order to predict and prevent potential
health deterioration well before the manifestation of a
pathology that is later difficult to reverse or treat.
We expect that by implementing 3PM as an integral part of
our professional medical care, parallel focusing on health-
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supporting services, alongside the standard therapeutic proce-
dures, we will, in the long run, significantly reduce healthcare
costs and make the future healthcare more sustainable and
evolving (Fig. 1).
Conclusion
In the current situation of unprecedented pressure on the quality
of the healthcare system, caused by the pandemic of COVID-19,
we realized that it is time to significantly change the healthcare
system and transform it to be more viable and pro-active. We
understand the worldwide outbreak of SARS-CoV-2 as an ulti-
mate “wake-up call” that essentially needs to be answered. We
are ready to complement, in parallel, the EPMA’s visions
[11,17,18] of specialized 3PM centers by implementing the
3PM attitude directly within the hospital structure, thus bringing
future 3PM healthcare closer to the patients as well as healthy
individuals. Such an evolutionary stepwould, of course, require a
broader collaboration at both the national and international levels.
The platform for such collaboration exists, so let us get started.
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Introduction
Plastic surgery is a surgical area which can be divided
into two categories: reconstructive and aesthetic surgery.
While reconstructive surgery aims to reconstruct a dam-
aged (post-traumatic, cancer-removal) body site or to
improve its functioning, the main purpose of aesthetic
surgery is improving the appearance. As an elective
surgery, cosmetic surgery has a highly specific risk/
benefit ratio.
The predictive and prognostic approach tailored to the
individualised patient profile is highly desirable in the
area, in order to develop perioperative stratification
tolls, predict postoperative complications and calculate
final treatment costs.
An evidence-based approach is essential to provide optimal
care in plastic surgery and protect interests of all key players in
the healthcare system (the treating plastic surgeon, the patient
him/herself and insurance).
The aim of this study is to identify which kind of parameters
are to be considered for individualised patient profiling,
evidence-based patient stratification and consequently true-
personalised treatment algorithms.
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Medline search results
In September 2019, we performed a Medline search to find
out how extensively the principles of 3PM, as well as corre-
sponding tools and approaches, are explored and utilised by
the plastic surgery community. The search results are summa-
rized in the Table 1.
Table 1.Medline search results utilising the below listed keywords; cor-










predictive preventive personalised medicine 2 (EPMA Journal)
Multiomics 1 (EPMA Journal)
3PM related conclusions and expert recommendations
Obviously, the area of plastic surgery still lacks
evidence-based 3PM approaches, including multi-
omic biomarker panels for predictive diagnostic pur-
poses, targeted prevention and true-personalised treat-
ment algorithms.
Non-modifiable risk factors include a genetic predis-
position to hypertrophic or keloid scarring, skin type
(pigmentation, elasticity, thickness, sebaceous quality,
location), Ehlers–Danlos syndrome, Pseudoxantoma
e la s t i cum, Cut i s l axa , Atax i a - t e l eang iec t as i a ,
Klinefelder syndrome (diminished fibrinolysis, high
levels of the fibrinolysis inhibitor PAI-1), disorders
of the immune system (Leukocyte adhesion deficien-
cies (LADs), TAP deficiency syndrome), disorders of
hemoglobin synthesis (Sickle cell anemia, thalasse-
mia), autoimmune diseases (rheumatoid arthritis, sys-
temic lupus erythematosus), accelerated and advanced
aging (Progeria, Werner syndrome, Down syndrome),
amongst others [1,2].
In turn, modifiable—meaning preventable risk factors—are
psychological stress, smoking, inappropriate alcohol con-
sumption, imbalanced diet, sedentary life-style, suboptimal
health conditions such as Flammer syndrome, disturbed
microcirculation, impaired wound healing, accelerated aging,
preventable metabolic syndrome(s) and cardio-vascular pa-
thologies, among others [1,2].
Consequently, a robust predictive/prognostic approach by
multi-level diagnostics should be based on the individualised
patient profiling essentially including
& family history (non-modifiable factor of genetic predispo-
sition, e.g. to accelerated aging)
& biologic vs. chronologic age
& anthropometric parameters
& tissue composition (fat/water/mussels)
& sub/cellular biomarker-panels providing information for
healing quality (e.g. scar formation), post-treatment sus-
tainability of the modification and potential complications
including chronic non-healing wounds, amongst others
[1–4].
Consequen t p reven t ive measures may inc lude
individualised patient consultations, dietary and life-
style aspects, adaptive modifications to the treatment
approach and/or overall disease management.
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Background
Flammer syndrome (FS) phenotype has been abundantly
demonstrated as a suboptimal health condition which,
if not corrected well in time, may potentially predis-
pose affected individuals to a cascade of secondary
complications, e.g. in pregnancy [1] and even severe
pathologies, due to chronic vasospastic condition and
significant alterations described at molecular, cellular
and systems level [2].
Working hypothesis
Potential impacts of FS phenotype to the altered vas-
cular status of pregnant women being potentially rel-
evant to foetal developmental particularities have
been hypothesised.
Material and methods
Forty-five pregnant women (mean age 28.4 ± 2.3)
were under observation. The target group comprised
21 pregnant women demonstrating clear symptoms of
FS-phenotype diagnosed by utilising the FS-specific
questionnaire [2]. The control group comprised 24
age-matched FS-phenotype-free pregnant women.
Vascular rigidity indices in each trimester, growth-
weight parameters of new-borns (Quetelet I index)
and delivery term were statistically evaluated for each
group.
Results
New-borns of mothers with FS-phenotype were
characterised by significantly lower weight (3169 ± 296
vs. 3620 ± 363 g), height (50.8 ± 1.51 vs. 53 ± 1.6 cm)
and gestational age (38.4 ± 0.81 vs. 39.5 ± 0.53). Trophic
status of new-borns, reflecting nutritional particularities
during the intrauterine period, differed markedly be-
tween the groups: a hypotrophy in new-borns was sig-
nificantly more frequent (40% vs. 5.5%), whereas both
the normotrophy (53.4% and 72.2%) and hypertrophy
were much rarer (6.6% and 22.7%) in the group with
FS-phenotype vs. control. Furthermore, the FS-group
had a significantly increased vascular stiffness compared
with the control. Significant differences were monitored
for peripheral augmentation index AIx75 in first trimes-
ter (−45% vs. −61%, respectively).
Conclusions and expert recommendations
The FS-phenotype of pregnant women is demonstrated
as being strongly associated with significant alterations
in maternal vascular status and, amongst other, trophic
parameters of the new-born; all other potential alter-
ations are to be explored further. The recorded alter-
ations are a clear indication to include the FS-
phenotype as a criterion for predictive diagnosis and
intensive care during pregnancy. In-depth follow-up
studies are essential to be performed, in order to elabo-
rate on targeted preventive measures and personalised
treatment algorithms tailored to the FS-affected women
in reproductive age.
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Background
Flammer syndrome (FS) was primarily defined as an ophthal-
mological phenomenon, associated with central and peripher-
al symptoms, resulting mostly from dysregulation of systemic
and local blood circulation [1]. Recently, a number of pathol-
ogies potentially linked to FS as a suboptimal health condition
have been described, making the FS-related research
field of great interest specifically in the context of pre-
dictive preventive personalized medicine (PPPM / 3PM)
[2–6]. As nutrition is a basic factor in the body’s func-
tions, including blood flow regulation and related phys-
iological manifestations, a dietary approach would be
assumed to contribute to amelioration of the various
disorders potentially linked to FS. The nutritional ap-
proach described here addresses some of the specific
symptoms and outcomes, and expresses shared nutrition-
al effects on biochemical and physiological mechanisms.
Cold extremities and primary vascular dysregulation in
FS
Cold hands and feet may indicate nutritional deficiencies, in-
cluding of B-vitamins, iron, magnesium, and proteins that result
from either dietary insufficiency or poor absorption. Folate and
vitamins B6 and B12 support blood hemoglobin synthesis.
Sufficient iron levels increase metabolic activity and conse-
quent peripheral blood vessel dilatation that results in warming
the whole body and extremities. Vitamin B3 supports blood
vessel functionality, and supplements have been shown to in-
tensify blood flow and warming of extremities.
Body dehydration as a consequence of decreased feeling of
thirst in FS
FS individuals demonstrate reduced feeling of thirst. Moreover,
systemic low hydration is directly linked to pathophysiologic
pathways triggered in the eye; for example, in dry eye syndrome,
cataracts, refractive changes, and retinal vascular disease.To this
end, the hydration factor was shown to be involved in the devel-
opment of both diabetic retinopathy and glaucoma [7]. Body
dehydration is a risk factor for breast cancer development [8].
Changes in odor perception are characteristic for FS
Taste and smell disorders can range from complete loss of func-
tion (ageusia and anosmia, respectively) to partial loss
(hypogeusia and hyposmia), and/or inappropriate sensation for
a given stimulus (dysgeusia and dysosmia). Changes in odor
perception are characteristic for both otherwise healthy FS indi-
viduals and different patient cohorts with characteristic FS phe-
notype conditions, such as glaucoma [1] and breast cancer [3].
Though chemosensory complaints identify both taste and smell
loss, olfactory dysfunction is primarily responsible. Zinc and
other micronutrients such as vitamins A, E, and the B-family,
as well as iron and iodine have been associated with
chemosensory function. The overall limited success of providing
these nutrients in supplement form for treating shifted taste and
smell perception suggests the greater potential of food sources in
this respect [9].
Arterial hypotension is characteristic for FS
Arterial hypotension is a key manifestation of autonomic dys-
function, typically observed when cardiovascular adaptive
mechanisms fail to compensate the reduction in venous return
that normally occurs with sitting up and standing. Arterial hypo-
tension is characteristic in FS individuals highly predisposed to
instability in ocular blood flow, oxidative stress and normal-
tension glaucoma [1]. Nutritional means aimed at hypotension
prevention include adequate dietary habits such as frequent and
small meals, limited alcohol consumption [10], sufficient body
hydration and intake of essential vitamins and minerals, includ-
ing sodium and stimulating phytonutrients. Among
micronutrients, vitamin C is supportive for blood vessel func-
tionality, vitamin D is essential for baro-reflexive mechanisms
[11] and folate together with vitamins B6 and B12 prevents
anemia and hyperhomocysteinaemia. Caffeine management
supports stable blood pressure [12].
Nutrition recommendations to protect FS individuals
against glaucomatous damage
Glaucoma refers to progressive optic neuropathy that can re-
sult in irreversible vision loss and blindness. Oxidative stress
is suggested as an important risk factor for glaucomatous ret-
inal ganglion cell loss [1, 6]. Here a dietary approach adapted
to the antioxidative diet is highly recommended [13]. Among
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micronutrients, magnesium supports blood flow and endothe-
lial function, and balances calcium influx and glutamate re-
lease, thus protecting against oxidative stress and cell death
[14]. Balanced calcium and iron levels [15], vitamin B3, and
flavonoids demonstrated protective effects against glaucoma
and further age-related effects. Phytonutrients such as
anthocyanosides from fruits and vegetables, catechins from
green tea and cocoa, flavonoids from cocoa, and curcuminoids
from turmeric, showed protection of retinal ganglions and
support of blood flow. Reduced caffeine is advised against
acute increase in blood pressure [15].
Conclusions and expert recommendations
A comprehensive nutritional approach, with emphasis on
specific components as reviewed above, offers a strategy
for treating individuals with the FS phenotype. A person-
alized approach based on individualized patient pro-
filing [16] is essential for a predictive medical ap-
proach in treating FS individuals with the FS pheno-
type [17–20]. Targeted preventive measures are pos-
sible and highly recommended [21, 22]. Most of the
FS symptoms are respond negatively to nutritional
imbalances and/or positively to corrections and func-
tional interventions. Recommendations related to gen-
eral dietary habits include small frequent meal intake,
avoiding starvation [6], as well as sufficient amounts
of essential minerals—mainly calcium, magnesium,
zinc, and iron—and vitamins—such as A, C, D, and
the B family. Phytonutrients and long-chain omega-3
fatty acid contributions have to be considered for strat-
ified patient cohorts [21]. Patient stratification for the
3P medical approach is recommended via individualized
patient profiling and non-invasive liquid biopsy [23,
24].
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Classification of voice perturbation and disorders
Voice disorders, also called dysphonia, are characterized by
abnormalities in vocal quality, pitch, loudness, and vocal ef-
fort resulting from neurological, structural or functional prob-
lems which affect the voice-related quality of life. Dysphonia
occurs in 3–9% of the population [1]. Factors, including fam-
ily history, gender, age, occupation, and smoking are obvious-
ly associated with the voice perturbation and disorders
Table 1.
Table 1 Risk factors of voice disorders
Risk factors Significance Reference
Gender •Higher prevalence of voice disorders in
women (p < 0.01)
1
Age • Increased laryngeal disorders within
elderly (>65 years old)
1





• Relationship between family history of
hoarseness and voice disorders in
teachers (P = 0.0001)
4
Occupation • Voice disorders in 66% of teachers,
59% of call centre workers, 47% of
singers
• Voice perturbation in 82% of teachers




• Higher risk of laryngeal disorder
(p < 0.05)
• Lower values of F0 and MPT
(p < 0.05)
• Increased jitter, shimmer percentage
(p < 0.05)
5
“F0”–Fundamental frequency; “MPT”–Maximum phonation time
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Dysphonia is aetiologically classified into three main catego-
ries: functional, organic, and neurological.
1. Functional dysphonia (FD)
FD involves voice abnormalities as the consequence of voice
misuse in the absence of anatomical or neurological perturba-
tions. FD includes psychogenic voice disorder (PVD), muscle
tension voice disorder (MTVD), stuttering, childlike prosody,
and articulation abnormalities. PVD and MTVD are the most
prevalent types of FD [6]. The clinical features of FD are
summarized in Table 2.
Table 2 Clinical features of FD
Disorders Clinical features References
Psychogenic
dysphonia
• Abrupt onset of dysphonia
• Hoarseness, chronic aphonia,
intermittent voicing
•Tremor, vocal fold adduction related
to muscle tone limitation during
phonation, glottic cleft





• Slow start of dysphonia
• Primary MTVD: dysphonia without
laryngeal pathology
• Secondary MTVD: dysphonia with
laryngeal pathology like vocal cord
lesion
8
Stuttering • Stuttering on every syllable, word
• Extreme variability
• Presentation of accent on wrong
syllable
6
Infantile prosody Infantile speech 6
Abnormal
articulation
• Lingual, facial weakness
incompatible with inaccurate
articulation on tasks irrelevant to
speech




Organic dysphonia, resulting from structural changes of the
larynx, due to malformation, trauma, infection, and tumors, is
non-related to voice usage and considered as the common
drawback of dysphonia [6, 7]. In Table 3, the laryngeal man-
ifestations of organic dysphonia are summarized.
Table 3 Pathologies related to organic dysphonia
Risk factors Significance References
Laryngectomy and
post-laryngectomy
• Increased jitter, shimmer
percentage
• Reduced MPT, HNR, mean F0
• Roughness, hoarseness after
radiotherapy




Post-thyroidectomy • Significant deterioration of F0 and
MPT
• Transient vocal folds paralysis
• Voice fatigue
• Voice pitch changes
• Significantly increased shimmer
15
Rheinke oedema • Significant improvement in
perceptual and acoustic vocal
features and MPT in women in
the postoperative
7
Acute laryngitis • Laryngeal oedema and erythema
• Inadequate phonation
pressureHoarseness
• Aphonia, breathy, raspy voice
• low pitch level
16
Chronic laryngitis • Continuous hoarseness
• Throat sensations
• Urge to clear throat
7
Vocal cord polyps • Hoarseness, breathiness,
roughness
• Vocal fatigue
• Adequate to low F0
• Increased noise in acoustic aspects
• Lower jitter values
• Airway blockage







• Blockage of respiratory tract
7
F0–Fundamental frequency; HNR–Harmonics-to-noise ratio; MPT–
Maximum phonation time
3. Neurologic dysphonia
Lesions in the central or peripheral nervous system have been
associatedwith neurologic dysphonia usually leading to low tone,
tremor, poor prosody, and impaired articulation. Changes in
voice features may accompany the development of neurological
disorders [6]. Evaluations of perceptual and acoustic vocal fea-
tures have revealed frequent voice dysfunction in neurological
disorders, such as Parkinson disease [8], Huntington’s chorea
[9], spasmodic dysphonia [6], multiple sclerosis [10], amyotro-
phic lateral sclerosis [8], stroke [10], myasthenia gravis [11],
bulimia nervosa [12], Down’s syndrome [13], vocal cord paral-
ysis [6], and depression [8].
Health conditions and disorders with the laryngeal
manifestation
Gastrointestinal reflux [7,8], autoimmune diseases [7] (e.g., rheu-
matic arthritis, Sjögren’s syndrome, systemic lupus erythemato-
sus, amyloidosis), respiratory disorders [18] (e.g. chronic obstruc-
tive pulmonary disease, cystic fibrosis, asthma), diabetes [3], thy-
roid disorders [3], acromegaly [19], postmenopausal period [3],
and cardio-vocal syndrome [20]— all frequently cause changes
in voice quality secondary to either functional or structural
laryngological alterations. Corresponding laryngeal symptoms
are summarized in Table 4.
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Voice perturbations as a predictor for disease development
and indicator for preventive treatments tailored to the person
As demonstrated above, voice perturbations might be an early
indicator of developing pathologies. Moreover, depending on
individual parameters, the voice perturbation can be instrumental
for a disease prediction and indicative of preventive measures
tailored to the person. One of the best examples is an individual
stress reaction causing a variety of disorders and thereby chang-
ing several biomarker patterns including voice parameters [21].
The technology of speech analysis has, therefore, great potential
in predictive, preventive and personalized medicine. Further, a
complementary application of specialized questionnaires, body
fluids, and multi-omic analysis may significantly improve the
overall predictive power of the approach providing also valuable
information for targeted treatments [22, 23].
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Intensity - - - - - (in PD)
F0 - -(SS) - (in COPD) not changed -(in PD)
Pitch Perturbaon
Quoent
+ + + unknown + (in HD)
Dry mouth unknown + + + +
MPT short short short short short
Shimmer + + + + +
Jier + + + + +
hoarseness + + + + +
Roughness + + + + +
Arculaon unknown inaccurate unknown unknown inaccurate
HNR - - - - -




“-”–decreased; “+”–increased; “COPD”–Chronic obstructive pulmonary disease; “F0”–Fundamental frequency; “HNR”–Harmonics-to-noise ratio;
“HD”–Huntington disease; “MPT”–Maximum phonation time; “PD”–Parkinson disease; “SS”–Sjögren’s syndrome
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Background
Heart failure (HF) is a life-threatening chronic and ris-
ing disease nowadays [1, 2]. HF risk factors comprise
both non-modifiable (e.g. inborn HF) and modifiable
ones [1, 3]. Collateral pathologies can contribute to
the development and progression of HF [1, 4].
Patients diagnosed with HF need permanent monitoring.
Regu l a r v i s i t s t o the ca rd io log i s t and acu t e
hospitalisation and life-threatening risks increase the
overall costs of the HF related healthcare. Contextually
dedicated devices for non-stop disease monitoring (ap-
plication of artificial intelligence in medicine) are con-
sidered to provide cost-effective solutions for improved
HF care.
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For such devices, multi-professional input by clinicians, bio-
technologists, designers and computational scientists is need-
ed to carefully stratify the patients for individualised monitor-
ing and to adapt the device to the personalised needs of the
patient. As the “proof-of-principal” healthcare model, the HF
patient stratification based on characteristic clinical parame-
ters and biomarker sets is crucial for creating an optimal de-
vice for disease monitoring and non-stop personalised patient
care. This is a consideration by internationally highly
recognised consortia [1].
Materials and methods
The project utilised the SCAIView, a Semantic Search Engine
for Biomedical Research Utilizing a Microservice
Architecture, which is the IT tool for biological and medical
literature search developed by the Fraunhofer Institute for
Algorithms and Scientific Computing, Sankt Agustin,
Germany (SCAI). SCAIView provides an easy and fast liter-
ature review based on an automatic information extraction of
the knowledge in the literature available. SCAIView offers the
possibility to search in more than 90 databases and ontologies
worldwide. The research was performed using two portals,
SCAIVIew and PubMed; the former provided the first direc-
tions for the research, and the latter provided more detailed
information for the project. With all the obtained information,
a wide analysis for preventing HF was performed.
Results interpretation and conclusions
HF events prevention is complex and requires the analysis of
many indicators. Factors such as age [5,6], BMI [7,8] or blood
pressure [9,10] help influence the prognosis of HF.
Biomarkers have proven a key role in the diagnosis of HF
and its prevention [11, 12, 13].
Regrading the indicators analysed, patients can be classified,
and HF events can even be predicted depending on the
individual.
Figure 1 provides a clue to contrast clinical situations chal-
lenging the overall HF management that clearly demonstrates
why a detailed patient stratification is needed to optimise pre-
dictive, preventive and personalised medical approach. Both
patients suffer from HF. However, the disease origin and ac-
companying risks differ dramatically from each other in both
clinical situations. Consequently, predictive biomarker pat-
terns and preventive measures are highly individual for both
patients.
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Introduction
It is well known that the patient’s response to the phys-
ical agents as used in contemporary physiotherapy is
person dependent;however, this phenomenon is seldom
taken into account in daily practice. The proper anam-
nesis, allowing to collect the necessary information on
patients medical history such as illnesses, underwent
treatments, family diseases and lifestyle, may help to
choose or to restructure the current treatment.
Therefore, the individualized patient profiling may lead
to proper evaluation of individual details and play a
crucial role in the proper approach for the patient. For
example, recently, a case study on Flammer syndrome
to understand the patient’s illness and family history, in
order to make recommendations based on predictive,
preventive, and personalized medicine (PPPM), was re-
ported [1]. To understand the individual details is an
important issue in view of prediction of therapy results.
Such an approach may result not only in improved ther-
apy outcomes but may have a direct economic impact
(earlier rehabilitation of the patient, cost effective treat-
ment strategy etc.). Additionally, the exact information
on a patient should ease the stratification [2, 3]. Proper
stratification is also very important in physiotherapy.
Therefore, we would like to demonstrated that response
to physical stimuli is an individual feature, even for
consensual reaction. The aim of the study was to assess
the contralateral response in healthy volunteers exposed
to various physiotherapeutic treatments such as local
cryotherapy, ultrasonotherapy, electrostimulation with
diadynamic currents and visible-near infrared (VIS-
NIR) light irradiation. Treatments were performed on the quad-
riceps muscle of the right leg, whilst corresponding place on the
left leg was the reference limb. Thermographic images were tak-
en before and after the procedure at set intervals. Altogether, 712
thermograms were analyzed. The temperature differences
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between the treated limb and the reference limb, were observed,
confirming the presence of consensual reaction after the four
monotherapies were analyzed. It was observed that the consen-
sual reaction depends on the age and gender of the patients, and it
is an individual characteristic of the person, and thus can be used
for patient stratification and lead to personalization of
physiotherapeutic treatment.
Material and methods
The study was performed under the permission from the
Senate Commission of Bioethics of the Wrocław
University School of Physical Education, maintaining
the ethical guidelines of the Declaration of Helsinki.
The research group consisted of 178 healthy volunteers, in-
cluding seniors (aged 58–80) and juniors (aged 19–28 years).
The participants were a priori informed about the course of the
experiment and voluntarily agreed to take part in it. The thermal
response of the organism was examined using the FLIR
T335 camera. All treatments were performed on the
quadriceps muscle of the right tight. The left leg was the
reference limb and was used for evaluation of the consensual
reaction. Four images were captured for each volunteer—before
the treatment (T0), immediately after the treatment (T1), and then
15min (T2) and 30min (T4) after the procedure. Altogether, 712
thermograms were recorded and analyzed using ThermaCAM
Researcher 2.10 software.
Results
The experiment shows that the duration and strength of
the contralateral reaction depends on the gender of the
patient (Table 1). Both, cryotherapy and infrared radia-
tion cause a strong contralateral response of the body,
which persists for up to 30 min after treatment.
Ultrasonotherapy and electrostimulation with diadynamic
currents also cause a consensual reaction, but less inten-
sive.
Age of the patients also seems to be a factor that affects the
contralateral body’s response (Table 2). In all the analyzed
cases, the consensual reaction in seniors was stronger. A par-
ticularly strong response was observed after thermotherapy
involving infrared radiation.
Figure 1 shows the changes in average temperature of the
reference limb for the examined phases of the experiment,
compared to the initial temperature. The strongest consensual
reaction was observed in junior women and senior men just
after the treatment. The thermal response of the body after this
procedure was long-lasting. In no case, within 30 min after
completing the treatment, the reference thigh temperature
returned to the initial value.
Figure 2 shows the consensual reaction observed in patients after
thermotherapy with use of visible and near infrared radiation. In
this case, immediately after the procedure response was stronger
in women, but in men the reaction lasted longer.
Table 1 The differences of mean temperatures between women and men
for experimental phases (T1, T2, and T3) in comparison to the temperature
before treatment (T0) for the left limb
T [°C]
Cryotherapy VIS-NIR radiaon Ultrasonotherapy
Diadynamic 
currents
Women Man Women Men Women Men Women Men
T1-T0 -1.21 -1.03 1.97 1.11 0.38 0.07 0.75 0.42
T2-T0 -0.81 -0.94 0.93 0.05 0.41 -0.19 0.70 0.18
T3-T0 -0.74 -0.86 0.76 -0.35 0.29 -0.39 0.56 -0.04
Table 2 The differences ofmean temperatures between Juniors and Seniors
for experimental phases (T1, T2 and T3) compared to the temperature
before treatment (T0) for the left limb
T [°C]
Cryotherapy VIS-NIR  radiaon Ultrasonotherapy
Diadynamic 
currents
Juniors Seniors Juniors Seniors Juniors Seniors Juniors Seniors
T1-T0 -1.08 -1.14 1.60 1.91 0.13 0.32 0.19 1.03
T2-T0 -0.84 -0.83 -0.07 1.51 0.08 0.28 0.04 0.90
T3-T0 -0.80 -0.72 -0.38 2.42 -0.15 0.19 -0.16 0.74
Fig. 1 Changes of the mean temperatures of the left limb after local
cryotherapy’ application
Fig. 2 Changes of the mean temperatures of the left limb after VIS-IR
radiation’ application
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Figure 3 presents analogous data for ultrasonotherapy.We can
see strong consensual reaction in the case of the senior women.
The final figure illustrates the contralateral response observed
after application of diadynamic currents (Fig. 4). Again, the
reaction in women was more visible than that in men.
3PM related conclusions regarding the physiotherapeutic
treatment
Modern physiotherapy is based on a comprehensive approach
to patients and includes many methods that can have a
synergistic effect in the treatment and prevention of
diseases. Physiotherapeutic procedures, including
kinesitherapy, massage and physical therapies are now-
adays used mainly for combating pain and inflamma-
tions, speeding up the healing process of soft and hard
tissues and improving general patients’ mobility.
Parameters of physical stimuli are determined in accor-
dance with accepted standards as well as knowledge
and experience of a physiotherapist. Procedures are
personalized to a small extent, mainly due to the lack
of tools to assess the patient’s response to a given
stimulus. Contemporary physiotherapy should consider
the general recommendations of PPP medicine [4–6],
but gaps remain.
Most of the physical treatments cause thermal effects,
resulting in a change of the temperature in the treated
region, as well as the reaction occurring on the oppo-
site side of the body—called consensual response [7,
8]. Here, infrared thermography is a valuable tool be-
cause it is fast, non-invasive, non-destructive, and an
accurate method of the evaluation of the surface tem-
perature. A contralateral reaction occurs due to seg-
mental innervation of the body and is defined as the
response of a symmetrical body segment to a stimulus
acting on the opposite area. It arises from crossed va-
somotor reflexes and under certain circumstances, leads
to additional benefits for patients by engaging the
whole-body response. In other cases, however, it may
adversely affect the results of treatment and may even
be contraindicated.
Assessing the size and length of a consensual response
can be one of the valuable factors used for personali-
zation of physiotherapeutic treatment. Although the
contralateral reflex is a very important factor in
physiotherapeutic practice, it remains little-known and
minimal attention has been paid to it in the literature
attention has been paid to it in the literature. Our paper
intends to address this drawback.
The application of infrared imaging for monitoring the
physiotherapeutic procedures seems to have many ad-
vantages. Thermography may be a valuable tool for
preventing possible tissue damage during physiothera-
py procedures, e.g., as a result of incorrect selection of
physical stimulus parameters. It may also help to strat-
ify the patients based on factors such as gender, age,
thermal response of the treated region as well as the
contralateral one and further lead to more patient-
oriented therapy. If known, the patient’ thermal profile
may be used for personalization of physioterapeutic
procedures and help to increase the treatment’ efficien-
cy. Also, if needed, the thermal profile of the entire
stratified group may be used, this however requires
extended research, which will indicate the statistical
relationships between the stimuli parameters and the
group response.
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Introduction
Medical imaging plays a central role in modern medi-
cine. Besides assessing and monitoring the status of
patients with acute illnesses, it serves as an important
tool in cancer staging, restaging, and monitoring re-
sponse to oncological treatment [1]. Since the clinical
implementation of positron emission tomography/
computed tomography (PET/CT) and—later—positron
emission tomography/magnetic resonance (PET/MR), an
increasing number of oncological patients undergo such
exams, owing to their often decisive impact [1].
Traditionally, such medical images are assessed qualita-
tively by the trained human eye, in critical cases by
many eyes [2]. Nowadays, there is a trend toward
computer-based and artificial intelligence-aided ap-
proaches [2]. Innovative methods for the quantification
of imaging findings, or for extracting and translating
data within such images, might be particularly useful
in nuclear medicine [2]. Multiomics is one of the most
complex approaches to diseases [2]. In oncology, it
takes into account the molecular profile of cancer and
uses as information sources not only DNA but also
RNA, proteins, metabolites as well as medical imaging
(radiomics) [2].
Biomarkers in Nuclear Medicine
A biomarker is any characteristic item that can be mea-
sured with high reproducibility as an indicator of nor-
mal physiological or pathological processes, or re-
sponses to a given exposure or intervention, including
therapeutic ones [3]. Biomarkers are also present in im-
aging modalities and are expected to play an increasing
role in the medicine of the future [3].
In nuclear medicine, there are numerous radiotracers
that highlight specific organs, tissue, and even cellular
characteristics and functions [3]. One of the most im-
portant radiotracers is FDG (fluorodeoxyglucose) that
serves as a surrogate marker for glucose metabolism,
which is often increased in inflamed and neoplastic
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tissue [4]. Traditional nuclear medicine image reading
relies on the qualitative assessment of abnormal high
(or low) radiotracer uptake in certain body parts, or on
the quantitation of such uptake using measures of single
or multiple voxels [4].
Radiomics
Radiomics is an inherent part of the multiomics termi-
nology, which describes the use of computer-based
high-volume imaging analysis, generating mineable data
that can describe tumor heterogeneity features of, e.g.,
texture, shape, size, edge, and wavelet [5]. Radiomic
extraction need to be done systematically and follow
quality protocols. There are multiple challenges for
radiomics, practically mainly reproducibility and redun-
dancy, but also costs and transferability [5]. Innovative
studies involving multiomics technology have been re-
cently published in the area of predictive, preventive
and personalized medicine (3P medicine) [11,12].
Recent advances of radiomics and machine learning in
medical services
Arshad et al. in a multicenter study with 358 subjects
analyzed the validation of radiomics in FDG-PET as a
risk stratification image biomarker for non-small-cell
lung cancer (NSCLC) with regard to radiotherapy and/
or chemotherapy response [6]. They discovered a pre-
dictive radiomics feature that was independent of other
already known prognostic factors, such as tumor volume
and disease stage, and was also independent of the PET/
CT machines [6].
Vuong et al. tested the interchangeability of radiomic
features in FDG-PET/CT and FDG-PET/MR. They
found higher stability for shape, intensity and texture,
and lower stability for wavelet features [7]. They con-
cluded that the features of shape and intensity were
robust among the two imaging modalities. They also
concluded that instability of specific radiomic features
need to receive attention when being transferred from
PET/CT to PET/MRI or when are used in combination
[7].
While not exploiting radiomics as per definition,
Schwyzer et al. studied a machine learning algorithm
(deep neural networks) that was able to detect lung can-
cer fully automatically on FDG-PET images even at
very low dosage levels [8].
Biobanking in medical imaging
Biobanks play an important role in the discovery of
medical biomarkers [9,10]. A biobank consists of a da-
tabase of medical information derived from samples of
healthy and diseased patients [9]. Imaging biobanks are
also encouraged by international medical societies
[9,10].
Conclusions and PPPM recommendations
Predictivemedicine: Radiomics are a promising tool for
predicting individual outcomes such as tumor aggres-
siveness, tumor recurrence, therapeutic response and
tumoral gene expression [11]. Machine learning soft-
ware may improve the data mining of radiomics and
eventually automatize medical image analysis.
Preventive medicine: Image analysis through radiomics
and machine learning may prevent iatrogenesis, e.g.,
by decreasing unnecessary and ineffective treatments,
based on precogni t ion of t rea tment response .
Biobanks foster international medical cooperation
and drug discovery, revealing changes at the molecu-
lar level (multiomics approach) in a suboptimal stage,
with the ulterior motive of preventing disease or forc-
ing early diagnosis.
Personalized medicine: Multiomics are a bridge to per-
sonalized medicine. Radiomics personalize medical im-
aging, creating a new role for image analysis in tumor
staging [11]. Machine learning software may help indi-
vidualize image findings by data mining [2]. Biobanks
unify medical knowledge and improve individualization
of treatments.
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Introduction
Advances in modern medicine have given us the opportunity
to identify many diseases before they occur and in a timely
enoughmeasure to apply preventative procedures so that mor-
bidity and mortality may be avoided. As maternal and perina-
tal mortality has decreased in many countries, the focus of
perinatal medicine continues to be expanded to include further
examination of maternal and fetal health indicators. The
laboratory’s role in risk management differs strategically ac-
cording to the phase of pregnancy [1].
As early as the first visit to the gynecologist, when the physi-
cian combines data about the mother with the findings of
biophysical and biochemical tests, specific risks that can lead
to a variety of pregnancy complications can be identified.
Those include: miscarriage and fetal death, preterm delivery,
preeclampsia, gestational diabetes, fetal growth restriction,
etc.
Screening for chromosomal aberrations
Down’s syndrome (DS) is the most common chromosomal
abnormality in humans. The risk of the birth of a child with
DS increases with the mother’s age. Currently, screening for
Down’s syndrome is offered to all pregnant women and the
screening test varies according to the week of pregnancy. DS
screening strategies involve the more traditional second tri-
mester serum biochemistry tests, the first trimester tests that
combine ultrasound markers and serum biomarkers, and the
most effective system is the integration of both tests.
Screening methods include detection of cell-free fetal DNA
from a maternal serum as well.
Between 10 and 12 weeks of pregnancy, a combined
test is offered. The test combines the results of the
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determination of pregnancy specific protein A (PAPP-A)
and free beta-hCG in maternal serum with measurement
of fetal nuchal translucency using ultrasonography
(USG). Additionally, the USG examination indicates
the presence of the nasal bone and flow in the ductus
venosus, hepatic artery, and across the tricuspid valve
bringing other screening improvements [2].
In the second trimester, the risk of having a child with DS is
calculated from the levels of alpha-1-fetoprotein (AFP), hu-
man chorionic gonadotrophin (hCG), unconjugated oestriol
(uE3), and inhibin A. This test is considered obsolete on its
own and is only intended for women who come to the gyne-
cologist after the 15th week of pregnancy.
The integrated test commonly evaluates the results from
testing in both trimesters. Its efficacy is the best (more
than 90%); it is also the safest and most cost efficient.
Where ultrasonography is not available, a serum inte-
grated test is recommended [3]. The risk is only calcu-
lated from the biochemical markers (free beta-hCG,
PAPP-A, AFP, uE3, and inhibin A) and the test is as
efficacious as the combined first-trimester test [2].
New developments in the area of screening include the possi-
bility of testing for Down’s syndrome by extraction of cell-
free nucleic acids from a maternal serum sample. The non-
invasive prenatal testing (NIPT) has a detection rate approxi-
mately 96% for trisomy 21, with a false positive rate of 0.04%
in a general obstetric population. This rate compares favorably
to the combined screening detection rate of 85–90% and false
positive rate of 3–5% [2]. There are different models of im-
plementation NIPT in the screening, one of them is on
Schema 1.
NIPT is a profoundly important development in prenatal care
that is substantially advancing the individual patient and pub-
lic health benefits achieved through conventional prenatal
screening. Even the best combination of USG findings, bio-
chemistry variables, and NIPT are only predictive screening
methods. Invasive methods (amniocentesis or chorionic villus
sampling) are used for confirmation of diagnosis by examina-
tion of the chromosomes of the fetus.
Preeclampsia
Preeclampsia (PE), which affects about 2% of pregnancies, is
a major cause of maternal and perinatal morbidity and
Schema 1 Screening algorithm with the involvement of risk assessment of early pre-eclampsia and thyroid disorders in chromosomal defects screening
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mortality. Preeclampsia is a complication of pregnancy in
which affected women develop hypertension and proteinuria.
However, only a minority of pregnant womenwith high blood
pressure are at risk of preeclampsia. Further examinations are
used to detect these women. It is a combination of maternal
characteristics and history with uterine artery pulsatility index
(PI), mean arterial pressure (MAP), serum pregnancy-
associated plasma protein-A (PAPP-A), and placental growth
factor (PLGF) at 11–13 weeks’ gestation [4]. The prevalence
of PE can potentially be halved by a strategy of early predic-
tive identification of the high-risk group and the prophylactic
use of aspirin (150 mg at night) [5,6].
Thyroid diseases in pregnancy
Thyroid diseases are quite frequent among young women.
Undiagnosed thyroid diseases can have serious consequences
during a person’s life. Pregnancy creates a burden on the thy-
roid, which can result principally in hypothyroidism and/or
postpartum thyroiditis in women having antibodies against
thyroid peroxidase (TPOAb) positivity. Thyroid hormones
are crucial for the growth and maturation of many target tis-
sues, especially the brain and skeleton. In case of maternal
hypothyroidism, substitution with levothyroxine must be
started in early pregnancy. After the 14th gestational week,
the fetal brain development may already be irreversibly affect-
ed by lack of thyroid hormones [7,8].
The prevalence of manifest hypothyroidism in pregnancy
reaches about 0.3–0.5%. The prevalence of subclinical hypo-
thyroidism varies between 4 and 17%, strongly depend-
ing on the definition of the upper TSH cut-off limit.
Hyperthyroidism occurs in 0.1–1% of all pregnancies.
Positivity for TPOAb has been reported in between
5.1% and 12.4% of cases [9].
The main laboratory parameters for thyroid diagnosis are
thyroid-stimulating hormone (TSH), free thyroxine (FT4),
and TPOAb. TSH in pregnancy is physiologically lower due
to the high level of hCG.
Thyroid disorders in pregnancy are associated with serious ma-
ternal, fetal, and newborn complications. The universal screen-
ing for hypothyroidism in pregnancy is recommended but it is
necessary to take into consideration the necessity to determine
the reference interval for the investigated region and the analyt-
ical method used [10]. If this specific reference interval is not
available, the recommended interval for TSH in the first trimes-
ter should be 0.1–2.5 mIU/L [7]. It is the aim of preventive
medical care to diagnose thyroid function failure as soon as
possible, when the disease is at its most easily curable stage.
For some diseases of the mother (thyroid disorders, gestation-
al diabetes, preeclampsia) or fetus (chromosomal deviations,
growth restriction), a single blood collection is enough for a
screening examination.
Conclusions and PPPM-based expert recommendations
& Screening programs are an important part of modern med-
icine and fit the PPPM principles.
& Screening for chromosomal aberrations combines USG
and biochemical markers. A suitably selected algorithm
will incorporate NIPT into screening with increasing de-
tection rate without unnecessarily increasing costs.
& Screening for preeclampsia allows early detection and pre-
vention of serious fetal developmental complications that
may also endanger the mother’s life.
& Screening for hypothyroidism allows an early diagnosis of
thyroid function failure, when the disease is still in a cur-
able stage.
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Introduction
3PM concepts. The high prevalence and increasing intensity
of periodontal disease make urgent the problem of active pre-
vention of periodontal disease. In this aspect, clinical peri-
odontology needs early diagnosis, prevention and early treat-
ment of the corresponding disease [1].
Periodontal diseases are becoming more common among
young patients [2,3].
Bad posture caused by excessive use of computers and elec-
tronic gadgets can affect dynamics of blood flow greatly. A
prolonged static posture leads to constriction of vessels of
neck, in particular, external carotid artery, as a result of which
centralization of blood circulation occurs, blood is
redistributed and its main volume flows to the brain. Thus,
periodontal tissues cease to receive sufficient blood supply
[4,9].
The “Text neck” syndrome has taken on an epidemic charac-
ter and is most acute for schoolchildren, students, and IT-
specialists [5].
The purpose of the study was to reveal the existence of the
causal connection between incorrect posture when using com-
puters and mobile devices and circulatory disorders in peri-
odontal tissues.
Methods The study involved 60 persons aged 19 to 25 years
(female – 73.2%, male – 26.8%) and used the following
methods—questionnaire, survey, standard dental examination
(determination DMF, PMA, BOP, OHI-s indexes)), and func-
tional examination using the ultrasonic dopplerography
“Minimax-Doppler-K” [6,7]. The participants in the study
were people whose activities do not involve daily work on
computers and mobile devices and people associated with
information technology.
The research objectives also included the development of a
leaflet-memo for the prevention of the “Text neck” syndrome.
Results According to the questionnaire, subjects use
smartphones more often (95%). At the same time,
41.5% of the subjects spend from 2 to 4 h daily with
a mobile device in their hands (group No. 1), 39% –
more than 4 h a day (group No. 2), 19.5% – less than
2 h a day (group No. 3).
Moreover, questionnaires showed that only 21.9% of respon-
dents know about the syndrome.
The results of the survey in both groups turned out to
be different. According to the survey, characteristics of
the representatives of each group of subjects were
compiled.
In a functional study, initial level of the average linear velocity
of blood flow in group A was 0.57 cm/s and 0.47 cm/s in
group B.
After a 30-min experiment, indicators decreased to 0.35 cm/s
(group A) and 0.32 cm/s (group B).
After 1 h, hemodynamic parameters in both groups were al-
most equal and amounted to 0.30 cm/s (groupA) and 0.28 cm/
s (group B).
After 2 h it was 0.27 cm/s (group A) and 0.22 cm/s (group B).
3PM related conclusion and outlook
During the study, it was established experimentally that long
head tilting and poor posture when working with computers
and electronic gadgets have a negative effect on microcircu-
lation in periodontal tissues.
Early diagnostic of the initial manifestations of periodontal
diseases is very important to prevent the development of more
severe forms of the disease, which was previously lacking [8].
The overall approach provided here will allow more accurate
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predictions, which will enable better patient stratification and
early detection of predispositions followed by preventive
measures. Text neck syndrome disorders should be included
in the list of globally screened diseases because it can change
the local periodontal microenvironment [10].
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Introduction The most common problem in managing
of patients with bronchial asthma (BA), especially
children, is to predict and the means to prevent exac-
erbations in their early stage in order to maintain
sufficient control over the disease and prevent further
progression and deterioration. BA is certainly a com-
mon disease in pediatric group of population, with
signif icant disrupt ion of qual i ty of l i fe (QoL)
[1,2,7]. Children with BA show the decrease in all
of their quality of life areas, specifically physical
and emotional, which primarily affects their personal
school study profile, social activity and psycho-
emotional development [3–6]. Such a preventive ap-
proach is especially relevant in the aspect of the con-
cept of PPP-medicine that allows personalising the
prediction of the disease progression and maintaining
the optimal health status at the level of both second-
ary and tertiary prevention in chronic diseases, which
is especially important in children and young people
[8–10].
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Aim To identify the early signs of exacerbations, in terms of
prevention and prediction of further progression and deterio-
ration of disease, in children with bronchial asthma.
Materials and methods In this study, which was conducted
in the Samara Regional Children’s Sanatorium, 62 children
with moderate BA, aged 5 to 11 years (9.6 ± 1.7 years old):
38 boys (9.7 ± 1, 7 years old) and 24 girls (9.6 ± 1.8 years old),
participated. The patients received the basic therapy by GINA
as step 2/3. The children were observed during their treatment
in the pulmonological sanatorium, highlighting the areas of
the child’s personality functioning, most affected by BA/
clinical and functional signs of BA control, BA-test question-
naire and BA-quality of life (QOL) questionnaire (assessment
of symptoms, physical and emotional sphere) were analysed.
Statistical analysis was carried out with SPSS Statistics 19.0.
Results Significant differences were found in the integral
QOL indicator by the end of the sanatorium treatment
course: integral QOL indicator at admission to the san-
atorium - 123.4 ± 20.5, integral QOL indicator before
discharge from the sanatorium - 97.2 ± 9.7* (p < 0.05).
Significant differences were established in the following
parameters: the restrictions on the vital activity before
discharge over the last 7 days; the restrictions of vital
activity 3 months after discharge in total: restrictions of
vital activity in general - 31.67 ± 3.343, emotional
sphere in general - 6.170 ± 0.924 (p < 0.05). When
analysing the average values of the integral QOL indi-
cator at admission and before discharge from the sana-
torium, depending on the sex, significant dynamics dif-
ferences in QOL were found at: integral QOL indicator
in boys with BA - 97.220 ± 9.668, restrictions of vital
activity in boys with BA - 6.300 ± 0.949, BA symptoms
in boys with BA before discharge - 6.140 ± 0.770
(p < 0.05).
When comparing the individual answers scoring of the QOL
for boys, significant differences were found in the following
parameters. Restrictions on vital activity before discharge -
question 1 (How often BA bothers the child during his/her
physical exertion (such as running, swimming, other sports
activities, walking uphill/stairs and riding a bike) over the last
7 days?), Symptoms of asthma before discharge - question 20
(How often because of BA the child sleep badly at night over
the last 7 days?). In girls, before discharge from the sanatori-
um, the integral QOL indicator showed significant differ-
ences: integral QOL indicator in girls - 132.330 ± 11.622, re-
strictions of vital activity in girls - 33.86 ± 0.378, emotional
sphere in girls - 6.33 ± 1.211 (p < 0.05).
The discriminant analysis with the standardized canoni-
cal coefficient of the discriminant function (SCCDF)
was performed. The most informative indicators were:
Integral QOL indicator at sanatorium admission;
Integral QOL indicator before discharge from the sana-
torium; Integral QOL indicator at sanatorium admission -
1.292; Integral QOL indicator before discharge from the
sanatorium - 5.813. The AUROC-curve analysis showed
the reliable sensitivity/specificity and information con-
tent of such indicators as: The emotional sphere sum-
mary parameter upon admission and before discharge in
sanatorium in general. The integral QOL indicator be-
fore discharge was highly sensitive/specific. Integral
QOL indicator at admission - 0.595; Integral QOL indi-
cator before discharge - 1.000; The emotional sphere at
admission in general was as 0.627. The emotional
sphere before discharge in general was as 0.614, The
integral QOL indicator 3 months after discharge indicat-
ed as 0.515 (AUROC≥0.5).
Conclusion Thus, identification of early signs of exacerba-
tions in terms of prevention and prediction by assessing the
quality of life in children with bronchial asthma, in the chil-
dren’s pulmonary sanatorium, highlighting areas of the child’s
personality functioning, most susceptible to BA, against the
background of sanatorium treatment, revealed significant dif-
ferences in the integral QOL parameter in children with BA:
restrictions of vital activity in terms of physical activity and
emotional sphere with the final dynamics of the integral QoL
indicator. At the same time, discriminant analysis confirmed
the information content, and AUROC analysis showed signif-
icant sensitivity/specificity of QOL integral indicator parame-
ters in monitoring QOL in children with bronchial asthma at
the sanatorium stage which allow to predict and prevent ex-
acerbation and deterioration at all stages of medical care from
outpatient to sanatorium care with the generation of a
personalised long-term management and preventive plan.
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Introduction
Vitamin D is produced by the effect of sun rays on the
skin which is where vitamin D3 (cholecalciferol) is
formed. Vitamin D is metabolized in the liver to create
the “stock form” of vitamin D (calcidiol). Its blood
levels are commonly measured to assess the overall sta-
tus of vitamin D in the human body [1]. Types of vita-
min D are shown in Table 1.
Table 1 Types of vitamin D
Vitamin D type Trivial name Description
Vitamin D2 Ergocalciferol Present in plants and taken in
as part of the diet.
Vitamin D3 Cholecalciferol Animal origin and taken in
via diet or produced in the
skin.
25-hydroxyvitamin D Calcidiol Produced by metabolism of





Calcitriol Active metabolite acts as a
steroid hormone.Produced
by metabolism of calcidiol
in the kidneys and in other
tissues.
The synthesis of vitaminD in the skin only occurs if the angle of
impact is 45° or higher. In central Europe, vitamin D “from the
sun” is only obtainable from mid-April to the first week of
September [2]. The role of vitaminD in the prevention of rickets
in children, osteomalacia in adults and osteoporosis in the elder-
ly has been understood as important for many years now. A
significant effect on the cognitive functions has been recorded.
S43
EPMA Journal (2020) 11(Suppl 1):S1–S133
Furthermore, in elderly people with a vitamin D deficiency, a
higher number of fractures is attributed to their reduced coordi-
nation of movement and sense of balance [3]. Vitamin D en-
hances muscle protein synthesis, affects calcium and phosphate
transport through cell membranes, plays a role in muscle fiber
growth and differentiation, and has a positive effect on contractile
fibers and thus muscle strength. It is believed to boost faster
muscle regeneration after intensive training, and there is contin-
ued speculation on its potential for athletes’ performance capacity
[4]. Vitamin D stimulates both innate and acquired immunity
throughout life. An association has been shown between winter
and spring viral and bacterial infection, and weaknesses in the
immune system caused by vitamin D deficiency [5].
Prevention of Vitamin D Deficiency
The general awareness of the benefits of sufficient levels of
vitamin D in the human body remains unsatisfactory.
Systematic and targeted prevention is the first and foremost
powerful PPPM tool which should be employed to raise
awareness among the professional and general public [6].
Proper stratification and spreading of potentially preventive
information are necessary in order to prevent vitamin D defi-
ciency and reduce the risks associatedwith inadequate vitamin
D levels [7].
Insufficient Serum Levels of Vitamin D as a Predictive
Factor for Supplementation
The link between low levels of vitamin D and many civiliza-
tion diseases has been recognized: e.g., autoimmune diseases,
multiple sclerosis, diabetes, infertility, osteoporosis and differ-
ent types of cancer [8]. Confirmed low vitamin D levels
should always be considered a predictive factor for vitamin
D supplementation with respect to the conditions presented by
each individual (age, gender, genetics, comorbidities, etc.), all
of which must be carefully considered and taken into account
as part of a personalized approach [9,10].
Personalization of Supplementation
According to the available statistics, 70% of the world popu-
lation is vitamin D deficient. This includes people living at
higher latitudes but, surprisingly, also populations living at
latitudes where sunshine is plentiful year round [11].
Vitamin D supplementation is a logical preventive step which
could be used to rectify this current unfavorable status.
However, only personalized doses can lead to effective and
safe supplementation [12]. Each supplementation should be
initiated as a result of the measurement of calcidiol, the main
stock form of vitamin D. Recommended doses of supplemen-
tal vitamin D are shown in Table 2 in correlation with the
serum levels of calcidiol measured.
Table 2 Calcidiol levels and the corresponding supplementation doses









Vitamin D3 (cholecalciferol) is the preferred form for supple-
mentation. The daily requirement of vitamin D3 is reported to
be 15–20 μg/day (600–800 IU/day). This value is now only
considered to be satisfactory in subjects with regular exposure
to sunlight. In cases where lower levels of are suspected (e.g., if
exposure to sunlight is limited) the recommended dose should be
increased to 50 μg/day (2000 IU/day), or higher [13]. A notice-
able effort has been made to achieve better standardization in
vitamin D measurement over recent years [14]. Even though
toxic or side effects are relatively rare, measurement of vitamin
D levels helps monitor treatment and helps prevent overdose
[15]. Therefore, measurement of vitamin D serum levels is ap-
propriate. Only this described procedure can assure proper, per-
sonalized supplementation with the highest efficacy and a posi-
tive impact on the health status of patients [16].
Conclusions and PPPM-Based Expert Recommendations
& Vitamin D acts as a steroid hormone and is involved in
many metabolic processes in the human body.
& PPPM principles can serve as a useful tool in the preven-
tion of vitamin D deficiency by indicating predictive and
personalized supplementation.
& Low vitamin D serum levels should be the clear predictive
factor for supplementation in each age group; from new-
borns to the elderly, and not only in childhood, as was
previously routinely applied.
& Methods for vitamin D monitoring are currently available
in almost every laboratory. When supplementation of vi-
tamin D is indicated, the monitoring of vitamin D
(calcidiol) serum levels is strictly recommended to assure
optimally personalized vitamin D doses.
& The toxicity of vitamin D was overstated in the past.
Recent research has emphasized the optimal vitamin D
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levels required to assure its proper effect in all the vitamin
D related metabolic processes.
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The aim of study was to develop personalized treatment
schemes using the acupuncture (AP) in combination
w i t h p h a rma c o p u n c t u r e ( P hP ) a n d p s y c h o -
pharmacotherapy (PPhT) in order to reduce number of
side-effects, relieve depression and microcirculation dis-
orders for elderly patients with polymorbid pathology
and provide evidence of the effectiveness of complex
treatment in comparison with PPhT.
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The study outlines. The study included 127 patients (30 men
and 97 women), average age 65 ± 4.6 years, treatment dura-
tion from 5.4 to 11.5 years. Patients were treated at the Center
of borderline disorders with a diagnosis of chronic cerebral
ischemia (CHCI) (ICD - 10), diabetes mellitus of type 2 [1,2].
The Minnesota Multiphasic Personality Inventory question-
naire was used for the personalized treatment approach. The
questionnaire helped to reveal anxiety-depressive syndrome
in 52 people and depressive-hypochondria syndrome in 75
patients.
Patients who were assigned (according to the randomi-
zation procedure) to the control group (n = 30) received
only PPhT: antidepressants, tranquilizers, nootropics, va-
soactive, hypoglycemic drugs. The treatment group of
97 patients was divided into three subgroups split by
acupuncture treatment methods in combination with
PPhT:
Group 1, received AP, (n = 34): the course consisted of
10–12 sessions, conducted every other day;
Group 2 received PhP (n = 32) with antihomotoxic
drugs (AHTD) from the Biologische Heilmittel Heel
GmbH company according to the developed recom-
mendations [2]: Traumeel S, Cerebrum compositum
N. Injections were performed into the area of acu-
puncture points at 0.3–0, 5 ml each. The course
duration was 4 weeks, twice a week;
Group 3 received a combination of AP and PhP, (n = 31):
pharmaco-puncture sessions were held three times a
week, simultaneously with acupuncture sessions lasting
4 weeks.
According to the PHQ-9 health questionnaire, different
level of depression were observed: mild in 11% pa-
tients, moderate in 47.3%, middle severity in 37%, se-
vere depression in 4.7%.
Cerebral microcirculation (CMC) was examined using a
Slit Lamp SL-45 Shin Nippon (Japan). The conjunctival
microcirculation index (CMI) was calculated; 63.8% of
patients had mild CMC disorders, and 36.2% of patients
had moderate severity CMC. Among patients with
anxiety-depressive syndrome, spastic characteristics in
the microvasculature were prevailed. In the patient
group with depressive-hypochondriac syndrome, disor-
ders of venous outflow and rheology prevailed. A de-
crease in the number of functioning capillaries was ob-
served in 28 patients with severe asthenic symptoms.
Microcirculatory disorders with different qualitative
and quantitative characteristics were regarded as predic-
tors of treatment effectiveness. Depression rates and
CMC parameters were evaluated on the 28th day.
Results
Clinical indicators improved significantly in treatment
groups: headache, dizziness and gait unsteadiness de-
creased 4–5 days earlier than in the control group
(p < 0.05); blood pressure stabilized in the AP groups
after 6th–8th session (see summarising Fig. 1).
Complex therapy including PhP and a combination of
AP + PhP had a significant effect for the reduction of
microcirculatory disorders. Using AP in patients with
anxiety-depressive syndrome, CMI decreased by
21.3%, and in patients with depressive-hypochondriac
syndrome, CMI decreased by 17.5%. The therapeutic
effect was reached faster and was more long-lasting
due to steady anti-depressive and vegetative-stabilizing
effects.
In the control group, the decrease in microcirculation
disorders was not significant, and PPhT reduced the
severity of anxiety and depression. However, the con-
trol group could not get a pronounced improvements in
affective and vascular disorders by the 28th day in com-
parison with AP groups. Patients felt weakness and de-
creased appetite.
Improvements in clinical and psychological symptoms
and in the level of microcirculation were observed ear-
lier in AP groups: for patients with anxiety-depressive
syndrome results were achieved at the 6–7 session, for




















Fig. 1 Dynamics of conjunctival microcirculation index (CMI) in the main
and control groups with various psychopathological syndromes (*p< 0.05)
before and after treatment. Footnote:A–D – patients with anxious-depressive
syndrome. D–H – patients with depressive-hypochondriac syndrome. PPhT
– control group. AP – acupuncture group. PhP – pharmacopuncture group.
AP+PhP – acupuncture and pharmacopuncture group
S46
EPMA Journal (2020) 11(Suppl 1):S1–S133
were achieved at the 8–9 session. Combined therapy
significantly reduced the side-effects of PPhT [3,4] and
significantly increased adherence to treatment at the
same time. This specificity of AP determined the com-
patibility between patients and physician’s efforts to
overcome risk-factors.
Conclusions
1. The use of AP and PhP with antihomotoxic drugs helped
to improve the clinical and psychological condition and
level of the microvasculature in patients from treatment
groups in shorter terms. In the control group, which used
PPhT, improvement was achieved on 22 ± 1.5 day, which
corresponded with the l manifestation of antidepressants
efficacy.
2. The effectiveness of complex treatment, including AP
and PPhT at the same time, is significantly higher for
elderly patients with chronic cerebral ischemia, metabolic
and depressive disorders, than in the group only taking
psychopharmacological drugs.
Current research shows the role of acupuncture in the
complex treatment of elderly patients. This combinated
treatment correlates with principles of PPPM: a personal-
ized approach takes into account the psychological status
of the patient; it prevents side-effects of pharmacotherapy.
Collaboration with patients is crucial involving them in
the treatment process that helps to overcome the modifi-
able risk-factors effectively for patients in the treatment
group.
References
1. Camus V, Kraehenbuhl H, Preisig M, Bula CJ, Waeber
G. Geriatric depression and vascular diseases: what are
the links? J Affect Disord. 2004;81(1):1–16. https://doi.
org/10.1016/j.jad.2003.08.003
2. Duarte AA, Mohsin S, Golubnitschaja O. Diabetes care in
figures: current pitfalls and future scenario. EPMA J.
2018;9(2):125–131. https://doi.org/10.1007/s13167-018-
0133-y.
3. Sabel BA, Wang J, Cárdenas-Morales L, Faiq M, Heim
C. Mental stress as consequence and cause of vision loss:
the dawn of psychosomatic ophthalmology for preven-
t i v e and pe r sona l i z ed med i c i n e . EPMA J .
2018;9(2):133–160. https://doi.org/10.1007/s13167-
018-0136-8.
4. Agasarov LG, Davyan OS, Edelev DA. Mechanisms,
efficiency and security of pharmacopuncture. J New
Med Tech. 2018;25(4):110–115. https://doi.org/10.
24411/1609-2163-2018-16280
Do Biomarkers Contribute to a Personalized Approach to
Obstructive Sleep Apnea Syndrome?
Slouka D1, Gal B3, Betka J4, Topolcan O2, Kucera R*2
1Department of Otorhinolaryngology, 2Department of
Immunochemistry Diagnostics, University Hospital in
Pilsen, Charles University, Faculty of Medicine in Pilsen,
Czech Republic
3Masaryk University, Faculty of Medicine, Department of
Otorhinolaryngology and Head and Neck Surgery, Brno,
Czech Republic
4Charles University in Prague, 1 st Faculty of Medicine,
Department of Otorhinolaryngology and Head and Neck
Surgery, Prague, Czech Republic
*Corresponding author: Radek Kucera, Ph.D., Associate
Professor, Department of Immunochemistry Diagnostics,
University Hospital Pilsen, Dr. E. Benese 1128/13, 305 99
Pilsen, Czech Republic; e.mail: kucerar@fnplzen.cz,
ORCID: 0000-0002-2739-2302
Keywords: sleep apnea syndrome, obstructive sleep apnea
syndrome, predictive biomarkers, pentraxin-3, primary pre-
vention, predictive factor, positive airway pressure therapy,
patient stratification, genetic burden, personalized treatment
Introduction
Sleep Apnea Syndrome (SAS) is defined as repeated apnea
breathing during sleep lasting more than 10 s. The incidence
of SAS in the adult male population over 40 years of age is 4%
and in the female population after menopause 2%. We distin-
guish 3 forms of SAS: obstructive (80%), central (10%) and
mixed (10%). Risk factors include obesity, large neck circum-
ference and anatomical obstruction in the upper airways.
Cardiovascular and metabolic disorders are common comor-
bidities of OSAS [1].
The basic diagnosis of OSAS consists of upper airway paten-
cy and sleep monitoring. Lighter forms of the condition are
indicated for surgical treatment while in heavier forms, posi-
tive airway pressure therapy (PAP) is preferred. Obese indi-
viduals need to lose weight and adopt a healthy lifestyle. The
current OSAS diagnostics is time consuming, placing high
demands on personnel and technology. In the past decade,
the principles of personalized medicine have begun to be ap-
plied to OSAS. The first task should be to improve prevention
by emphasizing a healthy lifestyle that minimizes OSAS risk
factors [2]. Personalized treatment, taking into account indi-
vidual conditions such as ethnic, gender, genetic or phenotyp-
ic differences, can bring increased benefits to the patient [3].
The use of biomarkers in OSAS diagnostics within the frame-
work of the principles of preventive, predictive, personalised
medicine is a field that is insufficiently explored [4]. We de-
cided to study the ability of selected biomarkers to identify
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OSAS patients among a wider cohort of healthy people. The
following blood biomarkers were tested: C-reactive protein
(CRP), pentraxin-3 (PTX-3), interleukin-6 (IL-6), high sensi-
tive troponin (hsTnI) and brain natriuretic peptide (BNP).
Materials and methods
In total we evaluated the results of 134 persons. The control
group consisted of 70 persons, the OSAS group of 64 patients.
Inclusion criteria: OSAS indicated for the treatment of positive
airway pressure (PAP) (apnea-hypopnea index, AHI ≥ 15), no
prior OSAS conservative treatment, no prior OSAS surgical
treatment, complete sleep monitoring results. AHI is defined as
the average number of apnea-hypopnoea events per hour of
sleep. Exclusion criteria: incomplete documentation of sleep
monitoring, chronic obstructive pulmonary disease, previous
OSAS treatment, previous upper respiratory tract surgery, patient
non-compliance. The age characteristics of the compared groups
are shown in Table 1. The age of the compared groups did not
differ significantly (p = 0.1443). Peripheral bloodwas drawn and
after serum separation the levels of CRP, PTX-3, IL-6, hsThI and
BNP were determined.
Table 1 Age characteristics of the studied group
Studied
Group





64 57.5 32.0 86.0 p = 0.1352
Control
group
70 56.5 38.0 81.0
Results
Table 2 shows the comparison of the biomarker levels be-
tween the OSAS group and the group of healthy persons.
With the exception of BNP, all the examined biomarkers
had statistically significantly higher levels in the OSAS group
compared to the control group. We calculated the AUC for
each individual biomarker. The values of the AUC are
shown in Table 3. The best values were achieved by
PTX-3 (AUC = 0.7346). We created a multivariate mod-
el using the logistic stepwise regression. The AUC of
the model was the highest (AUC = 0.7679) but with no
clinical relevance compared to the best individual mark-
er PTX-3 (p < 0.5556).
Table 2 Biomarker levels: OSAS group vs. control group
















































p value PTX-3 vs. 3-parameter model: p = 0.5556
Data Interpretation
The panel of biomarkers was selected based on their close relation
to the cardio- and cerebrovascular complications of OSAS.
Sahlman et al. [5] have explored CRP potential for use with
OSAS. The authors demonstrate a relation to OSAS, but with
no significant benefit for diagnosis. These results are in line with
our conclusions. PTX-3 is secreted in damaged tissue. In agree-
ment with our results, Kanbay [6] and Kobukai [7] reported the
benefit of PTX-3 for OSAS diagnosis. IL-6 is involved in the
activation of “acute phase” proteins. In our study, in agreement
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with Liu [8], we demonstrated the association between IL-6 and
OSAS, but with no wider clinical utility. The new generation of
highly sensitive troponin I assay has allowed for the
extension of indications from myocardial infarction de-
tection to small myocardial cell damage, particularly in
connection with a number of chronic diseases. Whereas
Maeder [9] did not show a significant increase in hsTnI,
we demonstrated the statistically significant increase of
hsTnI in the OSAS group. Serum BNP levels were not
associated with the presence of OSAS in our study. We
created a multi-parameter model, a proven tool of the
personalized approach in diagnostics [10], using PTX-3,
CRP and hsTnI. This model achieved the highest AUC
but we still have to prove the statistical significance in
a larger cohorts.
Conclusions and PPPM-based expert recommendations
& The primary prevention of OSAS should be im-
proved by placing a preventive emphasis on a
healthy lifestyle.
& Currently, sleep monitoring has no comparable alterna-
tive. There are, as yet, no simple applicable predictive
factors for the stratification of patients and the design of
personalized treatment.
& PTX-3 serum levels were identified as one possible bio-
marker for the above mentioned purpose.
& Themulti-parametermodel looks promising, butwe need larger
cohorts to prove its ability to identify patients with OSAS.
& Early diagnosis of OSAS made using technically simple
methods will allow a higher level of personalization of
treatment and thereby higher treatment efficiency.
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Introduction
Traditional medicine is aimed at the treatment of diseases and,
to a lesser extent, at their prevention. The future is for predic-
tive, preventive and personalized medicine [1–3]. The bio-
markers can be used as a first criterion in evaluation of the
development of an anti-premature aging approach in person-
alized medicine and to determine, monitor and track the aging
process. However, it is essential to demonstrate the clinical
utility of biomarkers prior to their implementation in medical
services [1, 2]. Recent studies show that the use of only bio-
markers is not enough in developing technologies of active
longevity and personalized medicine. Moreover, the publica-
tions in the field have highlighted the value of predictive,
preventive and personalized medicine and its effects on qual-
ity of life, active aging and life extension [4–6]. This paper
introduces an approach for developing active longevity tech-
nology based on the determination of the aging rate index.
Methods
Analytical methods have been used to analyze advantages and
disadvantages of existing medical methods for assessment of
biological age and aging rate index as well as current trends
and technologies of personalized medicine. Moreover, a sig-
nificant number of medical methods have been examined:
clinical methods, in/out lab-based testing methods and proce-
dures, methods of biomarkers assessment, biomarkers group
of physical examinations methods, olfactory test, mental
health and cognitive disorders tests, and biological/
chronological age estimation techniques.
Results and discussion
The aging process affects all the systems of a human being. In
general, an increase in chronological age results in an increase
in biological age. It means a reduction of physical and mental
health of individuals; however, the aging rate can be different.
The results revealed that the aging rate index is a complex
indicator calculated as an integrated index from a number of
following medical tests for a particular person at a specific
chronological age. In general, the calculation of the aging rate
index consists of the following stages: firstly, a selection of
specific indicators from which the integral indicator is built,
secondly, a transformation of indicators for the purpose of
comparability is needed, and finally, choosing a method for
aggregating the transformed specific indicators to unify the
index is required. The transformation stage is essential and
complex due to the fact that different specific indicators are
measured using different methods and units. It is also impor-
tant to have insignificant difficulties interpreting the overall
results of four or more biomarkers which are monitored con-
tinuously on a system basis.
Further studies should consider a number of tests. The bio-
markers (plasma albumin, alpha-1 acid glycoprotein, particle
size of low-density lipoproteins and citrates) are typically de-
termined based on a blood test (BT). A number of molecular
biomarkers relating but not limited to biological age are as
follows: a leukocyte telomere length, γ-H2A.X, DNA meth-
ylation, heterogeneity of CD38 in CD4+ CD27+ T cells, miR-
34a, miR-21, miR-126-3p and MIR31HG [7]. In addition, a
mental test (MT) is used to assess the contribution of the
current cognitive abilities [8]. For instance, 25–30% of people
aged 85 or older suffer from dementia diseases [9].
An olfactory test (OT) allows assessing age-related changes
[10], which are typically pronounced at the age of 65–80,
while an endurance test (ET) determines a reduction in phys-
ical ability due to daily physical activities, stress and fatigue.
Furthermore, the results of those tests vary for different indi-
viduals and relate to genetic and epigenetic factors. Thus, a
personalized approach to the results of four tests at different
periods of the chronological age of a person allows calculating
the aging rate index:
ARI ¼ f BT;MT;OT;ETð Þ
As a result a complex plan of medical and social activities
aimed at reducing the rate of aging and extend the active lon-
gevity of a person can be developed. The studies show that ARI
can be tailored for the needs of individuals in terms of person-
alizedmedicine, active aging and life longevity. It appears from
the studies that individuals can receive a targeted and precise
therapy, rehabilitation, physical excursuses, social programs,
environment and other technologies of personalized medicine.
Moreover, the integrated aging rate index with respect to per-
sonalized medicine is a useful tool for medical professionals
and policymakers to monitor outcomes of the public health of
society and take actions for the development and implemen-
tation of PPPM at the local, regional or country level.
Conclusions and outlook
The results revealed that it is hard to choose a specific aging
index, which reflects all the aspects of aging of human being.
The integrated aging rate index that was proposed in the paper
can be taken under consideration as an attempt to develop a
basis for choosing the technologies of personalized medicine
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for active aging and longevity. The index incorporates a num-
ber of markers for a given test, which are essential to carry out.
Furthermore, the integrated aging rate index can be a useful
tool for policymakers to monitor outcomes of public health
organizations and society and take actions for the develop-
ment and implementation of PPPM at the regional or country
level. Additionally, the future work will concentrate on devel-
oping and testing the models of personalized medicine for
active aging.We are confident that our research will also serve
as a base for future studies on predictive, preventive and per-
sonalized medicine and consolidate professionals in the field.
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Introduction
Sepsis and bacteremia of unknown origin remain a se-
rious problem in current healthcare. The prolonged in-
vestigations to discover the cause behind these condi-
tions can lead to a serious delay in starting targeted
therapy resulting in increased morbidity and mortality
[1]. Previous studies have confirmed that PET/CT with
the application of 18F-fluordeoxyglucose (18F-FDG-PET/
CT) is superior to computed tomography, magnetic res-
onance or conventional scintigraphy in detecting hidden
inflammatory processes [2, 3]. An analogous approach
to patients with sepsis of unknown origin could be
used. Such an imaging should detect the source of bac-
teremia which remains hidden on conventional imaging
methods [2]. In order to select a personalized treatment
for patients suffering from symptoms of sepsis of un-
known origin, 18F-FDG-PET/CT should be used in the
localization of the primary focal inflammation, and/or of
the metastatic spread of the infection within the same
organ system, or multi-systemic dissemination [4].
Moreover, personalized treatment is then tailored to the
affected organ or organ system using the targeted
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microbiological sampling (including the investigation of
antimicrobial treatment sensitivity), local surgical, or
mini-invasive therapy. Our investigation was aimed at
evaluating the value of 18F-FDG-PET/CT performed
early in the detection of the cause of sepsis of unknown




Our cohort was included a total of 50 patients (27
males, 23 females, mean age 56.6 years, ranging 26–
84 years) with SIRS of suspected or confirmed bacterial
origin. Imaging was performed when conventional clin-
ical or imaging strategy did not explain the patients’
condition within 72 h from the actual onset of SIRS
symptoms.
PET/CT procedure
We used PET/CT (BiographmCT 128 UltraHD, Siemens
Healthineers, Erlangen, Germany) for the hybrid imaging.
The glucose blood levels control was followed by an intrave-
nous application of 18F-fluorodeoxyglucose at 2.5 MBq/kg
per body weight. The data acquisition started 60 min after
the radiopharmaceutical application. The imaging covered
the whole body from vertex to toe. The data acquisition starts
with a CT after intravenous application of 80 ml of the iodin-
ated contrast material (Ultravist 370, Bayer Pharma, Berlin,
Germany), except in patients with renal failure, or with a doc-
umented allergic reaction to iodinated contrast material.
Analysis of the diagnostic performance
The laboratory findings prior to the imaging and during
the disease were documented in the digital clinical in-
formation system. The retrospective analysis was based
on a comparison between the 18F-FDG-PET/CT findings
and the clinical course of the disease, response to the
therapy (including documented changes after 18F-FDG-
PET/CT imaging) and microbiology lab results, includ-
ing cultivation and/or PCR. 18F-FDG-PET/CT results
were assumed to have a strong correlation to the cause
of the patient’s clinical state. The following modifica-
tions in therapy were considered triggered therapy:
change of antibiotics, surgery or mini-invasive abscess
drainage.
Results
18F-FDG-PET/CT results contributed to the detection of the
cause of sepsis of unknown origin in 46 patients (re-
sulted in 92%). Results are summarized in Tables 1–3.
Despite unexplained causes of sepsis, negative findings
that helped exclude the possibilities of inflammation in
the musculoskeletal system, including the vertebral col-
umn, and/or inflammation within the lungs, liver or
bowel, have helped personalized treatment in patients.
Table 1 List of findings
Finding of PET/CT No. %


















































Table 2 Microbial agents confirmation and treatment modification
Microbial agens confirmation (of 45) 42 93.33
Haemoculture





















Table 3 Microbial agents










Streptococus faecalis 7 16.67
Streptococcus pneumoniae 3 7.14
Escherichia coli 3 7.14
Klebsiella pneumonia 5 11.90
Mycobacterium tuberculosis 2 4.76
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Data Interpretation
The use of 18F-FDG-PET/CT has been discussed in several
studies in relation to the detection of uncertain causes of fever,
bacteremia or inflammation, yet only a few studies have suc-
cessfully exploited 18F-FDG-PET/CT in the indication of sep-
sis of unknown origin, or shortly after SIRS occurred [5, 6].
Precise evaluation of the extent of inflammatory focuses
forms the basis of a personalized treatment strategy. Early
use of 18F-FDG-PET/CT in predictive diagnostics will lead
to the personalized selection of local treatment alongside sys-
temic causal anti-microbial therapy.
We might have had more findings than other studies focused
on18F-FDG-PET/CT for two reasons: the selection of 18F-
FDG-PET/CT sooner than in other studies and the inability
to perform an examination in critically ill patients under arti-
ficial ventilation [4, 5].
The effectivity of the 18F-FDG-PET/CT could be high regard-
less of the state of the patients’ immune system.
Immunocompetent patients exhibit a strong inflammatory re-
sponse to common infections as well as to nosocomial micro-
bial organisms [8]. In addition, patients with a known im-
paired immune response tend to have positive PET/CT find-
ings. It has been shown in several studies that the infective foci
could be multiple and multi-systemic. Multifocal septic arthri-
tis or spondylodiscitis, or a combination of arthritis with spon-
dylitis are typical. The hybrid imaging covering the whole
body—from vertex to toe—is advantageous in such cases,
because the success of systemic therapy often has to be sup-
ported with the evacuation of abscesses. Our findings of
multi-focal afflictions in patients with a staphylococcal infec-
tion reflected the results of other studies [6, 7].
Conclusions and expert recommendations
The treatment of infection is based on the identification of the
microbial cause, the extent of disease and local disease control
[9]. Patients suffering from SIRS are conventionally investi-
gated using CT or MRI, rarely with the use of scintigraphy
using labelled leucocytes. Such a conventional approach leads
to many inconclusive or unexplained, findings.
Given the tried and tested high diagnostic performance of18F-
FDG-PET/CT in inflammatory diseases, this approach could
be very effective in the detection of the cause of septic state
and might lead to the personalized treatment [8].
– A high number of positive findings of 18F-FDG-PET/CT
led to the changes in therapy of patients; 18F-FDG-PET/
CT makes the diagnostics more precise.
– Targeted sampling using a fine needle biopsy could help
in identifying the microbial cause of infection. In some
patients, the cause of sepsis can be seen in the imaging,
for example, in patients with mycobacterial spondylitis or
lung infection.
– The use of 18F-FDG-PET/CT in the early phases of in-
vestigation offers a quicker route to the initiation of indi-
vidualized therapy, enabling the reduction of hidden sites
of infection not receiving local therapy
–
18F-FDG-PET/CT could be recommended as a reliable
instrument for the personalization of therapy as well as
a predictive prevention measure aimed at minimizing the
patient’s burden.
Acknowledgement: Supported by Czech Ministry of Health
by Conceptual Development of the Institution 00669806 – FN
Plzen and Charles University Project Progress q39.
References
1. Yu JC, Khodadadi H, Baban B. Innate immunity
and oral microbiome: a personalized, predictive,
and preventive approach to the management of
oral diseases. EPMA J. 2019; https://doi.org/10.
1007/s13167-019-00163-4.
2. Pijl JP, Glaudemans AWJM, Slart RHJA, Yakar D,
Wouthuyzen-Bakker M, Kwee TC. FDG-PET/CT
for Detecting an Infection Focus in Patients With
B lood s t r e am In f e c t i on : Fac t o r s Af f e c t i ng
Diagnostic Yield. Clin Nucl Med. 2019;44:99–
106.
3. Ferda J, Baxa J, Ferdova E, Kucera R, Topolcan O,
Molacek J. Abdominal aortic aneurysm in prostate cancer
patients: the “road map” from incidental detection to ad-
vanced predictive, preventive, and personalized approach
utilizing common follow-up for both pathologies. EPMA
J. 2019; https://doi.org/10.1007/s13167-019-00193-y.
4. Tsai HY, Lee MH, Wan CH, Yang LY, Yen TC, Tseng
JR. C-reactive protein levels can predict positive (18)F-
FDG PET/CT findings that lead to management changes
in patients with bacteremia. J Microbiol Immunol Infect.
2018;51:839–846.
5. Tseng JR, Chen KY, Lee MH, Huang CT, Wen YH, Yen
TC. Potential usefulness of FDG PET/CT in patients with
sepsis of unknown origin. PLoS One. 2013; https://doi.
org/10.1371/journal.pone.0066132.
S53
EPMA Journal (2020) 11(Suppl 1):S1–S133
6. Colombo J, Elzi L, Treglia G, Perren A. Light in the dark:
(18)F-FDG PET/CT in Staphylococcus aureus bacter-
emia of unknown origin. Intensive Care Med.
2018;44:488–489.
7. Berrevoets MAH, Kouijzer IJE, Aarntzen EHJG, Janssen
MJR, De Geus-Oei LF, Wertheim HFL, Kullberg BJ,
Oever JT, Oyen WJG, Bleeker-Rovers CP. (18)F-
FDGPET/CT Optimizes Treatment in Staphylococcus
aureus Bacteremia and Is Associated with Reduced
Mortality. J Nucl Med. 2017;58:1504–1510.
8. Kouijzer IJ, Vos FJ, Janssen MJ, van Dijk AP, Oyen WJ,
Bleeker-Rovers CP. The value of 18F-FDG PET/CT in
diagnosing infectious endocarditis. Eur J Nucl Med Mol
Imaging. 2013;40:1102–1107.
9. Abdelhamid AG, El-Masry SS, El-Dougdoug NK.
Probiotic Lactobacillus and Bifidobacterium strains pos-
sess safety characteristics, antiviral activities and host ad-
herence factors revealed by genome mining. EPMA J.
2019; https://doi.org/10.1007/s13167-019-00184-z.
Clinical effectiveness evaluation of remineralization ther-
apy in children with oncology disorders undergoing
chemotherapy
Vinnichenko Y1, Kupets T*2, Alexandrova O1, Matelo S2
1Central Research Institute of Dental and Maxillofacial
Surgery,
2WDS Laboratory, Moscow, Russia
*Corresponding author: Prof. Dr. T. Kupets, 2WDS
Laboratory, Moscow, Russia
Cancer chemotherapy can increase the risks of dental diseases,
which calls for enhanced preventive methods. Three different
products were tested and compared to select the most effective
for these particular conditions.
Osteosarcoma and Ewing’s sarcoma patients admitted in
Blokhin National Medical Research Center of Oncology, in
September–December 2016, were offered to participate in the
caries prevention program while undergoing chemotherapy.
115 children aged 12–17 signed up and randomly joined
groups 1–3. Refusers formed the control group (4).
Group 1 used a remineralizing gel containing Xylitol and
Calcium Glycerophosphate. Group 2 used a dental cream con-
taining Casein Phosphopeptides-Amorphous Calcium
Phosphate (CPP-ACP). Group 3 used a 5% sodium fluoride
liquid compound. Group 4 used no special caries prophylaxis
method. All participants were instructed on proper toothbrush-
ing techniques.
The average baseline DMFT for the four groups range from
4.04 to 4.48 with no significant difference. After 12 months,
groups 1 and 4 (р = 0.0017), 2 and 4 (р = 0.005), 3 and 4
(р = р = 0.009), 1 and 3 (р = 0.009) showed significant statis-
tical differences in DMFT values. No significant statistical
differences (р > 0.05) were found for groups 1 and 2, 2 and 3.
As a result of the prophylaxis undertaken, groups 1, 2, and 3,
achieved a reduction in caries increment of 67.7%, 52.3%, and
46.2%, respectively, compared to the control group.
It follows that the Xylitol and CalciumGlycerophosphate con-
taining gel is more effective in dental caries prophylaxis in
children undergoing cancer chemotherapy compared to both
the CPP-ACP and the 5% sodium fluoride containing
products.
3PM in oncology
Multiomics analysis of energy metabolism heterogeneity
and its molecular pattern biomarkers in ovarian cancer:
contribution to the 3PM approach in disease management
Li N1,2, Zhan X*1,2
1 University Creative Research Initiatives Center, Shandong
First Medical University, 6699 Qingdao Road, Jinan,
Shandong 250117, P. R. China
2 Key Laboratory of Cancer Proteomics of Chinese Ministry
of Health, Xiangya Hospital, Central South University, 87
Xiangya Road, Changsha, Hunan 410008, P. R. China
*Corresponding author: Xianquan Zhan, University
Creative Research Initiatives Center, Shandong First
Medical University, 6699 Qingdao Road, Jinan, Shandong
250117, P. R. China; e.mail: yjzhan2011@gmail.com
Keywords: predictive preventive personalized medicine,
multiomics, genomics, transcriptomics, proteomics,
metabolomics, interactomics, signaling pathway, molec-
ular network, biomarker, ovarian cancer, energy metab-
olism heterogeneity, Warburg effect, reverse Warburg
effect, glycolysis pathway, Krebs cycle pathway, oxida-
tive phosphorylation (OXPHOS) pathway, early diagno-
sis, prognostic assessment, lncRNA, miroRNA, RNA-
binding protein, SNHG3, EIF4A3
Multi-parameter systematic opinion of ovarian cancer
Ovarian cancer (OC) is a serious malignant tumor in
women with multi-causes, multi-processes, and multi-
consequences, which is involved in a series of molecular
changes in DNAs, RNAs, proteins, and metabolites, and
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those molecules function mutually in a molecular net-
work system [1–3]. It is very difficult to use a single-
one parameter model for accurately predictive, preven-
tive, and personalized treatment [4], and even for a tumor
pathophysiological feature such as chronic inflammation
in cancer [5]. The multi-parameter system model is nec-
essary to meet the real situation of an OC [6]. The de-
velopment of multiomics and systems biology has driven
the rapid transition of a single-one model to multi-
parameter systematic model. A multiomics-based molec-
ular pathway network study will significantly drive the
discovery of effective and reliable biomarkers to in-depth
understand the molecular mechanism, discover effective
therapeutic targets, and identify reliable biomarkers for
prediction, diagnosis, and prognostic assessment for OC
patients [1, 7].
Energy metabolism abnormality in ovarian cancer
Energy metabolism abnormality is an important patho-
physiological phenomenon in OC. Traditionally, the
energy supply of cancer cells is mainly derived from
aerobic glycolysis, but not from the Krebs cycle and
oxidative phosphorylation (OXPHOS), which is called
the Warburg effect [8]. However, the Warburg effect
cannot explain the energy supply of all cancer cells.
Thus, a novel reverse Warburg effect was put forward
in 2009 [9], which emphasizes the interactions between
cancer cells and tumor-microenvironment (TME), and
cancer cells and cancer-associated fibroblasts (CAFs)
become metabolically coupled. Cancer cells secrete
many reactive oxygen species (ROS) into TME to en-
hance oxidative stress in CAFs. When the inflamma-
tion, autophagy, loss of stromal caveoloin-1 (Cav-1),
and nitric oxide synthase (NOS) are increased in
CAFs, the aerobic glycolysis is prone to occur. As a
result, CAFs secrete lots of energy-rich fuels to TME,
such as lactate and pyruvate [10]. These nourishment
fuels feed mitochondrial OXPHOS and ATP supple-
ment. In this process, mono-carboxylate transporter
(MCT1 and MCT4) is highly expressed in cell mem-
brane in cancer cells and CAFs. MCT1 is upregulated
specifically in cancer cells to participate in lactate up-
take, whereas MCT4 is distributed specifically in CAFs
to participate in lactate efflux progress [11]. Some
studies also demonstrate that aerobic glycolysis is not
the main energy metabolism approach for many human
cancer cells [12]. The past decades’ studies regarding
Warburg and reverse Warburg effects have formed the
scientific frontiers and hotpot in the field of cancer
energy metabolism abnormality.
Mitochondria-based multiomics strategy for analysis of
energy metabolism abnormality in ovarian cancer
Mitochondria are the center of energy metabolism in
eukaryotic cells. Mitochondrial dysfunctions are closely
associated with tumor relapse, metastasis, and progres-
sion. Structural and morphological changes of mito-
chondria are observed inside cancer cells [13].
Further experimental evidence found that mitochondria
play essential roles in growth, survival, and therapeutic
treatment of OC cells [12, 14]. It is well-known that
the glycolysis pathway occurs in cytoplasmic region,
the Krebs cycle and OXPHOS pathways occur in mi-
tochondria, and energy metabolism pathways are regu-
lated by long non-coding RNAs (lncRNAs) [15], and
the TCGA database contains large-scale RNA data and
clinical data for several hundred OC patients [16, 17].
Thus, we designed a multiomic strategy to study ener-
gy metabolism abnormalities in human OC tissues, and
energy metabolism pathways-based biomarkers (Fig. 1)
[18]. (i) Quantitative mitochondrial proteomics is used
to study the changes of the Krebs cycle and OXPHOS
pathways [19]. The basic procedure is that mitochon-
dria are isolated and purified from human OC and
control ovary tissues. The extracted mitochondrial pro-
teins (cancers; controls) are subjected to digestion with
trypsin, 6-plex iTRAQ labeling, strong exchange cation
(SCX), and liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) analyses to identify mitochon-
dria differentially expressed proteins (mtDEPs), follow-
ed by molecular pathway network analysis. (ii)
Quantitative proteomics of human whole OC tissues
is used to study the changes of the glycolysis pathway
[20]. The basic procedure is the same as quantitative
mitochondrial proteomics, only the mitochondrial pro-
tein samples are replaced with the whole tissue protein
samples (cancers; controls), which results in identifica-
tion of DEPs between whole tissues of OCs and con-
trols, and changes in molecular pathway networks. (iii)
Quantitative transcriptomics data and the complete
clinical data from TCGA OC tissue RNA-seq data are
used to determine survival-related lncRNAs, RNA-
binding proteins, and microRNAs to be associated with
energy metabolism pathways in OC tissues [16]. (iv)
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The changed key molecules (mRNAs; proteins) in en-
ergy metabolism pathways are validated at the OC cell
and human tissue levels, with qRT-PCR and western
blotting [16]. (v) Comprehensive analysis of all above
data determines mulitomics-based energy metabolism
heterogeneity and its biomarker pattern in human OCs.
Molecule-pattern changes and their regulatory molecules
of energy metabolism pathways in ovarian cancer
Quantitative mitochondrial proteomics and quantitative
whole tissue proteomics revealed the changes of key pro-
teins in the energy metabolism signaling pathways [16,
20]. The Krebs cycle, and OXPHOS pathways were sig-
nificantly enriched from 1198 mtDEPs, and the key pro-
teins (PDHB, IDH2, and UQCRH) in these two pathways
were significantly upregulated (Fig. 2) [16]. It is coincid-
ed with the reserve Warburg effect [9]. Glycolysis path-
way was significantly enriched from 205 DEPs, and the
key enzyme PKM2 in this pathway was significantly
upregulated [20]. It coincides with with the Warburg ef-
fect [8]. The Warburg effect and reverse Warburg effect
are complementary in energy metabolism reprogramming
in OC tissues. Moreover, the key proteins (PFKP, PKM,
CS, PDHB, IDH2, IDH3A, IDH3B, OGDHL, ND5, ND2,
UQCRH, and CYB) were verified in OC cells (SK-OV3,
TOV-21G, and OVCAR-3) with qRT-PCR, and found
that PKM, PDHB, IDH3A, IDH3B, ND5, ND2, and
CYB were highly expressed in OC cells compared to nor-
mal cells [16].
Extraction of proteins from 







Energy metabolic heterogeneity and its molecular mechanisms
The Cancer Genome Atlas (TCGA) data (20115 
genes in 419 ovarian cancer patients)
lncRNA SNHG3 was related to ovarian cancer 
survival and energy metabolism
Integrated analysis of the
results of GSEA analysis and Starbase 2.0
SNHG3 was related to energy metabolism by 
regulating miRNAs and EIF4AIII
miRNAs and EIF4AIII had target sites with PKM, PDHB, 
IDH2, and UQCRH in the energy metabolic pathways
Alterations of the key proteins in glycolysis, Kreb's cycle, 
and oxidative phosphorylation pathways 
Preparation of  mitochondria 





Extraction of proteins from 
mitochondria
KEGG Pathways
Fig. 1 The experimental flow-chart to study energymetabolic heterogeneity and its molecular mechanisms. Reproduced from Li, Zhan, and Zhan (2018)
[18], with permission from InTech-Open science publisher open access
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Quantitative transcriptomics revealed that survival-
related lncRNA SNHG3 regulated the key molecules
(PFKM, PKM, PDHB, CS, IDH2, IDH3A, IDH3B,
OGDHL, ND2, ND5, CYB, and UQCRH) in three en-
ergy metabolism pathways by their RNA-binding pro-
teins (EIF4A3) to bind PKM in glycolysis, IDH2 in
the Krebs cycle, and UQCRH in OXPHOS pathways,
or by miRNA (hsa-miR-186-5p) to bind the 3’UTR of
PDHB linking glycolysis with the Krebs cycle [16].
Additionally, SNHG3 was significantly upregulated in
OC cells (SKOV3, TOV21G, and OVCAR3) relative to
control cells (IOSE80), and SNHG3 was associated
with drug sensitivity or multidrug resistance of tamox-
ifen in OCs. Moreover, inhibition of SNHG3 expres-
sion in OC cell (SKOV3) caused significant decreases
of the key molecules (PFKM, PKM, PDHB, CS, IDH2,
IDH3A, IDH3B, OGDHL, ND5, ND2, CYB and
UQCRH) in three energy metabolism pathways at the
levels of mRNAs and proteins [16].
Cancer cells and stroma cells (especially CAFs) have met-
abolic symbiosis
Cancer cells induce oxidative stress of CAFs by secret-
ing ROS to enhance aerobic glycolysis of CAFs. In
turn, CAFs produced lots of nourishment to be ‘eaten’
up by cancer cells for producing ATP through the
Krebs cycle and oxidative phosphorylation [10]. They
are connected by a lactate shuttle (MCT-1 and MCT4)
between cancer cells and CAFs [11], and MCT-1 and
MCT-2 are significantly upregulated at the mRNA level
in three OC cells [16]. The nanomaterial-siRNAs of
SNHG3 might be promising for OC patients to block
the abnormal energy metabolism [16].
Conclusions and expert recommendation
Energy metabolism heterogeneity is a hallmark in OC. The
changed key molecules and regulators in three energy metabo-
lism pathways are the precious resource to help discover effec-
tive therapeutic drugs and molecule-pattern biomarkers for
A B
Fig. 2 The changes of key proteins in oxidative phosphorylation, Krebs cycle, and glycolysis pathways. Reproduced from Li, Zhan, and Zhan (2018)
[16], with permission from Elsevier, copyright 2018
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PPPM in OCs and patient individualized stratification. We rec-
ommend the use of multiomics to study energy metabolism
abnormalities, and reveal the complete changes of molecules
in three energy metabolism pathways and their regulators.
Energy metabolism pathway network-based molecule-pattern
biomarkers and therapeutic targets have more important scien-
tific merits in OC.
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A deeper mechanistic understanding of epithelial-to-
mesenchymal transition (EMT) regulation is needed to
improve current anti-metastasis strategies in ovarian
cancer (OvCa). Here, by systematically analyzing
high-throughput gene expression profiles of both
lncRNAs and protein-coding genes in OvCa samples
with integrated epithelial (iE) subtype and integrated
mesenchymal (iM) subtype labels, we identified a
lncRNA-media ted compet ing endogenous RNA
(ceRNA) regulatory network that affects the expression
of many EMT-related protein-coding genes in mesen-
chymal OvCa. Using a combination of in vitro and
in vivo studies, we provide evidence that the lncRNA
PTAF-miR-25-SNAI2 axis controls EMT in OvCa. Our
results revealed that up-regulated PTAF induced elevat-
ed SNAI2 expression by competitively binding to miR-
25, which in turn promoted OvCa cell EMT and inva-
sion. Moreover, we found that silencing of PTAF
inhibited tumor progression and metastasis in an
orthotopic mouse model of OvCa. We then observed
a significant correlation between PTAF expression
and EMT markers in OvCa patients. These findings suggest
that the lncRNA PTAF, a mediator of TGF-β signaling, could
predispose OvCa patients to metastases and may serve as a
potential target for anti-metastatic therapies for mesenchymal
OvCa patients.
Liver carcinomas: the emergent field for the paradigm
shift from reactive to predictive, preventive and
personalised medicine
Barilo A1, Golubnitschaja O*2
1Center of Molecular Biotechnology, Friedrich-Wilhelms-
University of Bonn, Germany
2Predictive, Preventive and Personalised (3P) Medicine,
Department of Radiation Oncology, University Hospital
Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany
*Corresponding author: Prof. Dr. Olga Golubnitschaja,
Predictive, Preventive and Personalised (3P) Medicine,
Department of Radiation Oncology, Friedrich-Wilhelms-
University Bonn, Venusberg-Campus 1, 53127 Bonn,
Germany; e.mail: Olga.Golubnitschaja@ukbonn.de
Keywords: predictive preventive personalised medicine, liver
carcinoma, malignancy, patient stratification, hepatocellular
carcinoma, solid tumours, metastasis, multi-omics, biomarker
patterns, in-depth diagnostics, survival, therapy prognosis, liq-
uid biopsy, modifiable risk factors, risk assessment, multi-
parametric analysis
Highly heterogeneous origin of LC as a challenge for di-
agnostics and treatment
Liver carcinomas (LC) with highly heterogeneous origin are
one of the most widespread and severe cancer forms world-
wide with particularly poor prognosis.
Primary liver cancer includes hepatocellular carcinoma
(HCC) (75%–85%), intrahepatic cholangiocarcinoma (10%–
15%) and other rarer cases. According to the global cancer
statistics, in addition to 782,000 deaths from liver cancer, the
estimation of 841,000 occurred in 2018 [1]. Besides the pri-
mary liver tumours, almost any malignancy could metastasize
to the liver. To this end, the liver is one of the predominant
sites for breast cancer metastases contributing 21% to all the
cases. A recent paper analysed the data from 224,449 patients
from the USA; 11,997 (5.3%) patients had the metastatic dis-
ease, and 3276 (1.5%) patients were diagnosed with liver me-
tastases [2]. The liver is also a site for colorectal cancer me-
tastases occurring in 15% of all cases [3]. Liver metastases are
more common than primary tumours [3]. A recent study
looked at the patient treatment across the regions and showed
that more than 80% of patients from the Asia Pacific, Japan,
Europe, and the USA were males with median age over
54 years old [4].
Modifiable risk factors play a key role in LC
Noteworthy for the absolute majority of LC cases, modifiable
risk factors play a decisive role in the pathology manifestation
and progression and could be prevented by targeted measures
that should be well considered for educational programs in the
population. Risk factors include viral infections such as hep-
atitis B and hepatitis C (80% of cases) [3], hemochromatosis,
Diabetes mellitus (8%), abnormal alcohol consumption (7–
50%), unbalanced diet and smoking (25%), amongst others
[5]. Educational programmes could promote health literacy
and more effective prevention in the population.
LC is frequently diagnosed at advanced stages
Owing to the current lack of effective strategies for LC pre-
vention and targeted screening programs, the disease is fre-
quently diagnosed at advanced stages followed by palliative
treatment with 5-year survival rates of 0–10%. In contrast,
early diagnosed patients have been demonstrated as cured
with significantly better success; however currently still with
50% reoccurrence rate and about 25% survival within 5 years.
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LC management requires a paradigm change from reac-
tive to predictive, preventive and personalised medicine
To this end, the main problem is an extremely high heteroge-
neity of the LC patient cohort that requires a paradigm change
from cost-ineffective reactive medical services to an advanced
predictive, preventive and personalised medicine approach
based on the targeted preventive measures utilising education-
al programmes, innovative population screening, early multi-
level diagnostics, improved patient stratification and treatment
algorithms tailored to the person.
Application of l iquid biopsy, multi-omics and
multiparametric analysis is crucial to improve individual
survival in LC
A recent study demonstrated that application of liquid bi-
opsy, multi-omics and multiparametric analysis is crucial
for the patient stratification and accurate consideration of
therapy modalities that depends on the individualised pa-
tient profile including sub-cellular imaging by comet as-
say, expression patterns of specific biomarkers involved in
tumour development and progression and activity of
tissue-remodelling enzymes [6].
Outlook
Follow-up large-scale multi-centre research is essential to val-
idate the preliminary conclusions of the recently published
pilot study [6], in order to validate the presented biomarker-
panels and consequently optimise individual patient out-
comes.
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Background
Patients with primary and metastatic liver malignancies repre-
sent a highly heterogeneous patient pool characterised by
some of the shortest life expectancies amongst oncology pa-
tients. Computational tools utilising multi-parametric analysis
are instrumental for comprehensive individualised patient pro-
filing, predictive diagnostics and prognosis with a high poten-
tial for clinical implementation. This approach may signifi-
cantly contribute to the paradigm change from reactive to
predictive, preventive and personalised medicine benefiting
patients predisposed to and/or diagnosed with the liver malig-
nancies as well as healthcare systems at large [1,2]. A pro-
spective pilot research project performed at the UKB,
University of Bonn has identified potential multi-omic bio-
marker patterns for predictive stratification of liver cancer pa-
tients who underwent SIRT (selective internal radio-therapy)
versus TACE (trans-arterial chemoembolisation) treatment
[3,4]. It was concluded that the treatment option is decisive
for the quality of individual outcomes. Consequently, the
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treatment selection should be tailored to the individualised
patient profile.
Working hypothesis, materials and methods
In the current project we hypothesised that a comprehensive
multi-omic analysis may reveal differences in relevance of
individual biomarkers for overall survival, depending on the
original tumour diagnosed. Contextually, the patient stratifi-
cation was performed as following:
– colorectal carcinoma (CRC) patients with liver metastasis
and overall survival shorter than 6 months (18 patients)
– CRC patients with liver metastasis and overall survival
longer than 24 months (8 patients)
– hepatocellular carcinoma (HCC) patients demonstrating
the overall survival shorter than 6 months (11 patients)
– HCC patients demonstrating the overall survival longer
than 24 months (9 patients).
All CRC patients (26) underwent TACE, whereas HCC
underwent either TACE (11) or SIRT (9).
The multi-omic biomarker patterns used in this study were
proven earlier as being generally relevant for prediction of
the overall survival in the patients’ pool with liver malignan-
cies [3, 4], if measured before the therapy applied:
– gelatinase activities of metalloproteinases (MMP) 2 and 9
measured in blood serum
– expression patterns of calgranulin A, catalase,
superoxide-dismutase (SOD) 2, profiling 1, RhoA, and
thioredoxin (Trx) – all measured at the protein level in
circulating leucocytes
– sub-cellular imaging by “comet assay” DNA analysis in
circulating leucocytes.
The molecular pathways this biomarker-panel is involved in
and their relevance for liver malignancies and therapy success
were detailed by Golubnitschaja et al. [4].
Results Below presented figures (see summarising Figs. 1–3)
demonstrate the distribution of biomarker-patterns correlated
with the primary diagnosis (CRC versus HCC) and overall
survival of the stratified patient groups marked as short (<
6 months) and long (> 24 months). All the values were nor-
malised before plotting; consequently all the biomarkers are
scaled within the same range between 0 and 1.
Fig. 1 Distribution of the biomarker-patterns in CRC patients with liver metastases stratified by short and long survival: statistically significant
differences are demonstrated for patterns with an increased level of comet class I (intact DNA) and decreased level of class IV (apoptotic DNA) in
the group with the long survival; although being statistically non-significant the tendencies to decreased MMP-2 activity, decreased level of comet class
III (strongly damaged DNA), decreased expression levels of calgranulin A on the one hand, but on the other hand, increased expression levels of
catalase, SOD-2 for the long survival are demonstrated.
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Fig. 2 Distribution of the biomarker-patterns in HCC patients stratified by short and long survival: although being statistically non-significant, a
tendency to decreased MMP-9 activity, decreased level of comet class III (strongly damaged DNA) and class IV (apoptotic DNA), decreased expression
levels of calgranulin A on the one hand, but on the other hand increased level of comet class I (intact DNA), increased expression levels of catalase and
profilin for a long survival are demonstrated
A. Distribuon of the biomarker-paerns in HCC paents strafied by short and long survival, who 
underwent SIRT
Fig. 3 Distribution of the biomarker-patterns in HCC patients stratified by short and long survival as well as therapy approach (a) SIRT versus (b). TACE:
although being statistically non-significant, differences in the pattern distribution are evident for both long versus short survival and SIRT versus TACE in HCC
patients. This can be concluded as following: the comet patterns may be instrumental for the survival prediction under the TACE condition, whereas theMMP-9
patterns seem to be more relevant for the survival prediction under the SIRT condition
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Conclusions and expected impacts The pilot study demon-
strated evident differences in the biomarker-patterns correlat-
ed with the short versus long survival, primary tumour and the
therapy type applied. Besides in-depth understanding of the
molecular mechanisms which underlie the treatment ap-
proaches used and, consequently, individual outcomes, better
justified selection of the treatment algorithms is expected by
the above-proposed patient stratification considering the pri-
mary diagnosed tumour. Treatments tailored to the
personalised patient profile may lead to significantly im-
proved individual outcomes benefitting the affected patients
and the overall disease management. Multi-omic pattern rec-
ognition, individualised profiling and detailed patient stratifi-
cation are instrumental for the advanced concepts of predic-
tive, preventive and personalised medicine in the management
of liver malignancies [4–6].
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PCa incidence and related mortality in the global context
of oncologic diseases
Current statistics demonstrate PCa among the most frequent
types of cancer worldwide [1], see Fig. 1. Although on aver-
age PCa is ranked as the fourth most frequent oncologic dis-
ease, the prevalence and incidence rates differ significantly
from country to country.
Breast, prostate and lung cancers spread the highest
amount of CTC
Accumulated evidence demonstrates high density of circulating
tumour cells spread by primary tumours as a reliable indicator for
developing metastatic disease [2]. In particular, three types of
malignancies have been demonstrated to spread the highest
amount of CTC in blood, namely breast, prostate and lung.
Consequently, liquid biopsy tests for enumeration and molecular
characterisation of CTC are highly recommended for these pa-
tient cohorts to predict and prevent metastatic disease [3–5].
Incidence of metastatic PCa is increasing
As reported by several groups worldwide, incidence of
metastatic PCa is rapidly increasing in populations.
Although the epidemiology of the metastatic PCa is not
completely understood yet, and the reasons for the rapidly
increasing incidence remain unclear, multi-factorial risks
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Fig. 1 Global statistics of oncologic diseases released by GLOBOCAN in 2018 [1]: In total, 18,078,957 new cases and 9,555,027 related deaths were
registered for males and females of all ages
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PCa incidence and related mortality is increasing in older
adolescents and young adults
Since 1990, PCa has increased in most countries in older adoles-
cent and young adult men between ages 15 and 40 years—
globally at a steady rate averaging 2% per year since 1990
(P < .01) [7]. A prominent example comes from UK, where na-
tional records show that although PCa incidence is permanently
increasing in almost all age groups since 1990s, the increase is
disproportionally high for men aged 25–49 years by over 400%,
compared to 285% for men aged 50–59 year, 142% for men
aged 60–69 years, 42% and 23% for men aged 70–79 and 80+
years, respectively [8]. Several European countries and regions
report alarming statistics for PCa cases recorded in adolescence
(15–19 years of age) and young adults aged 20–24 years and
25–29 years as demonstrated in Fig. 2. Similarly to the in-
creasing incidence of metastatic PCa, the reasons for the in-
creasing PCa incidence in young populations is considered to
carry a multi-factorial character [7].
Conclusions and outlook
In summary, PCa belongs to the cancer types with highest
incidence recorded worldwide. The PCa incidence is annually
increasing. Moreover, the incidence of metastasing PCa is in-
creasing as well. Further, alarming statistics have been regis-
tered for adolescents and young adults aged 15–40 years with a
tendency to particular rapidly increasing incidence rates. Multi-
factorial risks for these trends have been proposed. One of the
evident deficits is the reactive character of medical services
provided, which does not meet the needs of the population
and in particular of young people [10]. Consequently, the par-
adigm shift is essential to provide cost-effective healthcare
utilising multi-professional expertise for predictive diagnosis,
targeted prevention and treatments tailored to the person—the
concepts of 3P medicine presented by the EPMA [11].
Concretely, innovative screening programmes are essential to
identify persons in suboptimal health conditions (such as suf-
fering from systemic hypoxic conditions and low grade
inflammation) followed by the targeted primary prevention
[12–14]. Secondary prevention of PCa metastatic disease is
based on the liquid biopsy tests for CTC enumeration and their
molecular characterisation. Comprehensive individualised pa-
tient profiling is to be used for in-depth diagnostics and
personalisation of medical services [14].
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Fig. 2 PCa as a burden in young European populations: Incidence rates per million of inhabitants recoded in years 2004–2010 [9]
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed ma-
lignancy and the fifth leading cause of cancer-related death
among males in Western countries. Worldwide 1.4 million
new cases of prostate cancer occurred in 2016 [1]. The rising
burden of prostate cancer requires the active role of PPPM in
predicting PCa more precisely and providing a reliable risk
stratification of patients. This aim could be satisfied by novel
diagnostic and prognostic tools.
Nowadays, PCa is diagnosed by a histological inspection of
prostate needle biopsies, generally indicated by an elevated
serum prostate specific antigen (PSA) test and/or a suspect dig-
ital rectal examination (DRE) [2, 3]. PSA has low specificity for
PCa while biopsies have high false negative rates. The intro-
duction of novel biomarkers will help prevent overtreatment or
delayed intervention [4, 5]. New molecular biomarkers could
furthermore improve the accuracy of PCa detection and con-
tribute to predictive diagnostics, patient stratification and the
subsequent design of individualized treatment [6, 7].
Prostate cancer, novel biomarkers
An EPMA position paper reviewed protein candidates for
novel prostate biomarkers: members of the Cip/Kip family,
p21 and 27, are potential prognostic factors while upregula-
tion of the HER-2/neu protein bFGF VEGF has been proven
to be associated with adverse outcomes and the over expres-
sion of bcl-2 is linked with acquired resistance [8]. Circulating
cell free molecular biomarkers could be a solution to the de-
mand for minimally invasive diagnostic tools made by EPMA
[9, 10]. Based on our own work, we would emphasize that
regulatory non-coding RNAs represent an interesting target
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for the discovery of biomarkers. This includes small ncRNAs,
including microRNAs (miRNAs), Piwi-interacting RNAs
(piRNAs), medium ncRNAs, including small nuclear RNA
(snRNA), small nucleolar RNA (snoRNA), and long non-
coding RNA (lncRNAs). The LncRNA group is now repre-
sented by the highly evaluated Prostate Cancer Antigen 3
(PCA3; originally referred to as DD3), which has been shown
to be a prostate-specific molecule upregulated in PCa and
androgen-regulator. It is said to be the most specific biomarker
of PCa identified to date [3]. This biomarker could serve as an
example of a successful molecular biomarker pipeline discov-
ery for personlized medicine.
MiRNAs and LncRNAs as Candidate Biomarkers for
Prostate Cancer
MicroRNA-based diagnostics show great promise in the field
of early cancer detection and secondary prevention [11]. Each
miRNA can target several hundred mRNAs, thus playing a
critical role in multiple physiological processes [12, 13].
Deregulated miRNA expression has been associated with tu-
mor progression in several cancer types. Circulating miRNAs
which can be isolated from the body fluids of cancer patients
offer many advantages as biomarkers: their high pH, resistance
to ribonuclease degradation, incubation at room temperature for
24 h, stability after frequent freeze thawing, and relatively sim-
ple quantification by PCR-based techniques [13].
There are many miRNA candidates—see Table 1 for a review
- that can be used to predict PCa (miR-21, miR-200b, miR-
429), as a prognostic marker (miR-141, miR-221, miR-375)
or as a diagnostic marker (miR-106a, miR-200c). The
LncRNAs could be represented by three promising bio-
markers for prostate cancer: Metastasis associated lung ade-
nocarcinoma transcript 1 (MALAT 1), Second Chromosome
Locus Associated with Prostate 1 (SChLAP 1 or known as
LINC00913) or FR0348383 [14].









hsa-mir-25-3p tissue diagnostic [10, 14–16,
19]
hsa-mir-32-5p tissue diagnostic [10, 14–16]
hsa-miR-93-5p serum, tissue diagnostic [10, 14–16]
hsa-miR-141-3p serum, tissue diagnostic, prognostic [2, 13,
15–17]
hsa-mir-143-3p serum diagnostic [17]
hsa-miR-155-5p serum diagnostic [17]
hsa-mir-375-3p serum, plasma,
tissue
diagnostic, prognostic [2, 13–17]
hsa-mir-429-3p serum, plasma,
tissue
predictive, prognostic, [2, 15]
hsa-mir-451a-5p serum diagnostic, prognostic [16]
hsa-mir-106a-5p serum, plasma,
tissue
diagnostic, prognostic [2, 15, 16,
20]
hsa-mir-145-5p plasma, tissue diagnostic [13, 16, 17]
hsa-mir-148a-3p tissue diagnostic [15]
hsa-mir-15b-5p tissue diagnostic [15]
hsa-mir-182-5p tissue diagnostic [15, 16, 18]




hsa-mir-200c-3p serum, plasma diagnostic, prognostic [2, 13, 15]
hsa-mir-20a-5p serum, plasma,
tissue




diagnostic, prognostic [2, 13,
15–17]
Expert recommendations and a PPPM relevant outlook:
& Wide-ranging and precise studies have to be conducted in
order to select candidates and clinically validate miRNA,
or their combinations, as biomarkers before we are able to
use them in non-invasive methodology for PCa diagnos-
tics and treatment management.
& Patients will benefit from novel validation studies directly
focused on developing a powerful diagnostic tool based
on circulating molecular biomarkers for patient profiling
and stratification. This will lead to predictive and
evidence-based treatment, individualized in order to re-
duce the use of invasive techniques such as biopsies or
radical surgical treatment, resulting in a higher quality of
life for patients and greater cost-effectiveness.
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Introduction
According to the International Comparison Diagnostics, the
treatment of prostate cancer in our country is of high quality.
Despite high incidence, the latest results published in
GLOBOCAN (citation) showed that the mortality of our pa-
tients is much lower, or similar, to other high income or high
human development index countries [1]. PSA testing is per-
formed by GPs and urologists in the early stages of the dis-
ease, as well as by medical and radiation oncologists later on
during follow-ups after oncological treatment other than sur-
gery or androgen deprivation.
PSA is a glycoprotein produced by healthy glandular cells and
ducts as well as in prostate cancer in response to some prostate
changes (e.g. benign hyperplasia, inflammation, cancer and
post biopsy – it has a high prognostic, but lower predictive,
value). PSA is also age dependent. Because of the disease’s
steeply rising prevalence we started an early detection program
aimed at primary prevention in patients who have been
followed-up for other malignancies in the Czech Republic since
April 2018. Our decision was intimately linked to the paradigm
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shift from disease care to a personalised and preventive attitude
to cancer care, de facto this means the employment of new
technologies and a multilevel diagnostic process [2].
Current situation in the clinical practice
In clinical practice we are well experienced with PSA testing
in patients treated by “older” methods such as androgen dep-
rivation, radical surgery (prostatectomy) or external beam ra-
diation with known and expected PSA response. However, we
remain unfamiliar with patient response to newer treatment
modalities. We compared our own clinical data with results
published in the literature describing studies that presented
conditions that, for various reasons, are different from those
in our department, or country.
Huge progress has beenmade; in radiation oncology.We have
completely moved from simple 3D conformal techniques to
4D radiation in the past two decades owing to better equip-
ment (enabling special techniques such as IMRT, arc therapy
up to IGRT with daily positioning and verification), more
sophisticated treatment planning systems (avoiding radiation
of surrounding healthy tissues, using data from modern
mpMRI or even PET/CT for contouring) and/or immobilisa-
tion devices [3]. Moreover, brachytherapy (source of radiation
placed right inside the tumour) has advanced and we are also
able to use the newest brachytherapy-like based treatments,
such as radium (Ra223) in bone metastases or PSMA-617
using beta radiation of Lu177 or Y90 and alpha radiation of
Bi213 or Ac225 isotopes, which show very promising results.
Treatment methods overview and PSA following a radical
approach
There are two radical treatment methods used in localised
prostate cancer; namely radical prostatectomy (surgery) and
radiation therapy. In some cases they can be supplemented by
an endocrine approach in the form of androgen deprivation
(ADT) and, most importantly, they can be applied to
advanced/recurrent disease, or metastatic setting in patients
with distant (mainly bone) metastases chemotherapy. As far
as newer androgen receptor targeted agents (ARTA) are con-
cerned, we have specific methods of cancer vaccination or
brachytherapy-based treatments by Radium223 isotope.
Furthermore, prostate specific membrane antigen (PSMA)
guided therapy is used today. Simply put, prostate cancer
treatment modalities and possibilities have at least doubled
within the past few years. It has a clear impact on the need
for regular PSA testing to determine treatment response and
progression time because PSA levels in some cases are not in
correlation with the achieved response [4].
After radical prostatectomy (RP), a PSA decline to 0 ng/ml
(maximal detection level < 0,2 ng/ml) should be reached with-
in hours, or a few days. Higher levels are associated with the
presence of residual disease in the prostate bed or distant me-
tastases. A similar PSA course can be seen after radical
radiation (RT); however, it is much slower (weeks or months
because of tumour cell radiobiology). It could be faster after
some types of brachytherapy, or maybe extreme hypo frac-
tionated regimens, but this concept requires further investiga-
tion. In clinical practice we do not always reach an undetect-
able PSA level, but the nadir’s long-term stabilisation is also
considered a positive treatment result. Unfortunately, where
PSA levels are low, a minimal residual disease after RP or RT
is not detectable by any other method. When androgen depri-
vation (incl. new androgen receptor blockade by ARTA) or
chemotherapy is used, we expect PSA to decrease more slow-
ly (weeks or months) again. The flare phenomenon of LH-RH
analogues is also known to occur in the treatment of all stages
of prostate cancer. A similar bounce phenomenon with a tem-
porary PSA rise can be seen 1–2 years after brachytherapy.
Other therapeutic possibilities
Vaccination (e.g. allogenic GVAX, DNA or viral vectors-
based methods) is another treatment option available nowa-
days. Many patients are included in studies with anti-CTLA-4
or check-point inhibitor immunotherapy (ipilimumab,
nivolumab, atezolizumab). Autologeus vaccination by
Sipuleucel-T has already been approved in the US (but not by
the European EMA). We know treatment response cannot be
measured by PSA testing in this case. Even after special and
new RT methods such as Radium223 (Xofigo), we often see a
good patient response despite a rise in PSA. This means some
treatments used today are not necessarily associatedwith a PSA
decrease. PSMA isotopes might present the same dilemma, but
we are unfamiliar with this method. Preliminary data showed
about a1–2/3 PSA decline (by ≥50% in 30–60% of Lu177 cases,
by 60–70%, in 131I-labelled PSMA ligand and similarly by
255Ac-PSMA-617 even when complete response caused by
the treatment of the primary tumour was achieved, affecting
all the metastatic sites [5]. In other words, methods that work
on a similar principle could have a different PSA response.
Conclusions and PPPM-based expert recommendations
The incidence and prevalence of prostate cancer is rising fast.
Although there are some promising predictive diagnostic fea-
tures such as slow tumour growth and lower metastatic
potential—predominantly with bone involvement—enabling
waiting and observing in some cases, huge tumour heterogene-
ity, a high mutation burden and different intracellular signal
pathway activations are difficulties that lead to varied individual
treatment response and diverse efficacy of therapeutic interven-
tions [6]. PSA testing has an important role in disease staging
determination in prostate cancer, as well as in personalising treat-
ment in response to tumour relapse and distant dissemination.
Although a vaccination or Radium223 can be very effective, we
usually see some kind of PSA increase. It therefore seems nec-
essary to look for other treatment response parameters such as
quality of life or pain relief instead of measuring PSA levels.
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According to expert recommendations, PSA levels should be
evaluated individually which is in agreement with the principles
of personalised medicine [7].
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Introduction
Gliomas are a primary malignancy of the central nervous sys-
tem (CNS) [1]. Particularly high grade gliomas show poor
prognosis with limited survival despite standard therapy. A
novel approach is needed to advance glioma management
based on predictive diagnostics; targeted preventive measures,
as well as patient stratification should be carried out as part of
the individualization of treatment algorithms [2–8]. Treatment
personalization using targeted anticancer drugs and immuno-
therapy is the subject of extensive research in neuro-oncology
[9,10]. Gene fusions were identified as an emerging therapeu-
tic target for gliomas [11]. In this article we describe our use of
next-generation sequencing to identify targetable gene fu-
sions. We also discuss an innovative preventive, predictive,
personalized medicine (PPPM) oriented approach to glioma
management.
Patients and Methods
Patients with CNS gliomas were enrolled in the study between
2017 and 2019. Patients underwent a histopathological eval-
uation according to the WHO [1]. Mutation analysis and fu-
sion transcript detection in FFPE samples were performed
using TruSight Tumor 170 assay (Illumina, USA). All nucleic
acids were extracted using a FFPE DNA kit (automated on
RSC 48 Instrument, Promega, USA), quantified using Qubit
Broad Range DNA and RNA Assays (Thermo Fisher
Scientific, USA), and the quality of DNA was assessed using
FFPEQC kit (Illumina), and the quality of RNA using Agilent
RNA ScreenTape Assay (Agilent, USA). DNA samples with
Cq < 5 and RNA samples with DV200 ≥ 20 were used. After
DNA fragmentation with KAPA FragKit (KAPABiosystems,
USA), DNA and RNA libraries were prepared with TruSight
Tumor 170 assay (Illumina) and sequenced on NextSeq 500
sequencer (Illumina). Data analysis was performed using
TruSight Tumor 170 application on BaseSpace Sequence
Hub (Illumina). DNA variant filtering and annotation were
performed using Variant Interpreter (Illumina). The custom
variant filter set up included only variants with coding conse-
quences and a GnomAD database frequency value < 0.01
[12]. The remaining subset of variants was checked visually
and suspected artifactual variants excluded. Additionally, fu-
sion transcripts were detected by two FusionPlex kits (Solid
Tumor and Comprehensive Thyroid and Lung) [13].
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Results
Patients with gene fusions are presented in Table 1. Potential
for experimental personalized treatment is listed.
Table 1 Patients with gene fusions; histopathological diagnosis and po-
tential for experimental therapy
Age Gene fusion Diagnosis Experimental
therapeutics
[11]
























55 SRGAP3-BRAF Pilocytic astrocytoma
9 C11orf95-RELA Anaplastic ependymoma –
38 Anaplastic ependymoma




8 EWSR1-PALGL1 Low grade glial tumor, NOS –













34 FGFR2-CTNNA3 Diffuse astrocytoma,
IDH-wildtype









40 PTPRZ1-MET Glioblastoma, IDH-wildtype














Expert recommendation and PPPM relevant outlook
Several cancer syndromes increase the risk of gliomas
(Neurofibromatosis 1/2, Tuberous sclerosis, Lynch syndrome,
Li–Fraumeni syndrome, Melanoma-neural system tumor syn-
drome, Ollier disease) [14] as well as seven genomic variants
(TERT, rs2736100; EGFR, rs2252586 and rs11979158;
CCDC26, rs55705857; CDKN2B, rs1412829; PHLDB1,
rs498872; TP53, rs78378222; RTEL1, rs6010620). Beyond
genomics, specific phenotypic characteristics may play a role
in predisposition to CNS malignancies [15]. Innovative algo-
rithms reflecting these risk factors must be developed to im-
plement predictive diagnostics to glioma management.
Since the exposure to ionizing radiation is of the highest value
as a predictive risk evaluation factor for gliomas, with an
observed dose-response relationship, preventive measures
must be oriented at avoiding irradiation of subjects [14].
Prevention of other environmental hazards potentially associ-
ated with glioma development such as toxins (N-nitroso
compounds, pesticides) should also be stressed [16].
More precise patient stratification that will help personalize
the treatment algorithms to match patient profiles (personal-
ized medicine) can be achieved by employing advanced mo-
lecular technologies as was shown in our study. Patients with
specific targetable gene fusions could benefit from experimen-
tal therapies which might improve their quality of life and
survival in case of standard treatment options failure.
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Introduction
Colorectal cancer was estimated to be the second most
frequent cause of cancer related death in the EU among
men and the third among women in 2019 [1]. New clin-
ically relevant biomarkers could play an important role
in prevention and are needed for a more efficient man-
agement of patient quality of life [2]. Unfortunately,
there has been a decrease in the detection of new, clini-
cally useful biomarkers [3]. Interestingly, cell-free long
non-coding RNAs and mRNAs (cfRNA) in plasma have
received minimal attention. We have therefore tested
their potential as a source of novel biomarkers for the
personalization of colorectal cancer treatment.
Patients and methods
Two data sets were used for the analysis. The public one
contained datasets GSE100206 [4] with 32 normal samples
and GSE100063 [5] with 12 colorectal cancer samples. The
dataset produced in our laboratory was derived from cell-free
plasma collected from patients with colorectal cancer and
healthy controls in 2018 and 2019 at the University Hospital
in Pilsen. After precipitation by 8% PEG 6000, RNA was
isolated using a miRNA easy serum/plasma kit (Qiagen).
Libraries were prepared using a NEB next Ultra II directional
RNA kit (NEB). Kallisto and DeSeq2 were used for differen-
tial gene expression.
Results
The analysis of gene expression from the public and our data
yielded a set of 74 significantly differentially expressed genes
in both data sets with the same direction of change (Table 1).
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Conclusions and PPPM Expert Recommendations
Genes such as hypoxia marker HIF1A, or those associated
with mucosa and epithelial tissue maintenance (MUC4,
MUC5AC, MUC6), were upregulated in patients with colo-
rectal cancer. Downregulation was seen in many HLA mole-
cules, although they differed within HLA types and only
HLA-DOB was downregulated in both datasets. This indi-
cates an alteration in the immune system of cancer patients.
Overall, we were able to detect significant changes in gene
expression of colorectal cancer patients’ cfRNA from plasma.
We recommend further investigation of cfRNAs for biomark-
er discovery as our results show that the physiological changes
within the body are reflected in plasma cfRNA. The changes
are likely coming not only from tumor cells but also other
systems affected by disease, such as the immune system.
This might prove useful for the personalization of immuno-
therapy. cfRNA, similar to other liquid biopsies, allows re-
peated collection of samples. This enables easy follow ups
in patients and adds additional information about the course
of the disease that will contribute to treatment personalization.
The predictive potential of cfRNA can also be used for early
detection and prevention of therapy side effects, such as liver
damage. These could be effectively prevented by modifying
the therapy regimen, leading to improvement of patients’
quality of life and possibly contributing to therapy effective-
ness. As both 1) the collection of cell-free plasma and 2)
isolation and preparation of cfRNA are relatively cheap, sim-
ple and unintrusive. cfRNA has the potential to become a
routine practice with great potential for helping discover pre-
dictive markers. It could furthermore be easily combined with
other technologies to form multilevel diagnostics that are nec-
essary for a true shift to preventive, predictive, personalized
medicine (PPPM) [6–10].
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Table 1 Genes significantly changed in both datasets between patients
and healthy controls
AC006509.1 CDHR4 GRIK2 OR11G2 SVOP
AC009452.1 CFAP99 HLA-DOB OR2J2 SYPL2
AC009948.1 CLEC18B HLA-V PCDHB12 TAS1R1
AC021072.1 CSPG4 HNF1A PKMP1 TBC1D3P5
AC074019.1 CTXND1 HOXB13 PRR27 TEKT4
AC110053.1 CYP3A43 CHRM4 RPL7P41 TGM4
AC112777.1 DUOX2 INGX RPLP0P2 TMEM78
AC142086.5 EMX1 IZUMO2 SAA2 TMPRSS12
ADGRF1 EXD1 KDM4E SERBP1P5 TRPC4
AL512378.1 FAM83C LMX1B SERPINA10 TTBK1
ANKRD20A8P FAM92A1P2 MUC4 SHISA9 VWA7
ANKRD30BL FGF22 MUC5AC SLC13A3 ZIK1P1
C2orf80 FOXI3 MUC6 SLC38A3 ZNF75BP
C8orf86 GOLGA6L17P NT5C3AP1 SLC66A1L
CCDC198 GPR179 OGDHL SPATA21
Upregulated genes are marked in blue, downregulated in red
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Introduction
Lung cancer is a disease whose incidence has increased dramat-
ically over the past hundred years. The most common histolog-
ical type is adenocarcinoma [1]. New knowledge of the biology,
clinics and radiological images of adenocarcinoma has changed
the approach to its diagnosis and treatment, resulting in a new
classification developed in 2011. Among other things, uncer-
tainties regarding the variants of adenocarcinoma originally
called bronchioloalveolar carcinoma have been removed [2].
Non-invasive and minimally invasive variants of lung adeno-
carcinoma grow very slowly and have a very good prognosis
[3]. When these tumours are radically removed, patients have
up to 100% survival [4].
The aim of this study is to assess the ability of CT to distin-
guish non-invasive and minimally invasive types of pulmo-
nary adenocarcinoma by evaluation of the size of the solid
component, thus allowing prediction and personalised deci-
sion making regarding the next therapeutic approach.
Material and method
We enrolled a total of 64 patients (38 men, 26 women, mean
age 64 years) operated on for peripheral lung cancer with
histological confirmation of adenocarcinoma and preoperative
finding of a subsolid node on CT. CT scans were performed
less than 1 month before surgery on Somatom Definition,
Somatom Definition AS and Somatom Definition Flash mul-
tidetector devices (Siemens, Forchheim, Germany).
Pulmonary nodes were evaluated on thin sections with a col-
limation of 0.6 mm reconstructed using the edge enhancement
algorithm. The radiologist was blinded to the results of histo-
logical examination. A three-dimensional analysis was per-
formed on all nodules, including the automatic measurement
of the maximum dimensions of the entire node and the solid
component (Fig. 1). The findings were correlated with histol-
ogy. Nodes with a maximum size of 3 cm and a solid compo-
nent of up to 5 mm were evaluated as non-invasive or mini-
mally invasive tumour variants. We also calculated the vol-
ume doubling time for the nodes that were followed-up.
Fig. 1 Three-dimensional automatic analysis of semisolid nodule in the upper right lobe. a transverse scan, a solid component in violet and a complete
nodule in green. b three-dimensional model of the whole nodule. c three-dimensional model of solid part
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Results
According to the histological examination, 18 tumours were
non-invasive or minimally invasive and 46 were invasive.
Results of CT findings were correctly evaluated as non-
invasive or minimally invasive in 14 cases and as invasive in
45 cases. False positivity (overestimation of non-invasive min-
imally invasive tumour) occurred in four cases and false nega-
tivity (underestimation of invasive tumour) occurred in one
case. Thus, the CT achieved a sensitivity of 77.8, a specificity
of 97.8%, a positive predictive value of 93.3% and a negative
predictive value of 91.8% when distinguishing non-invasive
and minimally invasive variants of peripheral pulmonary ade-
nocarcinoma. We could determine the doubling time in 28 pa-
tients. This was on average 677 days for non-invasive and
minimally invasive variants and 588 days for invasive variants.
Data Interpretat ion and PPPM-based Expert
Recommendations
The results of our study demonstrate that CT is able to distin-
guish between invasive andminimally invasive variants of lung
adenocarcinoma. The differentiation of these tumour groups is
important in predictive diagnostics and can potentially be used
in making personalised decisions about a more precise treat-
ment. For example, in determining the timing of surgical treat-
ment, the extent of resection, or in deciding on the necessity
systemic treatment. The extent of solid tumour component can
be used as a predictor of invasiveness [7]. The gradual transition
between solid and ground glass opacities where the boundary
between the two components is very difficult to determine re-
duces CT sensitivity. Solid tumourous tissue may also be indis-
tinguishable from collapsed lung, fibrous tissue or mucin accu-
mulation. A possible solution could be to evaluate a solid com-
ponent in the mediastinal window, which filters out lower den-
sities [8]. The predictive potential of texture analysis using
mathematical and statistical methods seems promising [9].
Finding a subsolid pulmonary nodule does not always mean
that it is an adenocarcinoma. The literature indicates that up to
40% of these nodules may be of benign, primarily inflamma-
tory, origin. For this reason, subsolid (but also solid) pulmonary
nodules smaller than 8 mm are usually monitored preventively.
Malignancy is suspected in nodules that tend to grow. This is
expressed in terms of volume doubling time. It is generally
accepted that malignancy suspects are nodules with a doubling
time between 30 and 400 days. However, for subsolid nodule
these times may be longer, which is also evident from our
analysis. For this reason, subsolid nodules should be subject
to targeted prevention in the form of longermonitoring intervals
[10,11]. Another evaluation method of subsolid pulmonary
nodes is PET/CT with fluorine-18-labeled fluorodeoxyglucose
(18F-FDG). In contrast to the non-invasive component, 18F-
FDG has been shown to accumulate in the invasive component.
The problem however is the mucinous tumour variants which,
despite the presence of the invasive component, may not show
increased 18F-FDG uptake. It should also be noted that nodes
smaller than 5–8 mmmay be falsely negative due to their small
size. In such cases the CT finding should be taken into account
[12,13]. Inflammatory consolidations, such as FDG tumours,
may accumulate and be a source of false positives.
In conclusion, personalised medicine enables a whole new
approach to the treatment of patients with pulmonary adeno-
carcinoma. PPPM is optimal for the assessment of the tu-
mour’s invasiveness and therefore contributes to the long-
and short-term treatment strategies of pulmonary adenocarci-
noma patients. The PPPM approach entails the use of bio-
markers, imaging techniques and a clinical examination of
the patient. A personalised management of the disease is more
precise, can help time surgery better, decide on the extent of
resection and possibly indicate a systemic treatment that can
play a role in secondary prevention.
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Introduction
The aims behind the use of biomarkers are in concordance
with the principles of PPPM. Biomarkers enable the predic-
tion of individual predisposition before disease on-set, the
provision of targeted preventive measures and the creation
of personalised treatment algorithms tailored to the individual
[1]. They are strategically important for early diagnosis,
patient stratification, assessment of drug toxicity and efficacy,
disease risk, staging and prognosis. Biomarker applicability
greatly depends on a proper process of transition of each bio-
marker from primary research to proper clinical evaluation. A
standardised validation of biomarkers is crucial for PPPM
application in routine medical practice [2]. The laboratory
services have to become more complex, not only providing
a multifactorial analysis but also including recommendations
and active advice for clinicians [3]. Practical implementation
of novel and complex laboratory tests should be considered
according to their scientific value, cost-effectiveness and
added value for patients [4].
What is the current situation in the field of biomarkers?
A wide range of clinically used markers incorporates classical
tumour markers with unknown physiological roles or
increased/decreased factors of protein physiology, e.g. growth
factors, angiogenetic factors or apoptotic factors. In recent
times there has been a rise, not only in single candidate bio-
markers or their combinations but also in a whole novel class
of regulatory molecules from the fields of transcriptomics and
genomics. The expanding interest in molecular biology for
preventive, predictive and personalised medicine applications
could be illustrated by studies of cell free miRNA in serum for
potential biomarkers [5]. An example of this are the bio-
markers for hepatocellular carcinoma long non-coding RNA
Myd88, methylation of SEPT9 promoter or microRNA: miR-
122, miR-21 and miR192 for diagnostics, and plasma
miRNAs and low PD-L1 molecule expression or variations
in oncogenes for targeted therapy [6]. Traditional markers are
studied in novel formats; e.g. protein chip detection for diag-
nosis of pancreatic cancer incorporating CA19-9, NSE, CEA,
CA242 and CA125 [7]. The promising results support com-
binations ofmolecular and traditional routine biomarkers, suc-
cessfully combined microRNA and CEA and CA19-9 in co-
lorectal cancer [8].
Predict ive Biomarkers for Proper Treatment
Management
Predictive molecular biomarkers are already routinely used for
treatment and personalised stratification of patients in clinical
practice. To speed up research in the molecular biomarker
field, new molecular markers are often correlated with tradi-
tionally used biomarkers. Alternatively, the data driven ap-
proach is currently employed as a further option. This is based
on arrays of molecules designed to determine response/non-
response to treatment or presence/absence of disease. It is then
followed by molecular differential expression analysis for the
selection of individual molecules for further validation. To
further these novel approaches to systematic biomarker selec-
tion, the growing number of databases and computational re-
view systems should be used [9].
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The Systematic Genome, Transcriptome and Multiomics
Approach
The next level in biomarker studies is a broad approach fo-
cused on systematic genome/transcriptome/multi-omics. This
type of study is driven by large projects such as genome-wide
research projects. The progress in genomics helping understand
cancer, accompanied by a whole range of other omics, has cre-
ated a new biomarker multiplatform in PPPM medicine [10].
Golubnitschaja et al. proposed multi-omics as a promising tool
for diagnosis, targeted prevention and personalised treatments in
the management of triple-negative breast cancer [11]. The devel-
opment of high-output and cost-effective multiple omics technol-
ogies promotes an efficacious treatment of cancer [12].
Biobanks and New Biomarker Testing
Over the past 30 years, biobanking has grown dramatically
and has become an important source for biomarker research.
Biobanks are one of the pillars of personalised medicine.
Samples stored in biobanks are an important source of biolog-
ical material with appropriate data. Being as “civilisation dis-
eases” such as cardiovascular diseases, diabetes, neurodegen-
erative diseases or cancer are currently on the rise, biobanks
can help research, speeding up the search for successful solu-
tions to these serious diseases. Using biobank sources, both
individual biomarkers or multiparameter models can quickly
be tested and afterwards implemented into routine clinical
practice [13].
Expert Recommendations and PPPM Relevance:
& New options for biomarker discovery have already be-
come available and should be properly used to add new
biomarkers to those currently routinely used.
& Multi-omics, as well as computational frameworks, are
highly promising approaches that should be included in
the pipeline for the development of predictive diagnostic
biomarkers, biomarkers for targeted prevention and
personalised treatment in general.
& The most promising approaches in the search for
personalised patient-pathways and markers are those based
on system knowledge andmulti-objective optimisationwhile
taking into account the predictive power and functional rel-
evance of the biomarker. Samples stored in biobanks can
speed up current research into “civilisation diseases” and
help to find successful solutions to these serious conditions.
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Introduction
Biomarkers are efficient tools (features) for predicting
specific types of diseases, malignant and/or benign, as
well as enabling researchers to distinguish the origin of
the various types of normal cells and tissues in a patient.
One can say that the personalization of specific features
may influence the treatment as well as possible outcome
of disease [1].
Several biomarkers have been identified in cancer pa-
tients having significant value for treatment prediction
of the malignant diseases [2,3].
As a rule, these markers have been estimated before the
perspective treatment of the patients with the aim to pre-
dict the outcome of treatment applied and prevent thera-
py side-effects [4]. SOX2 and NANOG are markers usu-
ally associated with cancer stem cells [5]. The presence
of high numbers of undifferentiated stem cells in a tu-
mour usually is a marker of poor prognosis for the sur-
vival of the cancer patient, and consequently, low treat-
ment efficacy [6]. As surprisingly as it may seem, these
surviving cells are rarely being searched for and estimat-
ed after treatment procedures. Their features are rarely
studied. Partly, it is explained by difficulties of obtaining
these cells and studying them in vivo.
Our previous investigations in cell cultures undergoing
changes caused by chemotherapy agents have shown the
development of a population of small-sized cells, called
“microcells” [7]. Microcells are part of the cancer
population and their count usually increases after treat-
ment with anticancer agents. Phenotypically, they are
small round or oval cells with small rim of cytoplasm
around the nucleus, and they look darker when stained.
Working hypothesis, materials and methods
Our present hypothesis postulates that these microcells
gain resistance after treatment and present the anticancer
treatment resistant population within the tumour. The
aim of the present investigation is to reveal possible bio-
markers of this hypothetically treatment resistant cell
population within tumours under the influence of anti-
cancer agents.
Melanoma cells culture SK-MEL-28 were acquired from
the American Type Culture Collection and maintained
as producer recommended. All cell lines were seeded
into 24 multi-well plates with an initial density of
~1 × 105 cells/well and grown in a humidified atmo-
sphere containing 5% CO2 at 37 °C.
Paclitaxel (PTX, Paclitaxel - TEVA 6 mg/ml) was used as a
stress factor for 24 h at the end concentration of 0.6 mg/ml at
37 °C in a 5%CO2 atmosphere for cancer microcell induction.
A cultivation medium was replaced with fresh medium after
treatment, and cells were cultivated for 48 h at 37 °C in a 5%
CO2 atmosphere.
SK-MEL-28 cells were immunocytochemically stained using
standard technique and labelled with primary antibodies
SOX2, NANOG and PCNA antibody, conjugated with rele-
vant secondary antibodyAlexa fluor 488 or Alexa fluor 594 as
manufacturer recommended (Abcam, Origene). Nuclei were
counter stained with DAPI (MP Biomedicals) and cells
mounted in CV Ultra (Leica).
The Leica SP8 Confocal and ZEISS LSM900 microscopes
and 63x objectives (oil, apochromatic, aperture value 1.40)
were used. LAS X lite (Leica Microsystems) and ZEN Blue
lite (ZEISS) image analysis and processing programs were
used.
Results and data interpretation
PCNA (proliferating cell nuclear antigen) expression
(Fig. 1) mainly is related to cell replication and is in-
volved in DNA repair systems [8]; otherwise in control
cells, PCNA expression is observed in cell nuclei and in
cytoplasm. PCNA expression in cancer cells is more like-
ly as a result of post-translation modification, and it is
related to malignant breast cells [9]. After PTX treatment,
we observed microcells near macrocell nuclei (Fig. 1b, c
white➔). These are functional, small (only 2.56 μm per
diameter) cells containing DNA (Fig. 1C white➔).
Increased expression of PCNA represents high replication
activity in microcells (Fig. 2b and c), and it indicates their
high capacity for renewal.
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SOX2 is involved in somatic cell reprogramming, revers-
ing the epigenetic configuration of dedifferentiation of
cells [10]. After PTX treatment (Fig. 2D, SOX2), the an-
tigen SOX2 shows higher expression in nuclei than con-
trol cells (Fig. 2a, SOX2). SOX2 expression have been
shown as a potential CSC marker . Noteworthy,
NANOG-cell nucleus marker, is expressed in cell cyto-
plasm equally strong in both control and treated cells
(Fig. 2, NANOG). The antigen NANOG expression in
cell cytoplasm points to cell malignancy and therapy re-
sistance [11]. SOX2 and NANOG biological markers are
core proteins in stemness and regulating transcription fac-
tors in pluripotency to preserve cell self-renewal [5].
Microcells indicate homogeneous DNA labelling and high
expression of stem cell biomarkers, which characterize
microcell metabolic activity after anti-cancer treatment.
Conclusions
Compared to control cells, microcells have a higher capacity of
renewal and, at the same time, the ability to dedifferentiate to a
pluripotent cell, thus presenting an important source of cancer
resistance to repeated administration of anticancer treatment.
One can postulate that microcells are a predictive resistance fac-
tor of utmost importance. Newly developed microcells acquire
increased mobility and show potency regarding endocytosis.
Therefore, analysis of the microcell population in a tumour un-
dergoing anticancer treatment could be a strong prognostic factor
for patient’s survival, and on the other hand, be a basis for indi-
vidualized characterization (and profiling) because the cell pop-
ulation future structure changes during treatment of a patient.
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Introduction
Diabetes mellitus (DM) is a complex metabolic disorder lead-
ing to a cascade of collateral pathologies, including cardiovas-
cular and neurological diseases, cancer as well as diabetic
retinopathy as the worldwide leading cause of blindness in
humans. Owing to its high prevalence and comprehensive
character of the pathology, 3P medicine based on the predic-
tive diagnostics, targeted prevention and personalisation of
treatment algorithms is considered to be the most optimal
approach to DM management [1].
Visual impairments are characteristic for DM patients,
whereby pathological processes linked to the DM-
related cataract appear to be more complex compared
to the ageing-related non-diabetic one. Accumulated ev-
idence demonstrates the tear fluid analysis as a clinical-
ly relevant tool to predict disease development based on
the molecular make-up providing the targets which can
be further used for preventive measures and treatments
tailored to the person [2]—the concepts known as 3P
medical approach [3].
In contrast to the ageing-related non-diabetic cataract, the
diabetes-related cataract is considered to result mainly from
the antioxidant protection dysfunction. Indeed our pre-
vious investigations revealed peroxiredoxin 6 to be un-
derrepresented in the tear fluid of patients affected by
diabetic cataract [4, 5]. The current study is dedicated to
comparative analysis of peroxiredoxin 6 in the tear fluid
of treated versus untreated diabetic cataract compared to
that of the ageing-related non-diabetic cataract subtype
and healthy controls.
Patients’ recruitment and examination
Patients recruited for the study were 64.1 years old on average.
Three groups were created:
– the first group was diabetes-free; all 50 patients were
diagnosed with the ageing-related cataract; age in the
group was 66.5 ± 4.3 years.
– the second group comprised 50 patients with diabetic
history and DM-related cataract; age in the group was
59.4 ± 1.2 years.
– the control group comprised 25 healthy individuals; age
in the group was 44.3 ± 2.4 years.
Ophthalmological examinations were carried out according to
the generally accepted standard methodology [6].
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Tear fluid sampling and analysis
Of the tear fluid, 0.1 ml per patient was taken without
additional stimulation using a disposable sterile polymer
cannula, which was placed in the lower part of the
conjunctival sac. The tear fluid was frozen immediately
and stored at −20 °C.
The tear protein composition was analysed using mass spec-
trometry as described elsewhere [7]. Mass spectra were ob-
tained on a MALDI time-of-flight mass spectrometer
Ultraflex II BRUKER (Germany) equipped with a UV (Nd)
laser in the mode of positive ions using reflectron. Protein
identification was carried out using the Mascot program
(www.matrixscience.com).
The level of expression of PRDX6 was determined after a
careful analysis of the data obtained by spectrophotome-
try, which presented the total expression level of antioxi-
dant enzymes and the expression level attributable to all
antioxidants except PRDX6. Peroxiredoxin 6 levels were
additionally visualised and quantified using western blot
analysis as described elsewhere [8].
Statistical analysis
For statistical processing of the research results, the
STATISTICA 10.0 software package from StatSoftInc
was used. A statistically significant difference is noted
below as *p ≤ 0.05.
Results interpretation
Protein concentrations in the tear fluid are presented in Table 1
for each group of comparison.
Table 1 The level of peroxyredoxin 6 expression in the tear fluid of group
1 patients before and after surgical treatment compared to the control
group.
Indicators (expression units) Group 1 (n = 50) Control group
(n = 25)
Peroxyredoxin 6 before surgery 3.57* ± 0.35 2.74 ± 0.4
Peroxyredoxin 6 after surgical
treatment
6.92* ± 0.2 2.74 ± 0.4
*р ≤ 0.05 – significantly higher than in the control group
Protein concentrations in the tear fluid are presented in Table 2
for each group of comparison.
Table 2The level of peroxyredoxin6expression in the tear fluid ofgroup2
patients before and after surgical treatment compared to the control group.
Indicators (expression units) Group 2 (n = 50) Control group
(n = 25)
Peroxiredoxin 6 to surgical treatment 1.12* ± 0.3 2.74 ± 0.4
Peroxiredoxin 6 with the use of
Pirenoxine to surgical treatment
3.25* ± 0.5 2.74 ± 0.4
Peroxyredoxin 6 with Pyrenoxine
after surgical treatment
4.07 ± 0.2 2.74 ± 0.4
*р ≤ 0.05 – significantly higher than in the control group
The level of expression of peroxiredoxin 6 in the tear fluid:
– healthy controls: 2.74 ± 0.4 activity nMol/mg/10
– group 1: before surgical treatment 3.57* ± 0.35; after sur-
gical treatment 6.92 ± 0.2
– group 2: before surgical treatment 1.12* ± 0.3; with
Pirenoxin before surgical treatment 3.25* ± 0.5; with
Pirenoxin after surgical treatment 4.07 ± 0.2
*p ≤ 0.05 – significantly higher than in the control group.
Case report
– A 52-year-old patient with compensated DM type 2
– Complains of dryness and itching of the skin
– Ophthalmic complaints: complaints of lack of vision of
the right eye; visual acuity of the right eye is 0.01; visual
acuity of the left eye is 0.7 n/a.
– Diagnosis: OD – Complete Diabetic Cataract; OS – in-
complete diabetic cataract, non-proliferative diabetic
angioretinopathy
The tear protein spectrum was determined for the patient: the
average tear protein concentration was 7.85 μg/ml; active
peroxyredoxin 6 (14 kDa) is not detectable, see Fig. 1.
NANOG
Fig. 1Western blot analysis of the tear fluid proteins: peroxyredoxin 6 is
undetectable before surgical treatment
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The patient was treated with pirenoxin to stabilize the
clouding of the lens and to increase the antioxidant protection,
see Fig. 2. The average concentration of tear proteins was
7.35 μg/ml, active peroxyredoxin 6, 14 kilodaltons – 4.01;
an increase in the activity of peroxyredoxin 6 was recorded.
Conclusions and expert recommendations
The study demonstrated significant qualitative and quantita-
tive differences in protein profiles between non-diabetic age-
ing-related and diabetic cataract. Furthermore, the antioxidant
protection in eyes of diabetic patients is evidently suppressed
as demonstrated for the peroxiredoxin system which is a use-
ful target for both predictive diagnostic analysis and preven-
tive measures to restore the antioxidant defence and protect
lens against oxidative cloudiness. Recommended treatment
with pirenoxin appeared to be beneficial to compensate
diabetes-related antioxidant deficits. Personalised algorithms
might be useful to optimize treatments before and after cata-
ract surgery. Further molecular biological analysis of the tear
fluid in both ageing-related and diabetic conditions is highly
recommended to investigate potential targets for a predictive
and preventive approach.
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Background
To determine the predictors of primary open angle glauco-
ma (POAG) progression successful monitoring and a per-
sonalized treatment approach. This postulate is an integral
principle of predictive preventive personalized medicine
(PPPM) that is to predict a disease development/
progression and targetly prevent it by providing a treat-
ment tailored to the person.
DAPI, SOX2 , NANOG
Fig. 2 Western blot analysis of the tear fluid proteins after pirenoxine
treatment: peroxyredoxin 6 (14 kDa) is wellbdetectable
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Increased intraocular pressure (IOP) and its fluctuations, thin
cornea, low corneal hysteresis, optic disc hemorrhages,
peripapillary atrophy of the choroid, age of patients, female
sex, pseudoexfoliations, late detection of glaucoma, and arte-
rial hypotension or hypertension are commonly considered to
be the main recognized factors of POAG progression. Though
systemic and local vascular factors in regard to glaucoma pro-
gression have been emphasized in literature [1–3], the predic-
tive role of retinal microcirculation is not elucidated.
Optical coherence tomography angiography (OCTA) is a new
non-invasive method for examination of the microcirculation
of retina, optic nerve and choroid—the key structures affected
by glaucoma [4].
The purpose of the present work is to study the predictive
ability of peripapillary and inner macula microcirculation in
glaucoma progression.
Materials and methods
In the prospective and observational study, 85 patients (85
eyes) were followed-up for 2 years and were divided into
two groups on the basis of the presence/absence of pro-
gression detected using the Guided Progression Analysis
(GPA) software on the Humphrey Field Analyzer II.
The study was approved by the Ethical Committee
(Institutional Review Board) of the Institution of Federal
Medical and Biological Agency of Russia and was conducted
in accordance with Good Clinical Practice within the tenets of
the Declaration of Helsinki (Protocol N 5, 05.02, 2016).
At follow-up visits with a 4-month interval, all the pa-
tients underwent complete ophthalmologic examinations
and several imaging and functional tests [4]. The vessel
density (VD) of the parafoveal superficial plexus and in
whole image (wi) en face VD in the disc/peripapillary
region were assessed using optical coherence tomogra-
phy-angiography. Retinal nerve fiber layer (RNFL) and
ganglion cells complex and the inner macular thickness
were measured by SD-OCT, IOP, and corneal hysteresis
using the Ocular Response Analyzer.
The inclusion and excludion criteria have been detailed by
Kurysheva et al. [5].
Mean ocular perfusion pressure (MOPP) was calculated using
the formula: MOPP = (2/3 diastolic blood pressure + 1/3 sys-
tolic blood pressure) × 2/3 –IOP.
Statistical processing
Mann–Whitney U test using Rosner–Glynn–Lee method and
Pearson chi-squared test were applied to compare two inde-
pendent groups by one characteristic.
The area under receiver operating characteristic curve (AUC)
as a parameter’s importance measure for distinguishing the
progression from non-progression eyes was accessed.
Cut-off value was determined by means of Youden’s index.
The numerical data are represented as the mean ± SD.
Statistical processing of the obtained results was carried out
using the standard package of statistical analysis software
“SPSS 16.0 for Windows.” Parameters with p < 0.05 were
considered statistically significant.
Results
The clinical variables with statistically significant AUC for
distinguishing the eyes with glaucoma progression and non-
progression eyes are represented in Table 1. According to this
data, wiVD disc and parafovea vessel density in superficial
plexus had the high AUC that was comparable with AUC for
peak follow-up IOP, MOPP, baseline corneal hysteresis, and
structural parameters measured by SD-OCT.
Table 1 Diagnostic ability of studied clinical parameters in differentiating
the POAG progression and non-progression groups and their cut-off scores




0.792 ± 0.05 (0.677 0.880) 0.000 > 23.8
Corneal hysteresis,
mm Hg





0.736 ± 0.07 (0.589 0.853) 0.001 <=105




0.707 ± 0.07 (0.558 0.829) 0.005 <=45
Age, years
along with
0.710 ± 0.07(0.588 0.813) 0.001 >70
Avg, RNFL, μm 0.692 ± 0.06 (0.567 0.799) 0.002 <=95.7
MOPP, mm Hg 0.682 ± 0.08 (0.521 0.819) 0.030 <=40
Abbreviations: AUC – area under ROC curve; CI – confidence interval,
S.E. – standard error; OCT – optical coherence tomography, ILM – in-
ternal limiting membrane, IPL – inner plexiform layer
A positive correlation was observed between the thickness of
the retinal inner layers in parafovea and the parafovea vessel
density in the superficial layer (r = 0.4, p = 0.01).
Conclusion and expected impact
To the best of our knowledge, this is the first study where the
predictive ability of OCTA parameters in glaucoma progres-
sion was comparable with well-known clinical predictors such
as IOP, corneal hysteresis, and RNFL and OCT thickness
ILM-IPL in inferior hemisphere. There is a growing body of
evidence that early glaucomatous damage involves the macu-
la, especially its inferior hemisphere [6]. The insufficient
blood supply to ganglion cells in macula occurs in early glau-
coma [7]. This is a reason to look more closely at the macula
VD in glaucoma monitoring in order to predict and to detect
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glaucoma progression earlier that corresponds to the first prin-
ciple of PPPM.
Identification of the progression predictors of any disease al-
lows determining a patient’s individual profile. This is re-
quired in accordance with the concept of PPPM [8].
In fact, when a disease is diagnosed for the first time,
prediction of its progression allows optimizing the treat-
ment methods in each particular case and making the
treatment personalized. In glaucoma it means the opti-
mized prescribed method, for example, an earlier transi-
tion to laser or even surgical treatment, that may prevent
further deterioration of visual function; in agreement with
the second principle of PPPM. Even in the case of disease
progression, the identification of individual markers of
this progression will allow choosing the personalised
treatment aimed specifically at these factors, for example,
at reduction of ocular perfusion pressure; in line with the
third principle of PPPM.
In conclusion, the present study has revealed new highly
reliable predictors of glaucoma progression that allow sig-
nificantly expanding the boundaries of generally accepted
standards for glaucoma monitoring.
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Introduction
According to WHO data there are currently 39 million
blind people worldwide, and cataract was found as the
cause of blindness in 51%. Most patients with combined
pathology of the organ of vision (cataract and myopia)
have complications in the early postoperative period
[1,2]. The first place among such complications after
cataract surgery belongs to neurodegenerative changes
in the retina [3]. A dynamic personalized diagnostic ap-
proach to patients with complicated cataract for the pre-
vention of complications in the early postoperative peri-
od in order to improve the quality of vision and quality
of life of this contingent was determined in the present
study.
Materials and methods
The study analyzed the examination of a clinical group
of 100 patients (100 eyes) with a diagnosis of compli-
cated cataract and myopia. All patients underwent cata-
ract phacoemulsification (FEC) with implantation of an
intraocular lens (IOL). Among them were 69 men and 31
women, with the average age of 58.5 years. For compar-
ison, a control group of patients was selected (100 pa-
tients, 100 eyes). These patients were diagnosed with
cataracts without combined ophthalmopathology. All pa-
tients in this group also underwent FEC with IOL im-
plantation. The control group consisted of 58 men and
42 women, with the average age of 60.6 years. Inclusion
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criteria: 2 degree of lens opacity and visual acuity reduc-
tion up to 20/40.
All patients of both groups underwent a morphometric study
of the retina before and on the second day after cataract sur-
gery. The diagnostic study was performed on a Cirrus HD-
OCT optical coherent tomograph (Carl Zeiss Meditec, Inc.,
USA) using Macula 3D for macula disease/single analysis
protocols. To identify neurodegenerative changes in the reti-
na, all patients underwent a qualitative retinal analysis and a
quantitative assessment of the average retinal thickness (total
area average, TAA) before and on the second day after cata-
ract surgery.
Results
An analysis of the protocols of OCT scans showed that in
the main clinical group, 62 patients (62%) on the second
day after surgery showed an increase in TAA by an aver-
age of 25% from the initial parameters, in 31 patients by
10%, respectively, and in 7 patients (7%) the TAA value
remained unchanged. In the control group, in most cases
(84%), the TAA value on the second day after the opera-
tion did not change.
Visometry (determination of visual acuity with optical
correction) on the 2nd day after the operation showed
that, in the main group of 68 patients (68%), the maxi-
mum corrected visual acuity (MCP) was 20/30, in 20 pa-
tients (20%) –20/25 respectively, and in 12 patients
(12%), MKOZ was 20/20. On the contrary, in the control
group, in 85 patients (85%), MKOZ became 20/20, in 10
patients (10%) it was reduced to 20/25, and in 5 patients
(5%) to 20/30, respectively.
In patients of both groups, the appearance of neurodegen-
erative changes in the retina in the form of the degree of
thickening of the retina on the second day after the oper-
ation correlated with the visual result of the operation
(MCH). However, the clinical efficacy of cataract surgery
in groups was different. The worst visual effect on the
second day after the operation was noted in the main
group and was due to the appearance of neurodegenera-
tive processes in the retina, confirmed by OCT data.
Therefore, in each case, depending on the parameters of
TAA, patients were offered an individual treatment regi-
men in the early postoperative period, which prevented
retinal complications in the late postoperative period and
obtained a high visual result on the 5–7th day after the
operation.
Conclusions
Optical coherent tomography of the retina is considered to
be a modern promising direction associated with predic-
tive preventive personalized medicine in complicated cat-
aract surgery [4]. It is advisable to include for each patient
with combined ophthalmopathology (cataract and myopia)
an innovative diagnostic technique—optical coherence to-
mography (OCT) with an assessment of the TAA param-
eter before surgery and on the second day after cataract
surgery. The conducted targeted diagnosis contributes to
suggest early detection of the initial neurodegenerative
processes in the retina [5]. Up to date prevention of retinal
complications in the early postoperative period of compli-
cated cataract surgery will improve the quality of vision in
particular and, accordingly, the quality of life of patients
as a whole.
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Multiple sclerosis (MS)
Epidemiology and symptomatology
Multiple sclerosis (MS) is the most common chronic autoim-
mune CNS disease in young and predominantly female adults
[1]. People with MS suffer from debilitating symptoms such
as poor vision, impairment of motor functions and ambula-
tion, sensory disturbances, bowel and bladder problems, but
also “covert” symptoms such as depression, fatigue, cognitive
dysfunction, pain, and poor sleep [2–4]. Most patients experi-
ence onset of the disease with a relapsing course (RMS), char-
acterized by attacks of neurological dysfunction lasting from
several days to weeks. Many patients advance to a secondary
progressive disease course (SPMS) with or without relapses
with longer disease duration. Up to 15% of patients exhibit a
primary progressive disease course (PPMS) with insidious
progression of neurological deficits from disease onset.
Etiology and risk factors of MS
Although the cause of MS is not known, individual disease
risk is influenced by both genetic and to a larger extent envi-
ronmental factors, the most important of which are Epstein–
Barr virus (EBV) infection, latitude (higher risk with increas-
ing latitude), vitamin D deficiency (associated with sunlight
exposure and thus the latitude gradient), obesity, and smoking
[5].
Neuropathological features
MS is neuropathologically defined by disseminated CNS
white matter demyelinating lesions (“plaques”), a large pro-
portion of which is located around small cerebral veins [6, 7],
suggesting that the vasculature may be involved in lesion for-
mation. However, advanced imaging and neuropathological
studies have demonstrated that tissue damage is not limited
to the white matter. Demyelination and lesions of both the
cortex and the deep gray matter (DGM) are frequently detect-
able in MS and significantly contribute to progression of dis-
ability and cognitive deterioration. In general, progressive
brain volume loss in untreated MS patients is about 1.5 to 2-
fold faster than the physiological brain volume decrease in
healthy aging.
The optic nerve and the retina as part of the CNS also show
frequent involvement in MS. Orbital MRI can visualize optic
nerve lesions in clinically overt optic neuritis (ON), and retinal
axons and ganglion cells degenerate after an ON attack, which
can be quantified by optical coherence tomography [8–10].
However, thinning of the retinal nerve fiber and ganglion cell
layer may also occur without optic neuritis, pointing to sub-
clinical optic nerve involvement or retrograde transsynaptic
degeneration within the visual pathway [11]. Loss of retinal
tissue is already measurable early over the course of MS and
correlates with poor visual function and reduced visual quality
of life.
The spinal cord is also frequently affected by demyelination
and axonal damage, which can result in substantial clinical
disability, such as walking difficulties and bladder problems,
and may lead to cord atrophy. Spinal cord atrophymay also be
caused by degeneration of tracts elsewhere in the CNS and
could indicate the inception of the progressive phase of MS.
Immunopathogenesis of MS
MS immunopathogenesis has not been fully clarified. It is
however generally accepted that the disease is a consequence
of a derailed immune system and that autoreactive T cells, B
cells, and the innate immune system are involved in
immunopathogenesis [12]. The influx of activated immune
cells into the CNS is enabled by a leaky blood–brain barrier
with increased vascular permeability and precipitates demye-
lination in experimental autoimmune encephalomayelitis
(EAE) and presumably also in human MS. The interaction
of CNS-invading activated immune cells with glial cells (oli-
godendrocytes, astrocytes, and microglia) and neurons and
axons initiates and perpetuates tissue damage.
Diagnosis of MS
An MS diagnosis is typically established when neurological
symptoms are paralleled by characteristic inflammatory white
matter lesions on brain and spinal cord MRI, and when the
cerebrospinal fluid displays increased intrathecal immuno-
globulin synthesis or oligoclonal bands suggestive of an im-
mune reaction in the CNS. Diagnostic criteria (the so-called
McDonald criteria) were established to enable MS diagnosis
as early as possible in the context of a typical clinical presen-
tation [13]. Exclusion of relevant differential diagnosis is par-
amount given there is no clinical or paraclinical feature unique
to MS, which is reflected by the high number of false
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diagnoses. Important differential diagnoses to be considered
are migraine, vascular diseases/comorbidities, neuromyelitis
optica spectrum disorders, rheumatologic diseases, Susac syn-
drome, and other less prevalent diseases (for details, see [14]).
Treatment of MS
Several immunotherapies for the treatment of MS have been
developed over the past decades [15]. These drugs are pre-
dominantly approved for RMS and reduced the attack fre-
quency by an order of magnitude of between 30 and 70%
compared to placebo or active comparator in phase III clinical
trials. Some of these medications may slow down progression
of disability. Post authorization studies posit that these immu-
notherapies have resulted in a better prognosis of MS and that
time to reduced walking distance or wheelchair dependency
can be prolonged. In addition, most drugs reduce the number
of new white matter lesions, and some medications may slow
down progression of brain atrophy. The approved drugs failed
to clearly demonstrate neuroprotective properties, which un-
derscores the urgent need for regenerative therapies [16].
Several attempts to target potentially modifiable environmen-
tal factors inMS (for example, diet, obesity, smoking, vitamin
D supplementation) have yielded inconclusive results or re-
main underway [17–19]. Besides efforts to target the dysreg-
ulated immune system and hereby reduce relapse rates and
disability progression, therapeutic efforts to alleviate burden-
some and disabling fatigue, depression, sleep disorders, cog-
nitive dysfunction, and pain are equally important, although
evidence-based treatment recommendations on “symptomatic
therapy” are scant [20].
How could and MS and FS be interrelated?
Brain and retinal vasculature are involved in MS, and studies of
cerebral perfusion in MS have occasionally been performed.
Decreased cerebral blood flow has been found in both the gray
and white matter of MS patients as well as in the so-called
“normal-appearing white matter” (NAWM) [21]. Interestingly,
one study reported decreased CBF in the NAWM of patients
with CIS, and another study found reduced venous density in
the periventricular areas of patients with short disease duration
[22]. This suggests altered perfusion to be a phenomenon occur-
ring in early disease, although the underpinnings of cerebral
hypoperfusion in MS are incompletely understood. Initially, ce-
rebral hypoperfusion was believed to occur subsequent to axonal
and neuronal degeneration, reflected by brain volume loss and
resulting from reduced metabolic demand. However, this hy-
pothesis has recently been questioned, while an alternative direc-
tionality is also conceivable. In MS, impaired astrocytic energy
productionmight contribute to diminished arteriolar vasodilation
through lower K+ recovery in the perivascular space.
Preliminary OCT angiography and functional retinal imaging
studies reported reduced arteriolar and venular retinal blood flow
velocities in MS, and rarefaction of retinal vessels in eyes with
optic neuritis. Interestingly, rigidity of retinal vessels is a com-
mon observation in both MS and FS. Another commonality of
these conditions are increased concentrations of the vasoconstric-
tive endothelin-1.
Do MS and Flammer syndrome coincide?
Association between FS [23] and MS has been investigated
[24]. A questionnaire with 15 typical symptoms and signs of
FS was given to 58 people with MS who were hospitalized in
a Rehabilitation Centre and to 259 control subjects in shop-
ping malls. MS patients were on average 44.7 years old and
had relatively high neurological disability (above 5 on the
Expanded Disability Status Scale). MS patients reported six
of the 15 FS signs and symptoms significantly more often than
controls: dizziness, low body mass index, cold hand/feet, ten-
dency toward perfectionism, reduced thirst, feeling cold.
Additional symptoms (tinnitus, headaches, increased pain
sensation, long sleep-onset time, migraines increased response
to certain drugs, low blood pressure) also occurred more fre-
quently in MS than in controls, although not significantly.
Some of these symptoms are known to occur in MS and can
be related to the polyfocal affection of multiple areas of the
brain and spinal cord. The study is limited by a highly selected
MS cohort (inpatients with advanced disease). To further sub-
stantiate a possible association of FS and MS, newly diag-
nosed MS patients in the CIS or early RRMS stage will have
to be investigated. Moreover, causality of the reported co-
occurrence in either direction cannot be inferred. If FS in-
creases the risk of MS through vascular dysregulation or if
MS causes FS-like symptoms and signs through secondary
vascular dysregulation (see above) remains to be clarified in
subsequent studies.
Susac syndrome (SuS)
Susac syndrome is a very rare (several hundred published
cases), T cell mediated CNS disorder affecting small arteries
and arterioles of the brain, retina, and inner ear, hereby caus-
ing a clinical triad of visual disturbances, hearing deficits, and
encephalopathy. Abnormal neurologic symptoms and find-
ings such as vertigo, ataxia, gait abnormalities, upper motor
neuron signs, and sensory disturbances are found only in a
subset of patients. Diagnostic procedures include CSF analy-
sis (with typically elevated protein but rarely oligoclonal
bands), MRI (supratentorial white matter lesions, affection
of the corpus callosum (CC) with “snowball lesions” in acute
stage and pronounced atrophy of the CC in chronic stages),
and fluorescein angiography (FAG) and OCT to detect retinal
affection (branch retinal artery occlusion and arterial wall
hyperfluorescence). Establishment of SuS diagnosis may be
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delayed because the clinical triad is rarely complete at onset
[25]. SuS is amenable to treatment with high dosemethylpred-
nisolone and eventually plasmapheresis in acute phases and
prednisolone, intravenous immunoglobulins, azathioprine,
methotrexate, rituximab, and others as maintenance therapy,
while many MS immunomodulators seem to be inefficacious
or even harmful. Some authors propose the use of antiplatelet
or anticoagulant therapy to reduce the risk of thrombosis in
small arterioles. Flammer and colleagues reported increased
ET-1 levels in SuS and proposed that patients with primary
vascular dysregulation/FS have an increased risk for SuS.
However, as Flammer et al. emphasize that SuS through its
involvement of microvessels may also cause secondary vas-
cular dysregulation, and rightly so call for further studies that
help clarify the presumed causality of the association between
SuS and vascular dysregulation and the temporal evolution of
pathogenic events.
Concluding remarks and expert recommendations
FS and MS seem to exhibit some overlap in clinical pre-
sentation and presumably share pathophysiological com-
monalities. However, an increased risk of MS in subjects
with FS and vice versa cannot be inferred due to the
scarcity of the data. Studies on symptoms of FS in pa-
tients with newly diagnosed MS need to be carried out,
and with regard to FS symptoms, these patients will have
to be followed longitudinally over the course of the dis-
ease. Structural and functional changes of the cerebral and
retinal vasculature should be investigated in people with
MS with and without additional FS symptoms. These
studies will hopefully help to clarify mutual pathogenetic
and clinical interrelations and leverage predictive diagnos-
tics for both conditions, thus identifying people at risk to
develop an overlap syndrome. This is a prerequisite for
targeted prevention that will be built upon better under-
stood clinical phenotypes and biomarker studies, which
will ultimately pave the way to a personalization of med-
ical services for patients with neuroinflammatory
disorders.
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Introduction
The high appealability of patients with anxiety disorders to
private clinics, including repeated ones, indicates the need to
look for effective treatment regimens.
Issues of effective correction of mental disorders based on a
personalized approach remain insufficiently studied in theo-
retical and practical terms.
The system of prevention, diagnosis and treatment in
Ayurveda is based on a constitutional approach. It can provide
prediction, personalized treatment, and effective preventive
programs.
The possibilities of using the potential of Ayurveda to develop
personalized medicine ideas have been discussed by re-
searchers [1–3].
Research confirms the relationship between the imbalance of
doshas and the results of psychopathological Western ques-
tionnaires. Thus, for example, there is a connection between
the imbalance of Vata and Pitta doshas and a high level of
anxiety [4].
Several clinical studies focus on the effectiveness of a diet
based on Ayurveda’s personalized approach in the treatment
of anxiety disorders [5].
The aim of the study is to assess the potential of Ayurveda for
the selection of personalized treatment regimens for anxiety
disorders.
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Materials and methods
Specialists at the Scientific and Practical Center for Traditional
Medical Systems of the Sechenov University have developed a
protocol for the diagnosis and treatment of anxiety disorders,
based on a personalized approach of Ayurveda in combination
with an assessment of the patient’s dominant representative sys-
tem (auditory, visual, kinesthetic).
The study involved 43 patients with an established diagnosis
of generalized anxiety disorder according to ICD 10.
The choice of a psychotherapeutic technique was determined
by the outcome of the Prakriti and Vikriti questionnaires de-
veloped in the Scientific and Practical Center for Traditional
Medical Systems and F. Puselik’s representative system ques-
tionnaire. The choice of diet was determined by the test results
of the Vikriti questionnaire. The effectiveness of the interven-
tion was evaluated on a Hamilton anxiety scale (HARS).
Results
According to the results of the Vikriti questionnaire, Vata
dosha prevailed in 26 patients, and Pitta dosha prevailed in
17 patients.
In each of these groups, indicators of a representative system
were evaluated. Among patients with Vikriti Vata, the audito-
ry system predominated (15 patients), there were also 11 pa-
tient with the kinesthetic system. Among patients with Vikriti
Pitta visuals prevailed (11 patients), there were also 6 patients
with a predominant kinesthetic system.
The treatment algorithm was developed on the results of
the Vikriti questionnaire and the dominant representative
system.
Patients with a predominance of the Vata dosha and the auditory
system had sessions of cognitive-behavioral therapy and existen-
tial psychotherapy, during which the cognitive component of
anxietywas corrected. In addition, patientswere trained in breath-
ing techniques. In this group, the HARS results decreased from
25.3 ± 2.7 to 5.8 ± 0.21.
In workwith patients with a predominance of the Vata dosha and
kinesthetic system, the emphasis was on the somato-vegetative
and anxiety components. The techniques of body-oriented psy-
chotherapy, Jacobson’s progressive muscle relaxation were used.
In this group, the HARS results decreased from 23.1 ± 2.7 to
8.2 ± 0.7.
A group of patientswith a predominance of the Pitta dosha and the
visual systemunderwent art therapy, patientswith a predominance
of the Pitta dosha and the kinesthetic system were trained in
Jacobson’s progressive muscle relaxation. The somato-
vegetative and behavioral components of anxiety were corrected
using these methods. The level of anxiety decreased from 22.3 ±
2.4 to 8.5 ± 0.8 and from 24.4 ± 2.6 to 7.3 ± 0.6, respectively.
The most persistent result was observed in patients with an
auditory representative system, which is consistent with se-
lected methods of therapeutic exposure. A significant number
of patients in this category maintained a stable therapeutic
effect, despite the impact of stressful factors in the follow-up.
Additionally, dietary and life style recommendations were in-
cluded in the treatment protocol; they were different for pa-
tients with a predominance of Vata and Pitt doshas.
The next stage, the follow-up study, was conducted 6 months
after the intervention. None of the patients had clinically sig-
nificant relapses.
Conclusions
1. Effective treatment of anxiety disorders requires ap-
proaches of predictive, personalized, preventive medicine
(PPPM). Ayurveda’s constitutional approach can provide
targeted treatment and prevention programs. Thus, when
selecting methods of psychotherapy, we can take into ac-
count the dominant dosha. For example, it was noted that
in patients with a predominance of the Vata dosha, the
cognitive component of anxiety and respiratory distur-
bances were expressed, and therefore breathing exercises
and cognitive therapy techniques were effective. In pa-
tients with a predominance of Pitta dosha, the behavioral
component of anxiety, muscle tension prevailed, and pro-
gressive muscle relaxation training and behavioral tech-
niques were effective.
2. The use of personalized secondary prevention programs,
including diet and lifestyle recommendations, is important
for the secondary prevention of anxiety disorders.
3. The study demonstrated the relationship between the
Prakriti–Vikriti Ayurveda concept and the representative
system. The identification of the auditory representative
system as dominant can be considered as a predictor of
effectiveness of psychotherapeutic intervention.
Outlook
A follow-up large-scale study is necessary to confirm the pre-
sented results or to optimize the results for individual patients.
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Introduction Strain redistribution and pressure points displace-
ment [1] of the feet are important points for detecting and per-
sonalizing treatment of the neurogenic feet deformities.
Predictive, preventive and personalized medicine predicts the
disease development and prevents its progression at all stages
of the disease.
Foot deformities can be caused by changes in the skeleton, mus-
cle function disturbances [6], central and peripheral nervous sys-
tem diseases, etc.
T h e c omp r e h e n s i v e e x am i n a t i o n , i n c l u d i n g
electroneuromyography (ENMG), stabilometry and functional
scale of the lower limb (LEFS) allows identifing the foot
disturbances.
The predictive, preventive and personalized algorithms allow
choosing the most optimal and effective approach taking into
account the individual characteristics of the patient [7].
The foot pathology—an important neurogenic diagnostic
criterion
Feet deformities are often the result of central and peripheral
nervous system diseases [4], such as Charcot–Marie–Tooth
disease (CMT), spina bifida [3], compression neuropathies
of the lower extremities [5], Parkinson’s disease, multifocal
dystonia, multiple sclerosis (MS) and mononeuropathy.
Mononeuropathy—the most common disease of the pe-
ripheral nervous system
According to statistics, mononeuropathies are quite com-
mon and account for approximately 50% of all periph-
eral nervous system diseases and occupy 2nd place for
the entire disability [2]. The study involves 39 patients
with mononeuropathies of the sciatic nerve compression
(PS), meralgia paraesthetica (Bernhardt–Roth syndrome),
common peroneal and tibial nerve compressions.
The personalized approach in the framework of feet de-
formities diagnosis
The personalized approach was used for the primary
diagnosis of neurogenic feet deformities. The obtained
diagnostic data significantly enhanced the therapeutic
effect and decreased further symptoms manifestation,
including muscle strength and tone descension, muscle
hypo- and atrophy, lower extremity joints and lumbar
intervertebral discs overload. The diagnosis included
electroneuromyography (ENMG), stabilometry and func-
tional scale of the lower limb (LEFS). The feet defor-
mities and impaired function presented in 55% of cases
as paralytic (equinopolar, equinovarus) deformity,
among which a hollow foot presented in 29% of cases.
The results were directly dependent on the affected pe-
ripheral nerve and impaired muscles involved in the
pathology. The paralytic feet deformities developed
due to the muscle imbalance, leading to the foot points
support displacement (calcaneus, distal phalanges of the
1st and 5th toes). The LEFS scale indicated a lower
limb function depression on the affected side.
The pathological stereotype of movement consequences
The patients had changes in motor status, sensitivity and
reflexes decrease on the damaged side. A number of
patients, due to the early stage of the disease, had
unmanifested neurogenic feet deformities. The impulse
average values on ENMG were below normal, corre-
sponding with the clinical diagnosis. Patients with mod-
erate neurological deficit showed a gait decrease accord-
ing to the foot contact time changes on the stabilometry.
In addition, the load reduction on the calcaneus and
distal phalanges of the 1st and 5th toes was detected.
PPPM—an effective method of rehabilitation and preven-
tion of foot deformities
Predictive, preventive and personalized medicine enables
us to diagnose and timely treat the compression
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symptoms, foot deformities, which prevents further
manifestations of the disease, such as muscle hypo-
and atrophy, joints overload with dystrophic changes
development and intervertebral hernias development.
The rehabilitation course includes manual therapy of
the feet and lower legs; the production of individual
orthopedic insoles, physical exercises affecting certain
muscle groups and specific drug therapy.
Conclusions The strain redistribution and pressure points
displacement assessment enables estimating the deformation
foot degree, taking into account the disease symptoms severity
in each patient. This algorithm fits into the foundation of
PPPM. The muscle and neural status assessment helps to pre-
vent further disease progression.
The treatment showed significant improvement of the impulse
velocity rate of motor fibers by ENMG in 88% of cases, align-
ment of the foot points is supported by the stabilometry and
improvement of the LEFS scale characteristics. Finally,
PPPM is essential to improve individual outcomes at any
stage and treat manifested symptoms of the disease.
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Introduction
The increase in life expectancy of the European population has led
to an increase in the burden of diseases occurring with cognitive
deficits (dementia, Alzheimer’s Disease). Brain-related disorders
are expected to affect at least one in three persons at the age of 75,
costing approximately 800 billion euro every year. The cost is
comparable to that of cardiovascular diseases, cancer and diabetes
put together [1]. To date, there is no generally accepted classifica-
tion of pre-dementia cognitive disorders (PDCDs): more com-
monly, the term “mild cognitive impairment” (MCI) is used for
assessing the prodromal stage of neurodegenerative diseases to
refer to the reversible disorders [2]. PDCOs are heterogeneous in
the mechanisms of their occurrence, involving genetic predisposi-
tion but also a number of modifiable factors, the synergic combi-
nation of which potentiates the risks. Thus, the search for new
markers for the reversible disorders at the stage of MCI, stratifica-
tion of patients and development of personalized treatment ap-
proach are the main ideas of predictive preventive and personal-
ized medicine (PPPM).
The aim of the pilot researchwas to develop risk-based screening
strategy for MCI and study the interconnections between brain
hypoxia, MCI and postural muscle stress.
The study outlines
The study included 118 patients (38men and 80women), average
age 65 ± 4.6 years,with “office syndrome” - combinedmyofascial
pain in the cervical part of the vertebral column, chronic fatigue
syndrome (CFS) and MCI. Neuropsychological tests—Mini-
Mental State Examination (MMSE) and Montreal cognitive scale
(MoCA)—were used to detect the cognitive and emotional status.
Neurological examination and magnetic resonance imaging con-
ducted were to identify the role of the biomechanical disturbances
in the cervical region of the vertebral column in affecting the state
of cerebral blood flow. Genetic tests used for assessment of
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tendency to depression, obsessive-compulsive disorders, demen-
tia, addictions (smoking, alcoholism, overeating), mood disorders,
and anxiety. The neuro-energo-cartography (NEC) method of vi-
sualization was used to study cerebral metabolism and measure
the degree of acidosis and hypoxia in the brain tissues.
Results
Themain complaints in patients were divided into two groups:
disorders in the cognitive, personal, emotional status, includ-
ing headache, fatigue, memory, and sleep problems; somatic
disorders, including persistent muscle pain, a sense of “stiff-
ness”, frequent pain (thorax, cervical spine), various joint pain
(without redness or swelling), and shortness of breath. Neuro-
vertebral examination revealed biomechanical markers, in-
cluding muscular discoordination, rigidity in the shoulder gir-
dle, myotonic “tunnel-syndromes” in cervical spine, and pos-
tural displacement in all patients. Muscle spasms, the fascia,
and cranial membranes kinetics restriction contributed to
slowing down of the cerebral blood flow and obstruction of
venous outflow. The NEC analysis revealed signs of function-
al inter-hemispheric asymmetry and different levels of cere-
bral acidosis as biomarkers for brain hypoxia.
The main treatment goals were creation of personalized inte-
grative programs of rehabilitation for patients with different
postural, neurovascular disturbances to remove the brain hyp-
oxia and return them into “corridor of self-regulation”.
Complex therapy included cognitive and behavioral therapy; com-
plementary therapies included connective tissue techniques,
methods of osteopathy for spasmodic muscles releasing, and the
neuro-vascular “tunnel syndromes” removal. Intermitted hypoxia
therapy and medicines (neuro-protectors, vitamins, anti-oxidants)
were used for patients with cerebral acidosis for normalization of
the brain metabolism and reduction of oxidative stress.
Coordination gymnasticswas used for patientswith postural prob-
lems. Recommendations to healthy lifestyle and working place
with ergonomic equipment were given to all patients. A compre-
hensive personalized rehabilitation program improved patient’s
clinical and emotional background, memory and cognitive func-
tions. NEC examination marked the trend in recovery of inter-
hemispheric connections and interactions; normalization of the
bioelectrical activity in the brain, improvement of cerebral metab-
olism, and plasticity (Fig. 1a & b).
Conclusions and outlook
In this pilot study, we compared the prognostic mani-
festations of postural muscle stress, cerebral metabolism,
and mild cognitive impairment in patients. A new pro-
tocol for personalized profiling of working-aged individ-
uals was developed. Neuropsychological, neuro-verte-
bral, and instrumental NEC express-visualization tech-
nologies for diagnosis of stress-induced conditions (dis-
turbed body posture, neuro-vascular “tunnel syndromes”,
cerebral acidosis) helped indicate the early stages of
neurodegenerative diseases and include the patients with
MCI into the risk group.
Conventional methods in PPPM programs (modification
of life style, diet, physical activity) can decrease side-
effects of drugs and motivate the patients to take per-
sonal responsibility of their own health.
Effective screening strategies may result in earlier dis-
ease detection, which provides possibilities for more
effective treatments, to diminish the disease burden,
and help transition the healthcare system to the preven-
tive, predictive, and personalized medicine concept.
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Fig. 1 a Cerebral acidosis in a 45 y.o. patient. b Decreasing of cerebral
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Introduction The piriformis muscle syndrome (PSM) pa-
tients’ treatment is difficult due to the late stage of diag-
nosis [2] and misjudgment of the magnitude of the dis-
ease. Piriformis syndrome is accompanied by biomechan-
ical dysfunctions at the pelvis and lower extremities and
tension of the myofascial components of the musculoskel-
etal system around the affected area. Predictive, preven-
tive and personalized medicine includes exact diagnosis
and timely treatment of the disease and is effective in
the later stage.
Risk factors can be fixed
Piriformis syndrome occurs quite often in the population.
According to statistics, 6% of all patients presenting with
low back pain had PS [2]. Several risk factors cause the
disease such as anatomic variation of sciatic nerve,
overloading the piriformis muscle with prolonged walk-
ing, running or prolonged sitting [6].
PS is frequently diagnosed at later stages
Usually, PS is confirmed in the late stages of the disease,
accompanied with the obvious symptoms, including inten-
sive pain in the gluteal region, while siting more than 10–
15 min, pain irradiation along the sciatic nerve and im-
paired gait. Periodic examination could promote early pre-
vention of the disease in the population.
Early diagnoses play a key role in PS manifestation
The physiotherapist’s knowledge of myofascial syndrome af-
fecting the piriformis may help in early diagnosis and treat-
ment [1]. In addition, PS can be detected with the aid of MRI
and rheovasography (RVG) [2]. The study involves 60 pa-
tients, with periodic non-intensive myofascial pain in the glu-
teal area, aged from 30 to 40. All participants passed MRI,
stabilometry, and rheovasography (RVG) of the lower ex-
tremities. The MRI showed the type B anatomic variation of
the sciatic nerve [4] in 42% and pyriformis muscle changes in
86%. In 95% of cases, there were changes in stabilometry,
including displacement of the pressure center [5] with a twist-
ed pelvis, and 82% of patients had changes in RVG, including
blood flow disturbance (spasm of arterioles and expansion of
venules) [3]. In 9% of cases, there were no changes in the
piriformis muscle and the sciatic nerve.
Short rehabilitation period
The remaining patients underwent the early rehabilitation
course, including pharmacotherapy, physiotherapy, and
acupuncture within 1.5–2 weeks. The effectiveness of re-
habilitation was evaluated with MRI, stabilometry, and
rheovasography (RVG). After the rehabilitation course,
the piriformis muscle changes decreased down to 0.9%.
Student’s t test proved the 3-P algorithm for rehabilitation
to be the most effective. The average value of t-emp ap-
plicability evaluating the proposed hypothesis is >2.042
of t-critical values (p = 0.05).
PSmanagement requires a new diagnostic approach in the
framework of predictive, preventive, and personalized
medicine
In the end, the main problem is undiagnosed PS, which re-
quires a new diagnostic approach in the framework of the
predictive, preventive, and personalized medicine approach
based on the targeted preventive measures correction of phys-
ical activity, early multi-level diagnostics, improved patient
stratification, and treatment algorithms, taking into account
their individual health characteristics and manifestations of
the disease.
Conclusions Thus, predictive, preventive, and personal-
ized medicine is effective in patients suffering from PS.
A population study at the initial stages of the disease is
necessary to prevent syndrome progression and enable
rapid recovery. Identifying the abnormal variation of the
sciatic nerve makes it possible to prevent future disease
development. Finally, 3PPPM is essential to improve in-
dividual outcomes at any stage and treat the manifested
disorder.
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Background
Despite the success achieved in treatment and prevention
of atherosclerotic cardiovascular (СV) diseases, they re-
main in leading positions in the overall structure of mor-
bidity and mortality worldwide [1]. This situation is
largely due to the lack of an effective system of mass
predictive diagnostics in active age individuals [2], which
until recently was limited to assessing the main risk factor
(RF) profile [3,4]. Meanwhile, young people (YP) may be
carriers of preclinical atherosclerosis [5]. It has already
been established that atherosclerotic diseases begin to
develop on average 30 years before their clinical manifes-
tation. The modern lifestyle predisposes persons to their
rapid rejuvenation. Recommended riskmetric scales were
studied primarily in persons of more mature age.
Therefore, hopes are pinned on the timely diagnosis of
original vascular phenotype, estimated by vascular age
(VA), which, in turn, is predetermined by an indicator
of arterial wall stiffness. Obtaining such data is necessary
to address the issues of individualized prevention of these
diseases and their further personalized treatment.
Therefore, some authors have recently proposed the con-
cept of early vascular aging or EVA syndrome [6]. Its
detection indicates that the patient has the most unfavor-
able vascular phenotype, in which his biological age ex-
ceeds passport (chronological) age [2]. A high level of
predictive potential in such phenotype has already been
proven [5]. Some authors believe that using vascular age
is associate with more effectively predicting features of
the atherosclerotic pathology course in comparison with
traditional riskometric systems.
Aim
To compare predictive instrumental screening data to detect
EVA cases among YP with results of common riskometric
scales, as well as to evaluate the possibility of correcting their
vascular stiffness in the course of preventive intervention.
Material and methods
Within the framework of the University’s preventive project,
angiological screening was performed in 243 YP 18–25 y.o.
using the VaSera-1500 device (Fukuda Denshi, Japan), which
allows evaluating suchmeasure of vascular stiffness as cardio-
ankle vascular index (CAVI). Quartile analysis of CAVI was
performed. According to experts, the fourth CAVI-quartile
corresponds to EVA-syndrome. The profile of main RF was
also assessed. We used European Society of Cardiology
(ESC) and Framingham riskometric scales. CAVI was evalu-
ated before and after an 8-month preventive intervention that
included correction of identified RF. The preventive program
was carried out under guidance of an interdisciplinary team of
specialists from the University Health Center using real and
Internet technologies to monitor implementation of the pro-
gram by each participant. Data was processed using the
“Statistica 10.0” software package (StatSoft Inc., USA).
Results
In this YP sample, the CAVIminimumwas 3.3 and maximum
was 8.1. The CAVI value corresponding to EVA-syndrome
was higher than 6.5 in boys and higher than 6.3 in girls.
According to results obtained using the accepted risk-
measuring scales ECS and Framingham, all young carriers
of EVA-syndrome had low CV risk. This suggests that, on
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one hand, these scales have no diagnostic value for YP, and,
on other hand, the assessment of VA is reclassifying potential
for CV risk in this age group. Due to this instrumental tech-
nology, YP have an understanding of the difference between
their passport and vascular age. It also influenced the motiva-
tion of YP in terms of their participation in preventive educa-
tional activities. The coverage of healthy lifestyle education
was significantly higher among those who passed this sur-
vey—95.4% compared to 37.8% in unexplored persons (p <
0.05). This YP expressed a desire to participate in a preventive
program for correcting behavioral RF. For eight months of such
preventive intervention, the CAVI-level among boys decreased
by 9.3% (n/s), and among girls it decreased by 14.2% (p <
0.05). The presented data are consistent with the opinion of
other authors on the feasibility of early predictive diagnosis of
preclinical atherosclerosis in YP [6]. Angiological screening is
optimally suited for this purpose. The predictive diagnostic ad-
vantages of vascular stiffness compared with other RF are due
to its nature as a “tissue” biomarker rather than a “circulating”
biomarker such as lipids and glucose [3]. Arterial stiffness in-
tegrates the long-term effect of all other RF.
PPPM-associated conclusion and prospects
Thus, angiological screening is a more informative meth-
od compared to riskometric scales for predictive diagnos-
tics in YP. Detection of unfavorable vascular phenotype
makes it possible to transfer young carriers of EVA-
syndrome from the low- to high-risk CV group. The time-
ly start of behavioral RF-correction within preventive in-
tervention with the aim of maximum individualization is
important. In the case of further development of clinical
manifestations of atherosclerotic CV disease, the avail-
ability of the premorbid dynamics of previous vascular
phenotype will contribute to more personalized therapy
of detected pathology. This approach to individualized
long-term management of persons starting from their
young age is fully consistent with the principles of pre-
dictive, preventive, and personalized medicine [7].
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Background
The progressive loss of elastic properties of large arteries is a
typical phenotype of vascular aging. The underlying mecha-
nisms (collectively known as “arteriosclerosis”) involve several
natural (age-dependent) pathophysiological processes, such as
the fragmentation and thinning of elastin lamellae due to its
“material fatigue” from cyclic loading, the cross-linking of col-
lagen fibers by advanced glycation end-products as well as sev-
eral others [1]. Arteriosclerosis coexists with atherosclerosis (the
development of intimal atheromatous plaques) and both process-
es jointly contribute to individual morbidity risk. Numerous
studies have demonstrated that increased stiffness of large central
arteries (quantified as aortic pulse wave velocity, PWV) is an
independent predictor of morbidity and mortality [2].
One of the most important mechanisms of arteriosclerosis is
the calcification of elastic elements in the vessel wall.
Vascular or tissue calcification represents a highly regulated
and potentially reversible process. On a cellular level, it shares
many pathways involved in bone mineralization [3]. The ma-
trix γ-carboxyglutamate protein (matrix Gla protein, MGP)
represents the natural factor of the “anti-calcification defense”
of human tissues (allowing even a reversal of the calcification
process) and vitamin K is the essential co-factor of its matu-
ration to biologically active forms [4]. Circulating
desphospho-uncarboxylated isoform of MGP (dp-ucMGP), a
biomarker of both vitamin K status and biological activity of
MGP, was associated with the extent of vascular calcification,
as well as the incidence risk of cardiovascular events [4,5].
Predictive, preventive, personalized medicine (PPPM) strate-
gies for cardiovascular diseases are receiving increasingly
more attention of late [6]. The immediate effort should be
focused on screening methods and the indication of suitable
interventions for particular individuals based on their cardio-
vascular risk stratification. In concordance with PPPM, new
biomarkers and multivariate models are frequently used and
the promising results achieved [6].
In line with the physiological role of vitamin K and MGP, we
have investigated the association between baseline dp-ucMGP
concentrations and the following natural course of arterial
stiffening in a prospective study based on the general popula-
tion setting.
Methods
The study cohort consisted of 541 individuals with a median
follow-up of 8.0 years, all examined as a part of the Czech post-
MONICA study in 2008 and 2016/17 [7].
Aortic PWVwas obtained after 15min of rest in a supine position
using a SphygmocorMM3 device ((AtCorMedical Ltd., Sydney,
NSW, Australia). Intra-individual PWV difference (follow-up
minus baseline value)was divided by the exact time between these
two visits and a parameter obtained (∆PWV/year, i.e. individual
change of PWV per year of follow-up) to be used as the primary
estimate of individual age-dependent arterial stiffening.
Accelerated arterial stiffening was arbitrarily set as ∆PWV/year
≥0.2 m/s. In addition to the basic parameters (lipids, creatinine,
glucose, etc.), the concentration of the soluble receptor for ad-
vanced glycation end products (sRAGE) was quantified using
ELISA methods (R&D Systems Inc., Minneapolis, MN, USA).
Dp-ucMGP was quantified in citrate plasma samples using the
InaKtif MGP iSYS kit (IDS, Boldon, UK), a pre-commercial
automated assay based on the sandwich (dual antibody)
ELISA kits developed by VitaK (Maastricht University,
The Netherlands).
Results
Detailed characteristics of the study sample at baseline are
shown in Table 1. The univariate association between ∆PWV/
year and other clinical parameters are shown in Table 2. Age,
male gender, history of vascular disease, treatment with antihy-
pertensives, with RAAS blockers and statins all significantly
positively correlated with ∆PWV, while a negative association
was found between sRAGE and baseline PWV. Both baseline
PWVand∆PWVper year increased across dp-ucMGP quintiles
(Fig. 1) and these trends in both dependent variables remained
significant after adjustment for potential covariates, i.e. age,
gender, mean arterial pressure, sRAGE, treatment with antihy-
pertensive drugs and with antidiabetics, plus baseline PWV if
∆PWV per year was compared (Fig. 1).




male gender [%] 45.2
manifest vascular disease [%] 5.3
current smoking [%] 30.6
body mass index[kg/m2] 26.9 (4.4)
systolic blood pressure [mmHg] 127.3 (16.0)
diastolic blood pressure [mmHg] 80.9 (9.0)
mean arterial pressure[mmHg] 96.4 (10.3)
any antihypertensives [%] 29.1
RAAS blockers [%] 18.9
arterial hypertension# 42.5
LDL cholesterol[mmol/L] 3.11 (0.89)
statins [%] 12.6
fasting glycemia[mmol/L] 5.21 (0.82)
antidiabetics [%] 1.9
overt diabetes$[%] 4.2
estimated glomerular filtration (CKD-EPI) [mL/min] 86.0 (15.3)
sRAGE [pg/mL] 1349 (758)
dp-ucMGP [pmol/L] 536 (273)
warfarin[%] 2.0
baseline PWV [m/s] 7.6 (2.0)
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follow-up PWV[m/s] 9.1 (2.3)
∆PWV/year§ [m/s] 0.18 (0.24)
RAAS, renin-angiotensin system; LDL, low-density cholesterol; sRAGE,
soluble receptor for advanced glycation end products; dp-ucMGP,
desphospho-uncarboxylated matrix Gla protein; PWV, aortic pulse wave
velocity
# systolic ≥140 or diastolic blood pressure ≥ 90 mmHg, or treatment with
antihypertensives; $ fasting glycemia ≥7 mmol/L or treatment with anti-
diabetics; § seeMethods for definition; italicized items are highly relevant
for conclusions
Table 2 Association between the individual progression of arterial stiff-
ening (∆PWV per year) and its covariates (Spearman’s rank correlation
and multiple linear stepwise regression)
Univariate model Multivariate step-wise
model
Spearman’s R p value β coeff. (SE) p value
age 0.154 0.0003 0.0073 (0.0009) <0.0001




current smoking 0.033 0.45
body mass index 0.069 0.11
mean arterial pressure −0.052 0.23
LDL cholesterol −0.036 0.41




any antihypertensives 0.133 0.0019 −0.1279 (0.0445) 0.004




sRAGE −0.192 <0.0001 0.3498 (0.0674) <0.0001
baseline PWV −0.310 <0.0001 −0.0801 (0.0051) <0.0001
dp-ucMGP 0.128 0.0032 0.1150 (0.0474) 0.016
const. 0.4406 (0.1847) 0.017
log-transformations were done in sRAGE and dp-ucMGP
Furthermore, arbitrary ∆PWV per year ≥0.2 m/s was used as a
dependent variable (reflecting the accelerated individual pro-
gression of aPWV during follow-up) and confirmatory
results were observed. After adjustment for potential covari-
ates, an increase in dp-ucMGP amounting to one quintile was
associated with approximately a 24% higher relative risk of ac-
celerated aortic stiffening (Table 3, model A). A confirmatory
finding was found by comparing the 1st quintile of dp-ucMGP
with the higher ones (2nd to 5th; Table 3, model B).
Table 3 Predictors of accelerated individual progression of arterial stiffness
(∆PWV per year ≥0.2 m/s) using multivariate logistic regression models
Model A Model B
Odds ratio p value Odds ratio p value
age ≥ 65 years 2.12 (1.28–3.51) 0.004 2.11 (1.27–3.50) 0.004
male gender 1.59 (1.07–2.37) 0.022 1.63 (1.10–2.42) 0.016
manifest vascular
disease
1.40 (0.57–3.43) 0.47 1.47 (0.60–3.59) 0.40
current smoking 1.43 (0.95–2.14) 0.10 1.40 (0.93–2.10) 0.10
body mass index
≥30 kg/m2
1.25 (0.78–2.00) 0.37 1.31 (0.82–2.10) 0.26
arterial hypertension 0.95 (0.58–1.55) 0.75 0.93 (0.57–1.50) 0.75
LDL cholesterol
≥2.5 mmol/L
1.49 (0.94–2.38) 0.093 1.52 (0.95–2.41) 0.75
overt diabetes 1.04 (0.38–2.83) 0.87 1.09 (0.41–2.93) 0.87
estimated glomerular
filtration≤90 mL/min
1.04 (0.68–1.58) 0.86 1.11 (0.73–1.68) 0.63
RAAS blockers 1.56 (0.86–2.82) 0.11 1.61 (0.89–2.90) 0.11
statins 1.51 (0.79–2.88) 0.21 1.61 (0.84–3.06) 0.15
warfarin 0.38 (0.09–1.61) 0.19 0.50 (0.12–3.00) 0.34
sRAGE<881 pg/mL 1.85 (1.13–3.02) 0.015 1.84 (1.12–3.00) 0.016
baseline PWV ≥ 9 m/s 0.35 (0.21–0.59) <0.0001 0.37 (0.22–0.61) <0.0001
increase of dp-ucMGP
by one quintile
1.24 (1.07–1.43) 0.003 –
dp-ucMGP in 1st quintile
(< 357 pmol/L)
– 0.57 (0.35–0.92) 0.021
Data interpretation
The key finding of this prospective, general population-based
study is that vitamin K status plays an important pathophysi-
ological role in the natural, age-dependent progression of ar-
terial stiffening. High vitamin K status (low dp-ucMGP) was
independently associated with approximately a 43% lower
risk of accelerated individual progression of PWV during
8 years of follow-up (defined as 0.2 m/s per year). It is gener-
ally accepted that the “natural course” of vascular aging cor-
responds to approximately a 1 m/s increase in PWV per de-
cade of life [8]. We might say that during the 8-year follow-
up, high vitamin K status “slowed” the aging of arteries by
about 5 years compared to the subjects with low vitamin K
status.
So far, at least 11 smaller or medium-sized interventional
studies have shown that supplementation of iso-vitamin K2
(menaquinone, MK-7) leads to a decrease in circulating dp-
Fig. 1 Baseline pulse wave velocity (left panel) and its progression
during follow-up (∆PWV per year, right panel) among dp-
ucMGP quintiles [mean (standard deviation)]; limits of dp-
ucMGP quintiles are as follows: ≤356, 357–468, 469–568, 569–
690 and ≥ 691 pmol/L; p value fully adjusted for potential covar-
iates (see Results for details)
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ucMGP [9]. Moreover, another intervention trial with MK-7
supplementation also demonstrates the effect on arterial stiff-
ness [10]. In line with our observations, the sub-study of the
ASTRONOMER trial also indicated high dephosphorylated
MGP concentrations independently associated with a higher
risk of progression of aortic stenosis [11].
Conclusions and expert recommendations
& Vitamin K status was identified as an independent predic-
tor of the individual course of arterial stiffening. In theory,
it can also be used as a therapeutic target to slow-down
vascular aging.
& dp-ucMGP was identified as a promising tool for risk pre-
diction and personalization of cardiovascular prevention.
& In concordance with PPPM principles, we support the
creation of new multiparameter algorithms and multivari-
ate models for risk assessment and patient stratification.
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Background
Over one million Europeans are stroke-diagnosed annually [1].
Manifested atherosclerotic lesions of the carotid arteries account
for approximately 40% of all ischemic strokes, and genetic pre-
disposition, hypertension, among others are considered the best
acknowledged risk factors [2]. However, the etiology of many
stroke cases remains unclear, particularly in young patients below
50 years of age [2]. To this end, one of the most promising re-
search areas involves the risks linked to the vascular inflammation
and the follow-up cascade of pathological changeswhich altogeth-
er may lead to the clinical manifestation of stroke [3].
According to the EPMA criteria, clinically relevant biomarker-
sets should serve for predictive diagnosis, targeted prevention
and personalization of medical services, in order to contribute
to the paradigm shift from reactive to 3PM [4]. Contextually,
consideration of multi-factorial risks and individualized patient
profiling provide comprehensive information for the clinically
relevent biomarker-sets and multi-parametric analysis as tools
for the 3PM implementation. A prospective pilot research project
was carried out at the Clinic of Vascular Surgery of the Eastern
Slovak Institute of Cardiovascular Diseases and the Faculty of
Medicine of Pavol Jozef Safarik University, Kosice. The main
criteria evaluated in our study included the degree of ICA steno-
sis, the morphological structure of the atherosclerotic plaque and
the level of lipoprotein-associated phospholipase A2 (Lp-PLA2)
concentration.
Working hypothesis
This project tested the hypothesis that the risk of stroke in pa-
tients with internal carotid artery (ICA) stenosis cannot be eval-
uated based on the determination of the degree of ICA stenosis
only. In addition to stenosis, the morphological structure of the
atherosclerotic plaque can serve as an important risk factor as
well, while ulceration and instability of atherosclerotic plaques
can be characterized by biomarkers.
Materials and methods
The study included 70 (27 females and 43 males) patients, who
were hospitalized for carotid endarterectomy. The patients were
divided into two groups depending on their symptoms: Group I
included 30 patients with symptomatic ICA stenosis >50%;
Group II comprised 70 patients with asymptomatic ICA steno-
sis >70%. There was no statistically significant difference in
age and sex between the groups. Ultrasound scans were used
to assess ICA stenosis, as well as the structure of the athero-
sclerotic plaque. Before surgery, blood samples were taken to
determine the levels of the following biomarkers: Lp-PLA2, IL-
4, hemopexin, and homocysteine.
Results
When assessing the morphological structure of the atherosclerotic
plaque using ultrasound, soft and mixed atherosclerotic plaques
were detected in 73% of the patients in group I and 55% of the
patients in group II. The comparison of Lp-PLA2 concentration
ratio revealed a statistically significant correlation (p< 0.001) be-
tween the increase in Lp-PLA2 concentration in the patients with
symptomatic ICA stenosis (285.30 ± 2.05 μg/l) compared to the
patients with asymptomatic ICA stenosis (274.35 ± 3.38 μg/l). In
15% of asymptomatic patients with soft atherosclerotic plaque,
Lp-PLA2 level was higher (293.90 ± 1.5 μg/l) than that in symp-
tomatic patientswith hard atherosclerotic plaque (261.40 ± 1.3μg/
l). The concentration of Lp-PLA2 correlated with atherosclerotic
plaque structure rather than its size.
The comparison of serumhemopexin levels in symptomatic (0.38
± 0.01 ng/l) and asymptomatic (0.351 ± 0.012 ng/l) patients re-
vealed no statistically significant difference between both groups.
In the patients with symptomatic ICA stenosis, the serum con-
centration of IL-4 (65.77 ± 3.78 ng/l) was found to be signifi-
cantly higher compared to the patients with asymptomatic ICA
stenosis (42.69 ± 1.73 ng/l).
The analysis of the homocysteine test revealed a statistically sig-
nificant difference between the patients with symptomatic ICA
stenosis and those with asymptomatic ICA stenosis. At the same
time, homocysteine as a marker of atherosclerotic complications
was inferior to Lp-PLA2 when comparing the following risk fac-
tors, namely the degree of ICA stenosis, the morphological struc-
ture of the atherosclerotic plaque, and the concentration of the
“optimal” marker.
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Data interpretation
There is a wide range of vascular biomarkers; however,
each biomarker has its own specificity and changes in its
concentration may depend on different factors [3]. Among
vascular markers analyzed, a statistically significant cor-
relation between the degree of ICA stenosis, the structure
of the atherosclerotic plaque and the clinical course were
observed only in the case of Lp-PLA2. The dominant fac-
tor for the increase in Lp-PLA2 was the structure of the
atherosclerotic plaque. According to the results of our
study, unstable atherosclerotic plaques are typical for
symptomatic patients, as well as for the patients with
asymptomatic ICA stenosis. Our results are consistent
with the results obtained by other authors who observed
the patients with asymptomatic carotid stenosis and found
that the patients with unstable echolucent plaques were
2.31 times more likely to develop stroke compared to
the patients with stable plaque based on ultrasound find-
ings [5]. Consideration of Lp-PLA2 concentration in the
patients with ICA stenosis may serve as an auxiliary cri-
terion at the stage of determining and selecting treatment
tactics for patients with ICA stenosis greater than 70%,
and finally to apply a predictive and prognostic patient-
specific treatment of atherosclerosis promoting the change
from reactive medicine to 3PM. In addition, the proposed
vascular biomarker Lp-PLA2, which depends on the indi-
vidual lipid profile, can be applied alternatively to the
typical post-symptomatic treatment of atherosclerosis.
HDL-associated Lp-PLA2 may substantially contribute to
the HDL antiatherogenic activity and could be additional-
ly used to predict the efficacy of medication prescribed.
Conclusions
Our research demonstrated a statistically significant cor-
relation between Lp-PLA2 and the degree of ICA stenosis,
the structure of the atherosclerotic plaque, and the clinical
course. The increase in Lp-PLA2 level (285.30 ng/ml ±
2.05) and ultrasound findings of soft atherosclerotic
plaque in combination with stenosis degree may indicate
a high embolic potential in the patients with ICA stenosis.
Consideration of the morphological structure of the atheroscle-
rotic plaque and Lp-PLA2 concentration in the patients with
ICA stenosis is recommended for the implementation of a per-
sonalized approach to therapies that meet the criteria of 3PM.
The implementation of the 3PM strategy and personalized ap-
proach is one of the optimal directions to find the additional criteria
for early identification of risk factors for stroke.
It is anticipated that, ultimately, this change in diagnosis and
therapy will help in the future design and development of new,
more selective, and effective therapies for each individual
patient.
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Introduction
The prevalence of abdominal aortic aneurysms (AAA) is
4–8%. In Western countries it is responsible for 4 to 5%
of sudden deaths [1]. Endovascular aneurysm repair
(EVAR) was introduced in 1991. EVAR is less invasive
than open surgery; however, it requires life-long moni-
toring due to potential complication [2].
Endoleak is the most frequently occurring complication
associated with EVAR. It occurs in up to 45% of pa-
tients. Treatment decisions regarding this complication
are made individually based on the detection and deter-
mination of the type of endoleak. The most frequently
occurring endoleak is type II ensuing from the superior
mesenteric or lumbar artery (Fig. 1). In approximately
50% of cases, the endoleak can close spontaneously,
and the initial treatment is conservative [3]. CT angiog-
raphy (CTA) is the most frequently used method of mon-
itoring the patients with EVAR. The alternatives of CTA
are, primarily, MR angiography (MRA) and contrast-
enhanced ultrasonography (CEUS).
Our study is aimed at verifying the use of contrast-
enhanced ultrasonography (CEUS) in monitoring pa-
tients after an implantation of aortic stent-graft.
Materials and methods
CEUS examinations were performed by two radiologists
with more than 5 and 7 years of experience. They were
blinded to the CTA results. The sonography result was
determined by way of consensus of both readers. The
examinations were performed using Acuson Antares
and Acuson S 2000 scanners (Siemens, Erlangen,
Ge rmany ) and a low- f r equency convex p robe
(3.5 MHz). We administered one or two doses of
2.4 ml of a 2nd-generation contrast medium (CM)
(SonoVue, Bracco, Milano, Italy) with a subsequent
10 ml saline flush into the cubital vein using 20 G can-
nula. We evaluated endoleak occurrence and type on the
postcontrast images.
CTA examinations were performed by Somatom
Definition and Somatom Definition Flash scaners
(Siemens, Erlangen, Germany) in arterial a venous
phase after application of 80 ml of CM (Iomeron 350,
Bracco, Milan, Italy). The same parameters as the ones
used for CEUS were then evaluated by a radiologist
blinded to the CEUS finding.
Results
Endoleaks were found in 32 examinations (3 endoleaks
type I and 29 endoleaks type II). CEUS detected
endoleaks in 29 cases, and 3 examinations were false
negative. Using CTA, we identified endoleaks in 33
cases. In one patient with false positivity, newly occur-
ring fine calcification in a thrombosed AAA sac was
determined as a potential endoleak. In this case, CEUS
provided a correct (i.e. negative) result. The established
sensitivity was 90.9% and the established specificity was
100% for endoleak detection. The overall share of cor-
rect decisions on endoleak occurrence made using CEUS
was 95.2%. Endoleak types were correctly determined in
27 cases, and incorrectly in two cases. Thus, the
achieved reliability percentage was 93.3% and sensitivi-
ty 84.9%. CEUS failed to correctly determine endoleak
occurrence and type recognition in 57 cases; its overall
accuracy being 91.94%.
Data interpretat ion and PPPM-related expert
recommendations
The study demonstrated the suitability of CEUS in the
detection of endoleaks after EVAR. Nevertheless, the
results show slightly lower accuracy for this method
versus standardly used CTA. Issues associated with
endoleak detection occurred in three patients; in all
cases, these were small type II endoleaks from the
lumbar artery behind the stent graft bifurcation or
proximal section of one of the iliac limbs. Issues with
detection can be caused by the metal artifacts or
stentgraft frame as well as proximity of the stent-
graft lumen filled with contrast medium [4–9]. In two
cases, the endoleak was correctly detected but incor-
rectly interpreted (overestimated) as type I instead of
type II. Overestimation of endoleaks leads to change in
treatment—anticipated interventional treatment need not
have been be implemented.
Fig. 1 Type II endoleak. The endoleak (b) occurs with delay over contrast
filling of the stengraft (a). Endoleak is indicated by the arrow in image b. CT
image correlates with US image (c), endoleak is highlighted by the arrow
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Endoleak types are evaluated with respect to the loca-
tion of CM leakage, direction of the bubble flow and
time span between filling of the stent-graft lumen and
inflow of bubbles into the aneurysmal sac. In type I, III
and IV endoleaks, the CM leakage appears simulta-
neously with stent graft filling. In type II endoleaks,
there is a period of several seconds between stent-graft
filling and the occurrence of bubbles in the sac (Fig. 1).
The information on blood flow direction in the
endoleak—which cannot be evaluated using CT—is al-
so essential. Undoubtedly, the potential advantage of
CEUS consists in the possibility of continual monitor-
ing of CM flow during longer periods, thus improving
the visualization of slowly occurring endoleaks that re-
sult only in a small change of density in CTA [10].
Evaluation of repeated examinations that were made in
identical persons is considered a limitation factor in this
study. However, the time span between the examina-
tions of all patients was long enough to avoid the pos-
sibility of retaining the preceding medical finding in the
memory of the radiologist. CEUS accuracy in evaluation
of endoleak types can be distorted by the prevailing
occurrence of endoleaks of types III—V.
We recommend performing follow-up examinations
immediately after EVAR, and subsequently after 1, 6
and 12 months during the first year. Afterwards, pa-
tients without complications are monitored once a
year. CEUS can be used as a replacement for CTA
follow-up examinations, where suitable. In addition,
CEUS examinations can be performed at shorter inter-
vals than CT without significantly increasing the bur-
den on the investigated person.
In conclusion, the results of our study support use of
CEUS in the secondary prevention of endoleak-related
complications in patients after EVAR. The advantages
of this method over CTA are that of reducing the burden
of patients and the financial costs of monitoring. Overall,
it may be said that CEUS can be used as part of a per-
sonalized diagnostic algorithm that contributes to the
early prediction of outcomes following EVAR.
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Background
The incidence rate of dental caries remains high at the popu-
lation level reaching 98% globally [1]. A large number of
medical technologies do not provide high quality and effective
treatment and prevention, which can lead to the development
of recurrent caries and the resulting complications of caries
sometimes lead to disability inmiddle-aged and elderly people
[2–3].
Comprehensive patient examination, using the patient’s
profile, including their age, gender, presence/absence of
general pathology and a whole rank of dental diagnostic
methods, is a crucial link for effective individual preven-
tion and treatment of dental caries. Statistical analysis of
these parameters contributes to their stratification
allowing picking out groups of patients with compensat-
ed and non-compensated caries forms with its substantial
progression in the near future. The new method based on
the microstructure modification of polymer-based filling
materials using electromagnetic field exposure provides
a comprehensive treatment approach allowing to enhance
the ion-exchange processes in hard dental tissues and
increase the level of enamel mineralization after the ma-
terials application, which will contribute to the preven-
tion of recurrent caries [4–7]. Such prognosis approach
to the diagnostics and treatment of dental caries corre-
lates with the main concept of predictive, preventive and
personalized medicine (PPPM) and has a high potential
for clinical implementation.
The purpose of our scientific work is to study the preventive
ability of dental filling materials with modified microstructure
in dental caries progression.
Materials and methods
A personalized approach was applied to select patients with
medium caries and without any general pathology for further
investigations. The inclusion criteria were enamel resistance
level, tooth plaque cariogenicity, and absence of peri-
odontal disease. The study subjects are a contingent of
204 people aged 18–45 with a diagnosis of medium
caries. Further, the contingent was examined to treat
the teeth with filling material Charisma with EMF exposure
(I – study group) and without EMF exposure (II – control
group). Each study group material was placed in the working
interpolar space for electromagnetic processing with the
strength of 22 × 104 A/m for 20 min [7].
This investigation was approved by the Ethical Committee for
research of the State Funded Educational Institution of Higher
Education «Voronezh State Medical University named after
N.N. Burdenko» of the Ministry of Health of the Russian
Federation (Protocol No. 1, February 25, 2016).
Dental examinations of patient’s health status for their inclu-
sion to our investigation provide integral data concerning their
age, gender, presence/absence of bad habits, quality of nutri-
tion, level of enamel resistance, tooth plaque cariogenicity,
etc. These parameters help us to create a specification rank
among patients allowing picking out groups of patients with
compensated and non-compensated medium caries. The in-
clusion and excludion criteria have been detailed by
Moiseeva et al. [5].
Furthermore, those patients underwent dental caries treat-
ment. At follow-up visits, all patients underwent complete
dental examinations including the assessment of filling
quality using the following methods: vital staining of
enamel at the border of filling, quality of filling according
to D.M. Karalnik and determination of the electrical con-
ductivity of enamel in accordance with the R.G.
Buyankina scale.
Statistical analyses
For statist ical processing, a standard package of
STATISTICA 8.0, Statsoft was used. The following parame-
ters were calculated: mean and deviation, median and the
standard error of the mean, asymmetry, minimum and maxi-
mum values of the data series, quantile value and quantile
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range. To compare the groups, we used a non-parametric
Mann–Whitney test, Kruskal–Wallis test and a median test;
the effect of multiple comparisons was taken into account.
The differences were considered significant at p < 0.05.
Results
After 1 year in the study group, the quality of filling ismaintained
at an appropriate satisfactory level, in contrast to the control
group, where clinical changes in the quality of the filling border
are recorded in 7.8–9.8% of cases. The results of the electrical
enamel conductivity are presented in Table 1 and in Fig. 1.
Table 1 The results of progression and non-progression of recurrent
caries by the electrical enamel conductivity data
Observation
stage
Group I with EMF
exposure
Group II control without EMF
exposure
p level




















1.897 ± 0.065 (0.78/3.2) <0.001
After 1 year 1.208 ± 0.051
(0.51/2.87)
2.601 ± 0.051 (1.56/3.72) <0.001
Abbreviations: Mean – average sample value; CI – confidence interval,
S.E. – standard error
During the observation period, the electrical conductivity pa-
rameters of the enamel stabilized only in the study group,
which indicates compensatory processes in the enamel and a
tighter filling. However, in the control group, a significant
increase in the digital values of electrical conductivity indi-
cates an increasing violation of the marginal fit of filling ma-
terial and may cause risks of recurrent caries in future
(p < 0.01).
PPPM related conclusion and expert recommendation
The results of studies contributed to an increase in the biocom-
patibility of the material and increased strength properties with
the structure of hard dental tissues, which brought us closer to
creating filling material with improved adhesion and strength
characteristics and increase the efficiency of caries treatment
and contribute to dental caries prevention in a long-term period.
Such a comprehensive approach to the diagnosis of the pa-
tient’s profiling status and further individualized caries treat-
ment correlates with the main postulate of the European
Association of Predictive, Preventive and Personalized
Medicine (ЕРМА) [8]. Received results allows improving the
quality of treatment and prevention of dental caries due to the
activation and normalization of the ion-exchange processes in
the enamel when using polymer filling materials with the elec-
tromagnetic field-modified microstructure.
The proposed concept allows creating an individual approach
to the implementation of high quality treatment of caries in
practice, which ensures maximum use of the principles of
prediction and prevention. From the results, it is possible to
recommend the use of a portable electromagnetic installation
at a specialized company for practical dentistry to influence
filling materials using an electromagnetic field. Thus, the de-
veloped method of changing the microstructure of polymer-
based filling materials using an electromagnetic field is a fun-
damentally new approach protected by the patents and con-
firmed by statistics [4–7] that contributes to filling quality
improvement and caries prevention.
Thus, better patient’s profile justification at the initial survey
study promotes targeted treatment algorithms tailored to the
person. Tailored treatment may lead to significantly improved
results in the long-term. All these aspects provide the ad-
vanced technology of predictive, preventive and personalized
dentistry in the framework of caries treatment.
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Fig. 1 The graph of the electrical enamel conductivity
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Toothache is a strong, unpleasant sensation in a tooth,
in a certain area of the gum or in the entire jaw. It
refers to those pains that do not allow you to sleep,
eat food, speak and perform normal actions. In its
strength and intensity, toothache can only be compared
with the pain from the exit of stones from the kidneys.
It will not be a mistake to say that the prevalence of
dental diseases in the human population exceeds all
other types of diseases. A large number of dental clinics
and surgeries in any, even a small, city evidences this
fact [1, 3].
“Teeth ache! Why?”—any person has faced a similar
problem at least once in his life. Pain is never without
a reason—this is a signal that some kind of malfunction
has occurred in the organ. If the pain did not occur, it
would be impossible to recognize the onset of the
disease, and patients would seek help only in a very
severe condition. Toothache can be classified based on
a number of signs. 1. According to the pain dynamics.
2. According to the pain intensity. In the acute form,
the pain is so strong that a person hurries to the dentist
without hesitation. 3. According to the pain localization.
Additionally, the causes of toothache are diverse: tooth
decay, pulpitis, periodontitis, periodontitis, etc. In our
research, we sought to understand why intact ,
“Hollywood white”, teeth ache after professional whit-
ening. In pursuit of a Hollywood smile, some patients
notice that they experience increased tooth sensitivity
(hyperesthesia). This means that, together with the re-
moved bacterial plaque, the mineralization of the hard
dental coating, enamel, was disrupted.
In our work, we sought to understand what is happening with
hard tooth tissues after professional whitening and how to
prevent the negative consequences of this fashionable and
sought-after procedure [2].
The aim of the study was to identify the effectiveness of
amino acids application in order to restore the physiology of
the tooth.
Materials and methods The study included 47 patients aged
19 to 45 years without severe dental and somatic pathology
after professional whitening of the tooth enamel. The methods
used in the study were:
Clinical: survey, examination, determination of the index
prevalence of hyperesthesia teeth (IRGZ), the index of
intensity of hyperesthesia teeth (IIHS); test of enamel
resistance (TER); clinical evaluation of the enamel
remineralization rate (KOSRE test – Russian
abbreviation).
Clinical and laboratory: acid enamel biopsy.
Performing the acid enamel biopsy in the groups
of patients.
Laboratory: scanning electron microscopy (SEM).
For microscopic examination, teeth removed accord-
ing to orthopedic and orthodontic indications were
taken. The enamel was whitened in accordance with
the instructions for use of the whitening system.
The chips were prepared and investigated under
450- and 1000-fold magni f ica t ion us ing a
“Camscan S4” scanning microscope.
Research results The results of laboratory investigations.
Changes in the structure of the tooth were traced when
performing a comparative analysis of the spectrogram
data of the enamel that was not exposed to whitening
and after the procedure. After the exposure to peroxide
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compounds, enamel roughness and cavities appeared; usuras
of tooth enamel, entrances to “enamel tunnels” became wider;
this may be considered as a reason for the occurrence of teeth
hyperesthesia in almost 100% of cases.
The entrances to the dentinal tubules became “open” and
wider (Fig. 1).
After whitening, the organic matrix of the tooth also suffered.
Important components of the protection of the tooth glycopro-
teins and “cationic” protein were destroyed; this is clearly
demonstrated on the slide.
The clinical result after whitening in all patients was
6–8 tones, which was a demonstration of the effec-
tiveness of the whitening system itself (Fig. 2).
However, after the procedure, almost all patients complained
of tooth sensitivity.
Fig. 2 Clinical result after whitening
The enamel resistance according to the results of TER inves-
tigation, as well as the remineralization rate—according to the
KOSRE-test results—decreased. The outcome of calcium and
phosphorus ions increased significantly. Thus, immediately
after the enamel whitening procedure, morphochemical
changes appear: the enamel resistance decreases and the
enamel acid compliance increases; this appears to be a prereq-
uisite for the occurrence of carious and non-carious dental
diseases. To restore the structure and function of the hard
tissues of the teeth, we applied three preparations: 1. based
on amino acids and calcium; 2. based on calcium and fluorine;
3. based on fluorine only.
We have obtained positive results in all study groups.
Hyperesthesia of the teeth was eliminated. The enamel has
become less acid compliant, i.e. its resistance has increased
according to the results of the TER investigation and KOSRE
test. The outcome of calcium ions and phosphorus ions de-
creased in the studied groups. All the drugs involved in the
study are relevant for use immediately after the whitening of
the enamel and are effective for reducing tooth sensitivity,
increasing acid resistance and resistance of the enamel. The
best results in a shorter period were obtained in the group
using the preparation based on the amino acid complex.
PPPM related conclusion and outlook Toothache treatment
is possible only within the framework of predictive, preven-
tive and personalized medicine. To solve this problem, it is
necessary to stratify patients by type of toothache. After pro-
fessional whitening, patients with hyperesthesia should re-
ceive mandatory targeted prevention of enamel destruction
and dental hyperesthesia. The best effect of the restoration of
hard tissues of teeth was registered with the combined action
of minerals and amino acids.
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Differential diagnosis of primary pathologies of hard tooth
tissues as a problematic issue in modern dentistry
Primary demineralization of the hard tissues of teeth is one of
the most common groups of both dental pathologies and the
general morbidity system, distinguished by an extensive list of
etiological factors. However, the basis of these conditions is
primarily a violation of enamel metabolism (the predomi-
nance of demineralization over remineralization) [1,2].
This group of nosologies includes primary subsurface demin-
eralization (82.4%) [3], primary superficial demineralization
(82%) [4] and primary superficial hypomineralization
(15.1%) [5]. Although the onset of caries worldwide is asso-
ciated with direct exposure to cariogenic microflora, often
primary enamel damage is associated with chemical, mechan-
ical or physical damage, as well as with other factors [1].
Reliable diagnostics include the key stages of primary preven-
tion of pathologies of hard tissues of teeth.Many authors often
turn to the fundamental aspects of the diagnostic problem of
these nosologies [6], rarely addressing the problem of the
clinical implementation of these methods in wide clinical
practice.
In our work, we propose to optimize and deepen the diagnos-
tic paradigms by introducing the previously unused CT den-
sitometry technique into them.
The aim of the study was to identify early diagnostic criteria
for the primary enamel demineralization necessary for the
formation of preventive and diagnostic methods.
Description of the study
For the selection of patients and their distribution into groups,
the methods of electrometric diagnostics of enamel (0–0.2 μA
for intact enamel) and light-induced fluorescence (no spots on
intact enamel) were used.
The investigated materials were obtained from 528 patients
and divided into 4 groups according to the criterion of detect-
ed signs above indicated pathologies: control (135 persons,
25.57%), persons with primary hypermineralization (124 per-
sons, 23.48%), persons with primary surface demineralization
(121 persons, 22.92%) and persons with primary subsurface
demineralization (148 persons, 28.03%).
The study was conducted according to analysis of the teeth
images obtained by densitometry using cone-beam computed
tomography.
Results
The study determined the normative values of clinically
healthy enamel, corresponding to the range from 2800 to
4000 Hounsfields (HU) with a uniform distribution of mineral
density.
In primary congenital hypomineralization of permanent
teeth, CT densitometry values correspond to 1600–2000
HU with a uniform decrease in the mineral density of
tooth enamel. With subsurface demineralization, the
values go into the range from 1500 to 2600 HU with a
characteristic bend of the CT densitometry section in the
prismatic enamel section in the direction of decreasing
values by more than 30%. In the case of surface demin-
eralization, the values are in the range from 1600 to 2900
HU with a thinning of the enamel layer less than 1 mm.
The data presented are in the field of statistically significant
values (p < 0.05).
Data interpretation in the context of PPPM
Densitometry results allow the differential diagnosis of
pathologies of tooth hard tissues in the early, preclinical
stages and maximize the effectiveness of preventive so-
lutions. Ultimately, an integrated approach to diagnosis
enables one to individualize the tactics of prevention for
each individual patient, not only in the context of prima-
ry demineralization but also in the general dental status.
This method enables one to more finely differentiate pa-
thologies, personifying them for certain groups of pa-
tients. The CT densitometry method will enable creating
an individual clinical picture and therapeutic plan based
on the specific clinical conditions.
Conclusions
Based on the data obtained, it is possible to conduct a
clear differential diagnosis of tooth enamel pathologies,
since each of them corresponds to a clear range of radio-
logical values. According to the severity of CT changes,
one can put forward a prognosis of the severity and con-
trol the effectiveness of remineralizing therapy. A clear
diagnosis makes it possible to conduct targeted therapy
and prevention of each nosology, personalizing the
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approach to each patient. Such an algorithm for detailed
preclinical diagnostics will allow moving away from
generalized treatment regimens that do not take into ac-
count the individual characteristics of the clinical course
of this group of pathologies [7].
This work was supported by the grant 16-15-00003 of the
Russian Science Foundation.
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Introduction
Preventive, preventive and personalized medicine (PPPM) is
an approach to medicine that proposes the customization of
healthcare in which decisions and treatment are personalized
based on the patient’s needs [1, 2]. The PPPM concept has an
important impact on dental and oral health care [3].
Dental caries is the most common chronic childhood disease.
Early childhood caries (ECC) is defined as tooth decay in
preschool children. ECC is a biofilm-mediated, sugar-driven,
multifactorial, dynamic disease that results in demineraliza-
tion of dental tissues. Its development is determined by bio-
logical, behavioural and psychosocial factors linked to an in-
dividual’s environment [4]. The mean caries prevalence for 5-
year-olds is 63%. Approaches to the reduction of ECC include
early prediction, prevention and personalized dental care.
Caries risk assessment (CRA) is the process of establishing
the probability of a child or group of children developing
caries over a certain period, or the likelihood that there will
be a change in size or activity of lesions already present.
Caries risk factors are variables that are thought to cause the
disease directly, or whose prediction has been shown to be
useful.
The aim of the study was to identify caries risk factors among
one-year-old infants.
Materials and methods
Our cross-sectional study is part of a long-term research
and was performed at the Department of Dentistry and
Obstetrics, University Hospital in Pilsen, Czech Republic.
The study comprised Caucasian women who were
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attending the Obstetric Department for an antenatal check-
up. The pregnant women were subsequently referred to the
Dentistry Department in February, March and April 2018.
The pregnant women were informed of the study; 142 of
them agreed to participate in the study. During the dental
visit all women were educated regarding the prevention of
ECC. Six months after birth they received repeated
information.
The research cohort comprised 116 infants: 54 boys
(46.6%) and 62 girls (53.4%). At the age of one year,
the infants and their mothers were invited to the CRA.
The following data were recorded: diseases, fevers, an-
tibiotics administration, nutrition and nutritional habits.
The oral examination comprised an evaluation of enam-
el quality and collection of a saliva sample. The pres-
ence and amount of Streptococcus mutans (SM) in the
saliva were detected by Dentocult Strip Mutans test,
Orion Diagnostica™.
Results
The presence of caries risk factors is mentioned in Table 1.
Table 1 The presence of caries risk factors
Risk factor Number of infants %
Fevers 39 33.6
Frequent use of baby-bottle
containing sweet liquids
29 25
Antibiotics treatment 28 24.1
Risk salivary SM levels 26 22.4
Nocturnal breastfeeding 25 21.6
Absence of oral hygiene 17 14.7
Presence of systemic diseases 15 12.9
Oral pathology 10 8.6
Conclusions and PPPM-related expert recommendations
The most obvious predictive factor for caries in the current study
was the presence of fevers during the first year of age. This
condition is connected with oral medicaments containing sugar
and hyposalivation. Several studies have been conducted with
the purpose of investigating the relationship between feeding
practices and ECC [4]. The majority of studies have confirmed
a high risk of ECC in cases of prolonged nocturnal breastfeeding
and bottle feeding—this is knowledge that can be used for
targeted prevention. Nocturnal breastfeeding was present in
21.6% of infants and bad habits connected with baby bottle in
25% of infants in the current study. An early colonization of the
oral cavity with SM and high amounts of SM in saliva are asso-
ciated with the development of ECC [4]. The finding that regular
oral hygiene had not yet started in 14.7% of the given cohort of
infants shows that not all previously educated mothers followed
the recommendation to begin with oral hygiene when the first
primary tooth appears in the oral cavity. In countries with ad-
vanced primary prevention, only 5% of one-year-old infants re-
main deprived of oral hygiene [5]. Of the infants, 24.1% were
taking antibiotics during the first year of life and 12.9% of infants
have a history of respiratory tract and ear infection and asthma.
Being as asthmatic children may have an especially high risk
of ECC due to the effect of their pharmacotherapy, mouth
breathing and frequent intake of sugary drinks, it is important
to pay attention to the patients’ individual profiles.
Pathological oral conditions were described in 10 (8.6%)
infants.
Targeted prevention of caries should take into account that
ECC shares common risk factors with other non-
communicable diseases associated with excessive sugar con-
sumption, such as cardiovascular diseases, diabetes and obe-
sity. A CRA should be carried out during the child’s first
dental visit. Children with an individual profile that includes
risk factors that are of predictive value for the development of
caries should be targeted for appropriate preventive care with
dental recalls based on individual need.
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Introduction
3PM concepts. Oral diseases such as dental caries and peri-
odontal diseases can lead to eventual tooth loss. Worldwide
severe periodontal disease in upward of 20% of adults, results
in tooth loss and about 30% of people aged 65–74 have no
natural teeth [1, 2].
In Europe and the USA, dental caries remains amajor problem
[3, 4].
The novel PPPM concepts have been suggested by EPMA to
benefit the impacts on the oral and dental health [5–7].
For many acute and chronic disorders, the current health care
outcomes are considered inadequate [7, 8].
The purpose of the study was to investigate the impact
of emotional self regulation upon the quality of individ-
ual oral care to establish a personalized approach in
dental prophylaxis.
Methods
A total of 99 persons (62 women and 37 men) 19 to 67 years
of age participated in the study which was conducted with the
use of the following psychodiagnostics methods: (1)
Leonhard-Smishek Characterological Questionnaire (version
for adults); (2) Individual Typological Questionnaire by L.N.
Sobchick (ITQ). The Green—Vermillion index was
defined at the beginning of the study and upon its com-
pletion (in a month). After the 1st examination, profes-
sional oral hygiene was performed on each patient.
Using this index, the examined patients were divided into
two groups by the dynamics of oral care performance
during the treatment period. The former group patients
demonstrated negative dynamics—deterioration of their
oral cavity status (increase of the Green—Vermillion in-
dex by the end of the study). The latter group patients
demonstrated positive dynamics—improvement of their
oral hygiene status (decrease of the Green—Vermillion
index by the end of the study).
Results
The study revealed statistically significant differences between
Groups 1 and 2 in terms of frequency of tooth brush replace-
ments. Group 1 patients replaced their tooth brushes less often
(0.94 ± 0.42) than Group 2 patients (1.34 ± 0.66).
Statistically significant differences between Groups 1 and 2
were also defined by the level of patients’ emotional lability
(disequilibrium): in Group 1, affective-exalted type of a per-
son was registered more often (19.05 ± 4.85) than in Group 2
(13.30 ± 6.07).
Statistically significant differences between Groups 1 and 2
were also defined by the parameter “hyperthymic type of a
person”: the value of this indicator was higher in Group 1
(16.05 ± 3.17) than in Group 2 (12.44 ± 6.0).
In Group 1 there were more patients of a cyclothymic type of a
person (16.4 ± 6.19) than in Group 2 (12.3 ± 4.9).
Statistically significant differences between Groups 1 and 2
were also assessed according to the scale “Extraversion”: the
highest value was registered in Group 1 (6.5 ± 1.8), and the
lowest was registered in Group 2 (4.7 ± 2.4), i.e. more sociable
and extroverted patients were observed in Group 1 than in
Group 2.
3PM related conclusions and outlook
The emotional lability, introversion, increased emotion-
al self-regulation and anxiety (concern) about the treat-
ment results are linked to the quality of individual oral
care.
This knowledge could help doctors in predicting the
result of the treatment and making it most effective by
increasing patients’ compliance level and attitude to-
wards their health and treatment through a psychologi-
cal approach [9]. Additionally, it is very important that
a disease can be predicted by self-control methods and
prevented or treated in the early stage with positive
therapeutic effect [10].
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Background
Despite the obvious success in caries prevention world-
wide the incidence of caries rate remains high and re-
sults not only in a medical but also in a global social
problem that requires an immediate solution.
Determining the predictor factors of initial caries pro-
gression is a key point of its successful prevention
and for a personalized treatment approach which fits
with the main concept of predictive preventive person-
alized medicine (PPPM). Therefore, a promising area of
preventive dentistry is the development of new highly
effective methods of enhancing the remineralizing activ-
ity of prophylactic means and the search for more ef-
fective ways for dental caries prevention [1–4]. Those
methods may significantly contribute to the paradigm
change from reactive to predictive, preventive and per-
sonalized dentistry as well as healthcare systems at
large. A prospective research study performed at the
Voronezh State Medical University named after N.N.
Burdenko included a comprehensive patient’s dental sta-
tus profiling and further applied modified and non-
modified polymer-based toothpastes for early caries pre-
vention [5, 6]. It was concluded that improving the mi-
crostructure of polymer-based toothpastes using an elec-
tromagnetic field could provide a highly effective caries
prevention by the targeted enamel remineralization and
promote a new quality level of dental treatment oriented
on dental caries prediction [5–8].
S112
EPMA Journal (2020) 11(Suppl 1):S1–S133
Materials and methods
Study subjects represented a randomly selected contingent of
62 patients aged from 18 to 35 years old with intact teeth and
without any general pathology, divided into 2 equivalent
groups, who underwent 1-month controlled tooth brushing
with (group 1) and without (group 2) electromagnetic field
exposure.
The scientific study was approved by the local commit-
tee for ethics in research of the State Funded
Educational Institution of Higher Education «Voronezh
N.N. Burdenko State Medical University» of the
Ministry of Health of the Russian Federation (Protocol
N 1, February 25, 2016).
Dental examinations of patient’s health status for their
inclusion to our investigation provided integral data
concerning their age, gender, presence/absence of bad
habits, quality of nutrition, level of enamel resistance,
tooth plaque cariogenicity, etc. Those parameters helped
us to create a specification rank among young people
allowing picking out groups of patients with potential
risk factors to caries appearance and its progression in
the near future. The inclusion and excludion criteria
have been detailed by Moiseeva et al. [5].
Furthermore, those patients underwent controlled tooth
brushing. To assess the effectiveness of the use of
toothpaste with the electromagnetic field in terms of
predictive caries prevention at follow-up visits, all the
patients underwent complete dental examinations and
several functional tests: Functional Enamel Resistance
(FER-test) , Cariogenici ty of Dental Plaque by
Hardwick J.L., Manly E.B. and the Electrical Enamel
Conductivity using the DentEst device (Geosoft Dent).
Statistical analyses
For statistical processing of the study results, a standard
package of STATISTICA 8.0 software programs by
Statsoft was used. The following parameters were cal-
culated: mean and the standard error of the mean. To
compare the groups, we used a non-parametric Mann–
Whitney and Kruskal–Wallis test. The differences were
considered significant at p < 0.05.
Results
After the controlled tooth brushing, the level of caries-
resistance in group 1 significantly increased from 21.8 ±
3.0% to 5.8 ± 0.6% (p < 0.01) and in group 2 from 20.8 ±
2.8% to 13.2 ± 2.1% (p < 0.05), which indicated a more
significant remineralizing effect of the toothpaste with
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Fig. 1 The functional enamel resistance before and after the electromag-
netic field exposure
The tooth plaque cariogenicity in group 1 significantly de-
creased after the controlled brushing of teeth from 21.8 ±
2.3% to 9.2 ± 0.5% (p < 0.01), and in group 2 from 21.6 ±
2.2% to 15.0 ± 1.2% (p < 0.05), which is due to the prolonged








without EMF with EMF
Group I
Group II
Fig. 2 The tooth plaque cariogenicity before and after the electromagnetic
field exposure
The electrical enamel conductivity decreased significant-
ly in group 1 from 0.8 ± 0.1 μA to 0.1 ± 0.01 μA
(p < 0.01), and in group 2 from 0.7 ± 0.1 μA to 0.4 ±
0.05 μA (p < 0.05), which indicated a more effective
caries prediction in group 1 (Fig. 3).
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Fig. 3 The electrical enamel conductivity
The positive preventive effect of the controlled tooth
brushing are due to the fact that its mineral and poly-
mer components structured under the influence of an
electromagnetic field provide for better penetration into
the enamel ensuring a prolonged remineralizing effect in
terms of highly effective caries prediction (р = 0.01).
Thus, the results obtained for electrical conductivity
confirmed a significant decrease in the parameters to
0–0.2 μA and the retention of such an effect for three
months, which indicates the effectiveness of preventive
measures and enables us to recommend the method of
improving the microstructure of polymer toothpastes for
practical dentistry.
PPPM related conclusion and recommendation
Thus, the obtained resul ts indicate a posi t ive
remineralizing effect of the toothpastes modified by
the electromagnetic field microstructure, both on the
enamel resistance level and on the dental plaque micro
flora, including the elimination of its cariogenic activity,
promoting highly effective preclinical caries prevention
and prediction of its progression at the early stage in a
long-term period which correlate with the main concepts
of predictive, preventive and personalized (3P) medicine
(PPPM) and will have a positive effect on the
healthcare economy in terms of cost-effective targeted
prevention and reducing financial costs for the treatment
of dental caries complications. Moreover, such integral
dental health status investigation allows distributing the
contingent according to the level of caries severity and
risk factors, which will promote early individualized
preventive therapy.
The results of the present study become the basis for
the formation of recommendations on the use of elec-
tromagnetic field-modified polymer-based toothpastes as
effective preventive technology for practical healthcare
as well as for their inclusion in dental diseases preven-
tion programs of Medical Universities worldwide.
In conclusion, the present study has introduced a new highly
effective method of dental caries prevention that enables
changing the generally accepted paradigm for dental caries
treatment to early caries prediction and prevention.
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Evaluation of the value and organization of the study light
factors for the prevention of caries
It is impossible to overestimate the influence of light fac-
tors on metabolic processes in the hard tooth tissues. An
integral effect of using fundamental physical and mathe-
matical research and their practical application predicts not
only a positive effect of prevention and treatment of caries
but also contributes to the achievement of a positive inte-
gral clinical result [1,2,3,4,5]. Cooperation of the
Department of therapeutic Dentistry of the Voronezh
State Medical University named after N. N. Burdenko
and the Physical Department of Voronezh State
University allowed conducting a series of research that
determined the influence of various parameters of light,
its induction, pulsation and its combinations on the level
of metabolic processes in hard tooth tissues and the effec-
tiveness of caries prevention.
What was the scientific basis of the study?
Previously, in order to activate the metabolic processes of the
tooth, helium–neon lasers were used and later the effective-
ness of light modulated light sources was proved with param-
eters from 625 nm to 760 nm. Analysis of the preliminary
results on 22 patients with intact teeth and dentine decay (car-
ies media) showed an advantage of using the wave length
760 nm. Determining the most optimal light parameters to
achieve maximum effectiveness of caries prevention, is the
basis for understanding predictive, preventive and personal-
ized medicine [1,6].
Methods
For this research, 152 patients were selected; 78 (51.3%) were
men and 74 (48.7%) were women, aged between 20 and 25;
36 (23.7%) of them had intact teeth and 116 (76.3%) were
diagnosed with dentine decay (caries media) after filling.
The method of primary prevention for intact teeth and second-
ary prevention (for elimination of reccurent caries) consisted
of optical emission at 760 nm for 76 patients (50%) with the
effect of light and 76 patients (50%) without it.
Positive results of the prevention of caries (the level of metab-
olism of the teeth was not reduced in the tooth and appearance
of active enamel remineralization was detected) were evaluat-
ed in terms of its electrical conductivity and light-induced
fluorescence. Light exposure was performed in 1.5 min daily
sessions for 3 days.
Results
In the light therapy group, electrical conductivity indicators
and light-induced fluorescence indicators did not show the
effect of enamel demineralization in both groups for the dura-
tion of one year. The start indicators of enamel conductivity
were from 0 to 25, and when dentine decay (caries media) was
diagnosed, enamel conductivity was from 3.85 to 4.5. Light-
induced fluorescence of intact enamel did not show the ap-
pearance of stain. Teeth, diagnosed with caries media border-
ing with the caries cavity showed as a shadow stain. This
indicator did not change after a year. Furthermore, in the teeth
diagnosed with dentine decay, the spots disappeared, and the
conductivity of enamel was 0.2 ± 0.05.
Caries cavities did not occur throughout this period, and the
100% effectiveness of primary and secondary caries preven-
tion was proved.
What was observed in the control group?
Over a period of one year, out of 76 patients diagnosed with
dentin decay and not exposed to the effect of light on the
enamel of the teeth, six (7.9%) patients were found to have
developed new caries cavities. Two of those (33.3%) six cases
of newly developed cavities were in the group of intact teeth,
and four (66.7%) cases were in the group of the patients diag-
nosed with moderate caries.
Conclusions
The optimal effect of the prevention in the group of pa-
tients with intact teeth exposed to light should be viewed
as a new major preventive program in dentistry.
According to academic sources, as of today, such results
had been impossible to achieve. In the group of patients
diagnosed with dentine decay, the absence of recurrence
of caries, due to the use of light in the course of treatment,
showed the adequacy of this type of treatment in normal-
izing the metabolic processes in the hard teeth tissues that
were destroyed by the carious process and the trauma
caused by teeth preparation during the main method of
caries treatment, which was proved in early research. It
was impossible to eliminate these negative factors without
the light treatment.
S115
EPMA Journal (2020) 11(Suppl 1):S1–S133
Using clinical, physical and mathematical methods to study the
influence of the modified red light on the hard tissues of the
teeth showed the great effect of normalization of the metabolic
process in the teeth. Additionally, as a result, it showed us the
optimization of caries prevention at the initial stage of enamel
demineralization, which is the most important indicator being
studied in predictive, preventive and personalized medicine [6].
How to use these findings in the future?
This apparatus (“STOMASvet”), developed by our team and
certificated in Russia, should be certified in other countries and
an international patent should be obtained. Furthermore, we
view it as necessary to train specialists to give master classes,
organized with EPMA. Such training sessions have already
been held in cities such as Voronezh and Lipetsk (Russia).
Implementation of the developed light characteristics for pre-
vention and prophylactic treatment is based on 10–15 years of
preliminary physico-mathematical digital research. Thus, the
breach between medicine and fundamental research is elimi-
nated with the help of modern methods, such as (atomic-force
microscopy, scanning microscopy, plane microscopy), which
led not only to new results but also verified their relevance for
caries prevention.
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3PM in inflammatory diseases
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Background
Predictive, preventive and personalized medicine (3PM/
PPPM [1]) represents a necessary change in paradigm in
medicine, to enable and grant efficient health services to
all citizens, in a society where a greatly extended lifespan
is not accompanied (yet) by a corresponding health span.
Among the many changes in mentality, which this new
paradigm entails, is the urgent duty to move away from
the current reactive medical paradigm, offering -
viceversa- cost-effective prevention, precise prediction
and sufficient personalization. Among the areas of medi-
cine that most crucially need this change is the vast and
fragmented area of specialties that are concerned with
non-communicable diseases (NCDs), characterized by
chronic low-grade inflammation and wound healing
gone awry [2]. Fragmentation is among the issues that
force patients classification into categories (diabetes,
rheumatoid arthritis -, inflammatory bowel disease -
IBD, to name a few) that may also benefit from a more
holistic approach to the low grade inflammatory and
impaired wound healing, going beyond specialization,
taking advantage of subtle phenotypic characteristics
able to preventively identify non-physiological mecha-
nisms at work, following the exemplar of Flammer syn-
drome [3] an approach promising to benefit a number of
related syndromes.
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Results
Mechanosensing and mechanotransduction are likely to rep-
resent overlooked biological features in inflammation, partic-
ularly in the potential they have to address chronic inflamma-
tion. Given the overwhelming number of individuals affected
by chronic inflammation (roughly 40 million deaths per year,
corresponding to 71% of all deaths of individuals between the
age of 30 and 69 [4]), all approaches susceptible to contribute
to the control of this pandemic are of interest in 3PM.
We here present results on rheumatoid arthritis (RA), a well-
known model for NCD, with a global incidence ranging from 1
to 4% worldwide, affecting mostly women (70%) and with
unclear etiology, although genetic and epigenetic alterations,
as well as modifications of the gut-intestinal microbiome com-
position (dysbiosis) are known characteristics of the disease [5].
In addition to chronic inflammation, impaired wound healing
(also known as epithelial mesenchymal transition type 2) is an
accompanying marker of such diseases. Wound healing phys-
iological progression is characterized by four main phases [2],
the first, very early consists of non-transcriptional signalling,
quickly followed by blood clotting and transient acute inflam-
mation, later replaced by longer lasting regeneration and re-
modelling phases. Wound healing is elicited in response to
stimuli perceived as injuries that can be mechanical, among
others. In such cases, the early phases of wound healing
ove r l ap / a r e p r e c eded by mechano s en s i ng and
mechanotransduction phenomena that convert the mechanical
stimulus into a biochemical signal.
Mainstream treatments of RA consist of disease modifying
anti rheumatic drugs (DMARDs) divided into conventional
(cDMARDs), including methotrexate (MTX) a low cost, an-
ticancer drug given in low doses, with immunodepressive ef-
fects and toxicity, effective in 60% of patients, and biologics
(bDMARDs) more targeted therapies, highly expensive, still
immunodepressive, and whose efficacy must be empirically
tested on patients that are non-responders to MTX [6].
Therefore, with the ambition to better treat more RA
patients, in addition to the design and/or repurposing
of drugs, non-pharmacological approaches are also be-
ing investigated. A surge of non-pharmacological ther-
apies is now investing medicine; these include, for ex-
ample, fecal microbiota transplantation (FMT, [7]), me-
chanical subcutaneous stimulations, mechanically in-
duced regeneration [8] and electrical stimulation [9].
In this context, we report and frame within 3PM the results of
our studies conducted to achieve a better, molecular under-
standing of the effects elicited by a mechanical subcutaneous
stimulation, making use of unbiased screenings (omics) col-
lected at different time points and from different tissues in
order to offer a systemic view on a systemic disease that also
have the potential to enable technological development for the
continuous real-time monitoring of biological therapeutic ef-
fects of mechanical stimulations [10].
The results [11], conducted on animal models, completed by
control arms and duplicated experiments, produced a series of
relevant information for the implementation of 3PM. Frist of
all, after validation of the effectiveness of the approach by
standard phenotypic traits assessment (i.e. paws’ thickness),
it has been possible to show that mechanical subcutaneous
stimulations released in the dorsal area of animals (local) can
elicit wound healing responses that are systemic, i.e. measur-
able in blood (peripheral blood mononuclear cells, PBMC),
stably over time after a transitory phase where inflammation
was dampened. Second, not only can blood be a mirror of the
return to homeostasis lead by reduced inflammation and
wound healing activity but the composition of the gut-
intestinal (GI) microbiome also undergoes a significant mod-
ification towards a more eubiotic composition and increased
abundance of genera (such as Roseburia) producing anti-
inflammatory metabolites (butyrate).
Indeed, we have shown [12] that computational approaches
can enhance and ease such type of analysis, demonstrating
that the algorithmically joint analysis of two easily accessible
bodily compartments (blood and feces) can provide a better
insight into the mechanisms at work under these conditions
(RA as a model of NCDs), showing that in addition to the
inflammatory and wound healing functions, mechanical stim-
ulation affects the sphingolipid metabolism, known to be al-
tered in RA.
Conclusions and expert recommendations
The complexity of the mechanisms revealed, and in particular
the overlooked connections between mechanotransduction,
wound healing, inflammation and associated dysbiosis, rein-
forces the necessity of a holistic, systemic approach tomalady.
In particular, the known connection between the autonomic
nervous system control of inflammation (including the inflam-
matory reflex [13]) as well as the connection between the gut-
intestinal microbiome and the central nervous system (gut-
brain axis [14]), ask for a revision of our understanding of
inflammation, accepting that the biological functions
involved—and possibly manipulable in view of a return to
homeostasis—are more numerous and complex than ac-
knowledged so far, and better described by a greater inflam-
matory pathway [15]. In short, we argue that an ample revi-
sion of all mechanisms known to impact directly on the con-
trol of inflammation, collected with the usage of tools typical
of computational biology—including, in particular, network
theory—will enable not only a better understanding of chronic
inflammation and wound healing gone awry in NCDs but will
also offer operational cues to design new therapies. This has been
the case, for example, in biolectronic medicine [9], which re-
quires the implant of a device, with the associated economical
and psychological costs; therefore, it is useful to explore all
means (mechanical stimulation, gut microbiome manipulation,
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etc.) to access and modify the inflammatory system, owing in
particular to all technological advances (includingNGS andmass
spectrometry-based technologies) enabling efficient multiomic
approaches in easy-to-access body fluids [16].
Understanding the greater inflammatory pathway in detail
[15] automatically enables 3PM, as expliciting the static and
dynamic factors affecting proper wound healing implies to
devote attention to the following aspects of patients life: (i)
contingent biochemical factors: high glucose levels, hypoxia,
pre-existing infection, macrophage activity (impaired by cor-
ticosteroids), bisphosphates, denosumab and biologicals; (ii)
contingent environmental factors: moisture, diabetes mellitus,
oedema, ethanol abuse, smoking, under nutrition, omega-3
fatty acids intake and lack of vitamins; (iii) genetics and epi-
genetic: causes for impaired WH.
As recalled above, the abundance and complexity of this
information can be leveraged with adapted computational
tools and mathematical theory, namely network ap-
proaches. Having such a systemic knowledge of individ-
uals, automatically enables personalized therapy with re-
spect to the return to homeostasis of inflammation, via the
study of patients personal history, granting personalized
acts to enable the return to homeostasis (diet, lifestyle,
drug therapy revision); better patients stratification,
granted by a deeper knowledge of the specific pathways
gone awry; and last but not least, preventive approaches
that enable physicians to choose more adapted therapies
in cases of comorbidities, and continuous monitoring of
patients propension towards impairment of wound
healing and inflammation via adapted questionnaires
and tests, carefully designed to assess personalized risk.
Given the numbers at stake and the difficulties that the
current medical paradigm shows in addressing the NCD
pandemic, all cues susceptible to enhance prevention
(questionnaires) and prediction (phenotyping and multi-
omics) are to be exploited. This includes the opening
towards non-pharmacological approaches and physical
therapies that take advantage of our body’s ability to
manage mechanical signals, an ability whose integrity
has a direct impact on the control of wound healing, a
hallmark of NCDs.
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Introduction
Rheumatoid arthritis (RA) is the most common chronic auto-
immune joint disease affecting synovial tissue in multiple
joints. Early detection of RA and the availability of biological
agents have markedly improved outcomes in patients [1]. At
present, composite indices (mostly DAS28, Disease Activity
Index) are used to monitor the activity of the disease. They
include clinical parameters (tender and swollen joints), and
two laboratory parameters of inflammation: C reactive protein
(CRP) and erythrocyte sedimentation rate parameter (ESR).
The disadvantage of these scores is the degree of subjectivity
of some of the criteria. Moreover, a significant proportion of
the patients with negative inflammatory tests still have active
disease.
Rheumatoid arthritis and PPPM
RA is a typical example of a disease that requires new early
predictive diagnostics measures. The principles of predictive,
preventive and personalized medicine (PPPM) [2] and their
appropriate application can be a good starting point for chang-
ing the general approach to RA management [3]. There is a
clear need to find efficient diagnostic and prognostic bio-
markers for this disease in order to prevent its rapid progres-
sion and subsequent functional decline [4]. PPPM enables the
prediction of individual predisposition to the disease, can help
with targeted preventive measures and dictates the design of
personalized treatment algorithms tailored to the individual.
Furthermore, PPPM contributes to the cost-effective
management of the disease [5]. PPPM principles are, at pres-
ent, slowly entering clinical practice. The effort to implement
this new approach in the field is most visible in the search for
new biomarkers: starting with genetic biomarkers, followed
by single blood biomarkers and finalized by the multi-omics
approach [6].
The role of biomarkers in RA diagnostics and treatment
The use of biomarkers in RA diagnostics began many years
ago in other fields of medicine; namely oncology [7]. PPPM,
as well as biomarkers, are making important contributions to
other fields of medicine [8]. There are several key stages of
RA, the proper management of which may influence progno-
sis, progression of disease and management (Table 1).
Table 1 Biomarkers in the PPPM approach
Early diagnosis Starting treatment in the early stages prevents
osteoarticular destruction







Biomarkers predictive of the response to treatment
Predictive diagnostics and immediate preventive therapy
are crucial for the halting of joint deterioration, functional
disability and unfavourable disease outcome. The 2010
RA classification criteria from the American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) consists of symptoms and laboratory find-
ings within 4 domains (total score 10 points). 40% of this
total possible score relies on laboratory tests. Up to 3
points are generated by the presence of rheumatoid factor
(RF) and/or anti-citrullinated peptide antibodies (ACPA).
Equal weight is given to RA and ACPA. Among ACPAs,
anti-CCP, the anti-cyclic citrullinated peptide assay, has a
superior diagnostic and prognostic value. The sensitivity
of the anti-CCP assay in RA is 60–80%, with a very high
specificity of 95–99%. The assay has a high predictive
value and the autoantibody can be found early, even in
the preclinical phase of RA.
Anti-mutated citrullinated vimentin (anti-MCV)
Vimentin is a protein that can be citrullinated, a reaction me-
diated by peptidyl arginine deiminase. A meta-analysis from
2010 that included 14 studies in which anti MCV and anti-
CCP were tested, concluded that there is no substantial differ-
ence between the two tests. Thus, determination of anti-MCV
seems to be useful as a line 2 test in patients suspected of
having RA but is negative for both RF and anti-CCP [9].
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14-3-3η protein
The 14-3-3 family of proteins is a family of chaperone pro-
teins. The combination of 14-3-3η protein, RF and anti-CCP
will help increase the sensitivity and specificity for patients
with early active disease, help stratify RA patients and enable
us to individualize treatments for patients in early stages. It
may predict both clinical and radiographic progression, as
well as treatment response [10]. Lower 14-3-3η levels were
found in patients who achieved remission during biologic
therapy with anti-IL 6 monoclonal antibody (tocilizumab).
Post-treatment 14-3-3η expression is significantly different
between stages.
Themulti-biomarker disease activity index (MBDA index)
During the development of the MBDA score, 96 candidate
biomarkers were reduced to 12 (CRP, leptin, resistin, serum
amyloid A, IL-6, TNF-RI, VEGF-A, MMP-1, YKL-40,
MMP-3, EGF, VCAM-1), that run as a single test and result
in a score of 0–100. Depending on the values of this score, the
disease activity can be classified into mild (1–28), moderate
(29–43) or severe (>44). The MBDA score is a very good
determinant of subclinical disease activity and progressive
disease with structural progression. In addition, the MBDA
score may help individualize treatment by determining which
patients should receive more aggressive/expensive therapy
and which patients may do well with conventional therapy
[11].
Calprotectin
Calprotectin (S100 protein) might be a valuable marker of RA
disease activity. Calprotectin differs from other labora-
tory markers in its local production from activated sy-
novial cells and release from inflamed synovium. As a
consequence, calprotectin directly reflects the amount of
activated macrophages and the extent of inflammation.
Calprotectin might be superior to CRP for the detection
of patients in clinical remission with subclinical disease
activity. Several authors have reported increased
calprotectin serum levels in RA patients, its association
with disease activity, its dynamic decrease after initia-
tion of effective treatment and its role in predicting
response to treatment [12].
Conclusions and PPPM-related expert recommendations
The goal of current and future biomarker use in rheumatic
diseases is to enable early detection, effective monitoring
and the individualization of treatment.
– Anti MCV, 14-3-3η protein, MBDA score and
calprotectin were identified as important parameters in
predictive diagnostics, as well as in the assessment of
patients’ response to treatment
– The MBDA index is a panel of biomarkers that correlates
with disease activity both clinically and radiographically.
– Serum biomarkers had stronger associations with joint
damage than did clinical assessment.
– A multi-biomarker score for structural damage has the
potential to aid the personalized assessment of joint dam-
age risk and identify patients who most need joint sparing
therapy, as well as track disease changes in response to
therapy.
– New biomarkers, alongside suitably applied PPPM rules,
help in the cost-effective management of diseases, includ-
ing RA.
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The aim of this study was to assess the relationship between
blood levels of adhesion molecules and results of biological
therapy in rheumatoid arthritis (RA); 35 patients with RA (29
women, 6 men) aged from 40 to 66 years, who were undergoing
biological therapy (tocilizumab – 20 patients, etanercept – 15
patients) in combination with methotrexate were examined.
Positive response on treatment was seen in 74.3% of pa-
tients, and in 25.7% of cases treatment was ineffective. The
control group consisted of 70 healthy individuals. Blood
concentration of intercellular adhesion molecule-1 (ICAM-
1), vascular cell adhesion molecule-1 (VCAM-1), platelet-
endothelial cell adhesion molecule-1 (PECAM-1) Е-, Р-
and L-selectins was carried out using ELISA before and
after 12 weeks of treatment. The diagnostic value of pa-
rameters were defined by their accuracy (Ac). In RA, an
increase in levels of all molecules of immunoglobulin su-
perfamily, P-selectin was observed. In patients with posi-
tive results for therapy, normalization of ICAM-1, P-
selectin and decrease of VCAM-1, PECAM-1 were ob-
served. In patients with no effect from treatment, only con-
centration of ICAM-1 was reduced. Concentrations of
ICAM-1 above 886 ng/ml, PECAM-1 above 101 ng/ml,
Е-selectin below 40 ng/ml, Р-selectin below 176 ng/ml
were associated with an increased chance of responding
to biological therapy. These values of ICAM-1 (Ac
88.6%), Р-selectin (Ac 82.9%) and PECAM-1 (Ac
71.4%) were characterized with high accuracy in delinea-
tion of treatment results. Therefore, we conclude that in-
creased blood concentration of adhesion molecules in RA
was decreased in dynamics of biological therapy. Initial
adhesins levels can be used as predictors of treatment out-
comes in RA.
DEFa1 and DEFb1 in the role of biomarkers of predispo-
sition to the activation of infectious process in inflamma-
tory diseases of the pelvic organs in women
Baturin VA1,2, Boshyan RO*1,2
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DEFa1 and DEFb1 are one of the first lines of defense
against the entry of bacteria, fungi and viruses. DEFa1 is
involved in oxygen-independent destruction of phagocy-
tosed microorganisms, in the systemic immune response.
DEFb1 is released on the mucosal surface and provides
anti-infective protection. The lack of defensins synthesis
leads to the development of infectious and inflammatory
complications. We studied the levels of DEFa1 and
DEFb1 in the blood and studied the species composition
of the microflora of the urogenital tract in 153 women of
reproductive age in the city of Stavropol of the Russian
Federation. The subjects were divided into groups: with
minimal clinical symptoms of the infectious process, with
moderate, with severe. The concentration of DEFa1 was
in the group with minimal symptoms of 21.1 ± 6.5 ng /
ml, and DEFb1 was 75.6 ± 14.4 ng / ml (p < 0.05). The
level of DEFa1 was 46.5 ± 12.5 ng / ml, and DEFb1 was
27.3 ± 7.8 ng / ml (p < 0.05) in the group of women with
severe symptoms. Concentration of DEFb1 had more high
values 90.2 ± 35.7 ng / ml in women at the end of the
second menstrual cycle, and a very high correlation was
found between the number of leukocytes in flora smears
and the expression of DEFb1(r = 0.97, p < 0.05). The au-
thors recommend taking into account the concentration of
DEFa1 and DEFb1 in the blood of women as a predispo-
sition to the activation of the infection process during
inflammatory diseases of the pelvic organs.
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Application of microbiome, immune-, pre-
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Introduction
Microbiome research is amongst the most innovative fields in
biomedical sciences being referred to as a second genome [1–
3]. The epidemic of obesity and associated comorbidities,
which apart from being a healthcare issue of modern society,
is a tremendous economic burden, although currently less ex-
plored, the microbiota specific for lean people demonstrates
its clear particularities and deviations compared to people with
both normal and increased BMI [2]. To date, the obesity spe-
cific microbiome has been prioritised for extensive studies
demonstrating human microbiota as affecting the thermogen-
esis, energy balance and even food consuming behaviour,
amongst others.
Specifically, in the context of predictive, preventive and
personalised medicine, the EPMA expert group has strongly
contributed to the recent knowledge accumulated towards
leanness specific microbiota [3,4]. The most comprehensive
updates to the topic are provided in the EPMA/Springer book
“Flammer Syndrome - From Phenotype to Associated
Pathologies, Prediction, Prevention and Personalisation” [5].
The current study is designed to correlate the leanness and
particularly the Flammer Syndrome (FS) phenotype (anorexia
nervosa as an extreme case of FS) with particularities of their
microbiome profiles.
FS phenotype associated symptoms and complications are
considered by the patient stratification, namely:
– primary vascular dysregulation;
– altered regulation of senses (thirst, pain, smell, etc.) and
sensitivity towards medications altered circadian rhythms
and sleep patterns;
– psychological and psychiatric aspects (e.g. tendency to
meticulous personality and depression)
– increased incidence of dry mouth and sicca syndrome;
– more prevalent impaired wound healing as well as a pre-
disposition to young stroke and aggressive metastatic
cancer subtypes in the family, amongst others [6–10].
The concept of the brain-gut axis suggests that modulating
the gut microbiome might be a strategy to prevent stress-
related disorders, such as depression, anxiety and CNS disor-
ders [11,12].
Sleep loss or disturbance, common for people having FS, may
act as a stressor changing the microbial composition, which
leads to metabolic dysfunction. Altered circadian rhythm in-
creases the permeability of the intestinal barrier increasing
risks of inflammation [11]. Bifidobacteria amongst others
are often underrepresented in depression [13].
Themicrobial composition of lean people is characterised by
high diversity and increased presence of bacteria responsible
for health beneficial short-chain fatty acids (e.g butyrate),
which is linked to a reduced risk of cardiovascular diseases
[14]. Prevotella has been outlined to exist in increased
amounts in obese compared to lean people due to its ability
to enhance the extraction of energy from starch and oligosac-
charides [15]. The “lean enterotype”, abundant mostly by
phyla Bacteroidetes and Firmicutes [16] although consid-
ered as ‘healthier’ requires careful reconsidering and valida-
tion of a patient-specific microbiome profiling for targeted
treatments and prevention.
Multiple approaches are being developed to prevent and
treat metabolic disorders by modulating gut microbiome,
these include the use of pre- and probiotics, altering the
diet, and fecal microbiota transplantation (FMT) [3,4].
Studies confirm that a modified diet positively influences
the gut of patients with metabolic syndrome, which lean
people can possess [17].
Bifidobacteria and Lactobacteria are the most studied
bacteria for the role of probiotics that demonstrate ef-
ficacy to reduce obesity, dyslipidemia, and improve
metabolic health [3,4].
Akkermansia muciniphila is a rather new application as
a microbiome marker in patients with non-obese meta-
bolic disorders and potentially most relevant probiotic
strain for Flammer phenotype, and hypoxia-associated
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conditions. A. muciniphila is Gram-negative, strictly an-
aerobic, able to use mucin as its sole source of carbon
and nitrogen, enhancing gut barrier function [18]. A.
muciniphila abundance negatively correlates with BMI
in adults [19].
Using novel substances demonstrating prebiotic qualities
open new perspectives for combined application with
probiotics benefiting the host health [20]. A very recent study
has presented that nanoceria together with L.casei ІМV В-
7280 demonstrates a great clinical potential to treat hypercho-
lesterolemia in affected individuals [21].
Hypoxia results in an altered diversity of gut microbial com-
munities, with a noticeable decrease of Lactobacilli.
Mesenteric ischemia (MI) can be a relevant marker to stratify
patients with metabolic disorders, in particular, in under-
weight being a source of hypoxic signalling [22].
However, Lactobacillus supplementation could recover
the function of deficient bone marrow mesenchymal
stem cells in the hypoxic rat model [23]. Modulating
gut microbiome via administration of Bifidobacteria
animalis probiotic strains can alleviate MI, as detected
by Doppler ultrasound [24]; short-term probiotic therapy
is effective if prescribed individualised.
A severe and commonmetabolic disorder such as gout leading
to kidney failure may develop in lean individuals, research
suggests that individualised probiotic treatments decrease in-
flammation in the body and improve metabolism [25].
Nevertheless, it remains challenging to establish a causal link
(cause-effect relation) between microbial composition and a
certain phenotype or disease.
Conclusions and PPPM related expert recommendations
Microbiology has been often considered as retrospective.
However, microbiome research together with the novel, com-
putational methods have great potential to lead the way to
predicted and personalised medicine of the future.
Considering metabolic and microbiome as targets in lean
individuals is an important task and requires a focused
approach, including individualised prediction and treat-
ments tailored to the person.
Individualised patient profiles might be used to optimise
the pre- and probiotic composition for treatment modal-
ities; for this the significance of stratification and pre-
treatment questionnaires should be emphasised. It is cru-
cial to pick the most appropriate strain and consider
utilising a synergistic effect between pre- and probiotics.
Follow-up translational measures to bring new knowl-
edge from the lab to the patient are strongly recommend-
ed. If validated in a large-scale clinical study, this ap-
proach might be instrumental for primary and secondary
prevention in affected underweight individuals and pa-
tients with metabolic disorders diagnosed with Flammer
syndrome.
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Introduction
The definition of metabolic syndrome (MetS) requires detec-
tion of central obesity +2/4 factors (hyperglycemia, dyslipid-
emia, cardiovascular disease, hypertension). Ultrasound (US)
can accurately detect visceral obesity and a number of markers
for stratification of patients with MetS.
The Aim: was to study the efficacy of individualized probi-
otic therapy of MetS according to the host’s phenotype using
multiparameter ultrasound markers.
Material and methods
We included 116 overweight subjects (age 23–74 years; 67
females), BMI > 30, waist circumference (WC) > 110, or con-
stituents of MetS and normal / low BMI, who underwent
general clinical, lab tests; radiology tests for stratification ac-
cording to the developed MetS biomarker panel, which
included:
& Anthropometric (weight, BMI, WC);
& Metabolic markers (NAFLD liver size and stiffness) portal
hypertension;
& Pro-inflammatory (visceral fat (VF), microsplenia, intesti-
nal wall thickness);




& ‘Mechanistical’ – posture parameters, muscle signaling,
trigger points, nerves.
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After careful examination we selected 10 patients for
probiotic therapy with patterns of MetS as follows:
DMT2; liver fibrosis, NAFLD; hyperuricemia, gout; ath-
erosclerosis; hypertension (early age); and 3 patients
with normal / low BMI with detected increased VF.
Probiotic strains were selectively given according to
[1 ,2] : a t a dose 108 CFU dai ly for 10 days :
L. acidophilus ІМV В-7279, L. casei ІМV В-7280,
L. delbrueckii subsp. bulgaricus ІМV В-7281,
L. rhamnosus LB-3 VK6, L. delbrueckii LE VK8,
L. plantarum LM VK7), Bifidobacterium genus
(B. animalis VKL, B. animalis VKB.
Results
Weight, BMI, WC and VF decreased after probiotic adminis-
tration. All studied parameters improved in all cases—US
markers of visceral obesity, gut motility, colonic wall thick-
ness, liver size and stiffness, mesenteric lymph nodes, spleen
size and Doppler markers of mesenteric blood flow.
Conclusion
Short-term probiotic therapy is effective for various metabolic dis-
orders in obese and lean individuals if prescribed
individualized (see Fig. 1).
Fig. 1 Positive progress of liver (left) and visceral fat (right) structure and
stiffness (upper –after therapy)
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Individual human microbiome as a potential tool in pre-
cise diagnostic and nosology-specific prevention and treat-
ment of noncommunicable diseases
The human microbiome determines our personal health,
thus prognostic correction of detected composition to ex-
pected functional activity by pharmabiotics and/or indi-
vidual nutrition is a promising approach for the preven-
tion and treatment of noncommunicable diseases (NCD)
triggered by low-grade inflammation [1]. These facts
along with the assessment of individual behavior and life-
style to determine personalized nutrition or individual
biotics appointment mean that the use of biotics (pre-,
pro-, syn-, immune, and pharmabiotics) should be individ-
ually designed to specific nosology.
Addressed nosologies of dominant noncommunicable dis-
eases and used methodology
The most typical and reported NCD, associated with “un-
healthy” microbiome changes were addressed in the current
study. The first targeted nosology was caries in children and
periodontitis in the elderly population connected with
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microbiome changes. Both diseases were supplemented with
enterocolitis. The second nosology group was formed by
women and men with so-called urogenital inflammation
symptoms, and the third group consisted of “metabolic disor-
ders” patients, ranging from overweight persons (obese), pa-
tients with detected diabetes type 2 (DT2), and individuals
with various stages of cardiovascular diseases (CVD). The
number of patients in the first group was 40 (20 for each oral
nosology), 40 for urogenital chronic inflammation processes
(20 for both genders), and 35 for each group of metabolic
diseases. The exclusion and inclusion criteria for these select-
ed nosologies were previously reported [2, 3].
Microbiome composition of secrets from oral cavity (saliva),
vaginal and genital washes, and gut content of patients were
detected by qRT-PCR (ParadontoScreen, Femoflor®-16,
Androflor®), and 16S rRNA sequencing techniques for the
gut specimens. In addition, the levels of pro- and anti-
inflammatory cytokines: TNF-α, IFN-γ, IL- 6, 10, 12, 17,
IL-1β, SIgA, IgA, were determined by ELISA, and biochem-
ical biomarkers (for obese, DT2 and CVD) relevant to early
inflammation were routinely detected. Individual profiles of
patients were developed, and, in order to recommend the indi-
vidual treatment eitherwithpharmabiotics or nutrition for these
different nosologies, the information system (IS) has been
built.
Information system was built and applied for the individ-
ual pharmabiotics creation and testing
The information system for personalized pharmabiotics crea-
tion and prescriptions aimed to regulate the saliva/gut micro-
biota ratio, biodiversity, and functionality had been
developed.
The proposed IS operates as an algorithm for the selection of
individually required contents from a large amount of data
(databases, DBs), in particular: i) patients’ anamnesis, medical
examination results, ii) biomarkers; iii) defined microbiome
representatives/ratio for the majority of NCDs, iv) biologically
active molecules (BAM) of edible plants, v) clinically proven
data available for the registered influence of BAM, fibers,
other food components, fermented products starters, and other
connected microbiota on human microbiome representatives
diagnostic ratio, vi) food composition DBs, etc. Further devel-
opment of the IS tool is oriented on precise diagnostic at
earlier stages of diseases and improvement of individual rec-
ommendations by machine learning techniques.
Using this system and the DBs, we designed and clinically
probed the efficacy of pharmabiotics of new generation brand-
ed as ProPhyLactOR™ for the oral “caries” and “periodonti-
tis” types microbiome correction, with two separate treatment
forms, and FlexiLactUR™with individually adjusted pre- and
probiotic components aimed to correct the microbiome com-
position of the urogenital tract. The initial composition
contains synergistically acting commensal microbiota repre-
sentatives and prebiotic ingredients from edible plants [4]. The
content of pharmabiotics could be slightly modified and ad-
justed to the patients’ individual microbiome-immune profile
and to the detected nosology. This developed and successfully
clinically tested algorithm for personalized nutrition (Fig. 1)
for prevention and treatment of 1) childhood and adult obesi-
ty; 2) DT2, 3) CVD, enabled the designing of the novel ethnic
fermented traditional foods and beverages branded as
Ediens™.
Fig. 1 Algorithm for personalized nutrition calculation
The limited controlled clinical diet study, where we apply a
two week individual nutrition plan by using food ingredients,
rich in BAM (local plants) in combination with prepared
fermented products with unique starters, showed a significant
decrease in insulin resistance.
Limited control diet study for the approval of accuracy of
the algorithm applied for prognostic microbiome correc-
tion by individual nutrition needs calculation
Trends to the normalization of glucose level and a sta-
tistically important decrease of very low-density lipids
(VLDL), triglycerides, glycosylated hemoglobin
(HbA1c), uric acid and creatinine had been detected,
while the level of high-density lipids (HDL) increased
in a non-statistically significant manner. Similarly to
biochemical indices, the physical parameters in the ex-
perimental group of patients had been changed. The
implementation of a control diet led to the normaliza-
tion of the majority of commensal gut microbiome rep-
resentatives, including beneficial anaerobes. The increas-
ing number of Lactobacil lus casei , but not of
L. acidophilus, was accompanied by the reduced levels
of HbA1c. The reduction of cholesterol and triglycerides
in the blood of patients had been correlated with the
decreased amount of Enterococcus faecalis, but not of
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E. faecium, in the gut microbiota content. The data of
the clinical trial (63 parameters of each patient) was
used for the development of a new methodology for
the detection of personalized treatment process bio-
markers. These biomarkers are essential for the develop-
ment of new machine learning models, which could
predict the success of a patient’s personalized treatment.
3PM related conclusion and outlook
The CVD are subject to prevention by correction of the
individual profile including each person’s unique
microbiome dependent on individual lifestyle, nutrition
and behaviour. To recommend prognostic treatment for
the patients with a diagnosed stage of “metabolic disor-
der”, IT tools (IS) need to be applied in order to calcu-
late the complex individual biomarkers in the context of
individual variations.
The algorithm under testing is a potential tool to esti-
mate (in addition to the detected genetic) lifestyle-de-
pendent, epigenetic, environmental and nutritional fac-
tors in an individual to provide the level of recommen-
dations and adequate prognostication that is crucial to
implement 3PM [5].
To prove and suggest a provisional role of individual
nutrition or pharmabiotics treatment in 3PM, the cohort
studies with precise individual measurements of the
biomarkers, prioritized with correlation analysis of the
initial data, analysis of the main components, cluster
analysis and a well-known machine learning procedure
“feature selection”, need to be performed. The strong
demands for the improving of the design of cohort
studies are highly recommended by 3PM experts [6].
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The principles for individual immunobiotics developments
and testing of their efficacy on the urogenital tract
infectious-inflammation diseases
Personalized use of immunobiotics is a promising direction in the
prevention of various infectious and inflammatory diseases asso-
ciated with microbiome changes of the genitourinary system in
humans.
Recently, the strain-dependent properties (adhesive ability, resis-
tance to antibiotics, and gut biological fluids) of probiotic strains
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(lactobacilli and bifidobacteria) were reported, and their potential
application for most effective individualized treatment for gut and
distant sites microbiome modulation was preliminary discussed
[1].
The objective of our study was to determine in a limited random-
ized clinical trial the patient- and nosology-specific efficacy of
immunobiotics, developed from different original strains of lacto-
bacillus (and their combinations), demonstrating both antimicro-
bial and immune-modulating functions preliminary examined on
animal and cellular models [2].
Patients with infectious-inflammatory diseases of the genitouri-
nary system were recruited from a regional hospital. Eligibility
requirements and enrolment procedures were performed in accor-
dancewith the EURegulationNo 536/2014. The inclusion criteria
for women were age over 18 years, urogenital pathologies of
different nosology, and exclusion criteria were detected antibodies
to hepatitis B or C; alcohol or drug abuse; HIV infection or anti-
retroviral therapy; diagnosed diseases of the cervix (dysplasia);
menstrual disorders; cancer; pregnancy.
Collected specimens were plated on chromogenic media for
detection of cultured urinary tract microbiota representatives
and were additionally genetically defined by qRT-PCR
(Femoflor®-16, Androflor® REAL-TIME PCR Detection
Kit, DNA technologies, Russia). Isolated microorganisms
were identified by using the Lachema biochemical tests.
Local immune response (IL-10, 17, 1b; TNF-a, SIgA) before
and after applied LAB treatment was measured by ELISA.
Lactobacilli strains in this study were sequenced and identi-
fied as Lactobacillus casei (2 strains) and Lactobacillus
acidophilus.
Individual gender and nosology specific microbiome
changes of infectious-inflammatory diseases of the genito-
urinary system by application of different lactobacilli
strains composition
The typical agents (nosologies) of infectious-inflammatory dis-
eases of the genitourinary system were identified. The female
bacterial vaginitis was characterizedmostly by the predominance
of Escherichia coli, Staphylococcus aureus, and Candida
albicans with or without the presence of Gardnerella,
Atopobium, Ureaplasma or Mycoplasma. Different nosologies
of the male urogenital tract diseases were characterized mostly
by the prevalence of such opportunistic microorganisms as
Streptococcus and Staphylococcus with or without
Ureaplasma, Haemophilus, Enterobacteriaceae, and Candida.
Thus, new effective probiotics and their compositions were
designed taking into account individual features of the com-
mensal microbiota of the patients and the dominating agents
of opportunistic infections of male and female urogenital
systems.
It has been proved that the use of the L. casei IMV B-7412
probiotic strain was the most effective in mixed infections
classified as a significant anaerobic/aerobic microbial ratio
of microbiome, a combination of strains L. casei IMV-B
7280 / L. casei IMV B-7412 enhances the antifungal effect,
while the composition of strains L. casei IMV B-7280 and
L. acidophilus IMV B-7279 promotes the restoration of
healthy microbiome, providing complete elimination of coli-
form bacteria and microscopic fungi, and reducing the number
of pathogenic staphylococci.
All LAB strains and their compositions were characterized by
strain and compositionally specific ability to restore the local
and systemic immune response by decreasing the level of IL-
17 and SIgA, and increasing the IL-10 level.
Proper combination of LAB strains pragmatically de-
signed is crucial to get prognostic healthy microbiome
changes
Efficacy of the application of different pharmabiotics is the
subject of great concern since the immunomodulatory proper-
ties of its LAB components are mainly strain-dependent and
connected to cell walls structure, as was recently demonstrated
[3]. There is also an open discussion about oral vs. intra-
urogeni tal administrat ion of various LAB based
biopreparation. Their efficacy is dependent on the proper
combination of LAB strains, correspondingly pragmatically
designed content of pharmabiotics is crucial. The combination
of commensal strains that are defining the efficacy by produc-
ing specific metabolites or preventing adhesion or even phys-
iological competition with strains should also be considered.
Previously, we were able to demonstrate that following the
oral administration of synbiotic Bifiten™, the vagina mucosal
sites were settled by both commensal and transit microbiota,
which in turns led to a reduction of the perinatal complications
for the mother and newborn [4]. At the same time, we were
able to observe side effects after application of such complex
synbiotics to healthy mothers, who did not require any treat-
ment and were initially characterized by a significant number
of their own lactobacilli strains.
3PM related conclusion and outlook
Prevention of infection-inflammatory diseases needs to be
based on monitoring of individual urogenital system
microbiome ratio, since this ratio determines the resistance
of the local immune system and initiation of low-grade
inflammation.
This approach is in line with proposed 3PM solutions to im-
prove sensitivity and specificity of early stage biomarkers and
currently well-discussed [5].
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Infants and young people’s urogenital health is dependent
significantly on women/mothers’ health encoding due to
early programming self-resistance to potentially pathogen-
ic bacteria, candida, but also viruses, mycoplasma, and
chlamydia. This preventive approach is crucial for spe-
cific person microbiome-based prophylactics.
Another issue is a specific mixture of etiologic agents causing
the infectious-inflammatory urogenital disease—“pathogenic
formula”, combined with the individual microbiome, connect-
ed to specific local immune response, modulation of which is
strain-dependent [1, 4]—this issue could be the limitation of
recommendation for application of any pharmabiotics strains
separately or in combination.
The predictive treatment effect of using any pharmabiotics
should be based on the microbiome phenotype of the uro-
genital system. Then the individual pharmabiotic content
selection based on IS models together with ML and data-
bases usage is the way for really prognostic individual
efficacy.
3PM requires the understanding of individual differences, thus
the “same” nosology needs to be treated differently, based on
at least each person’s microbial and immune profile.
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Introduction
Biobanking has been a fast-growing field in basic-,
clinical- and translational research over the past 30 years.
Biobanks collect, store and share biological material
alongside associated data and provide a fundamental sci-
entific infrastructure for personalized medicine [1].
Biobanks represent a key resource for predictive diagnos-
tics, research and experimental therapies [2] and follow
the whole chain of medical interventions. By placing an
emphasis on prevention, prediction and a healthy lifestyle,
biobanks have contributed to the current paradigm shift
within medicine from “one-size-fits-all” to “individual-
ized medicine” [3, 4]. Biobanking plays a crucial role in
the introduction and further optimization of personalized
medicine. Samples stored in biobanks provide information
about risk factors of diseases. They assist in the discovery
of biomarkers that aid in early diagnosis and a personal-
ized treatment choice, as well as biomarkers for the pre-
diction of initial responses to treatment. Biobank samples
also serve as unique sources in the search for drugs [5].
S129
EPMA Journal (2020) 11(Suppl 1):S1–S133
A Prerequisite for the Optimal Linking of Biobanks and
3P Medicine in Two Neighbouring Regions
International collaboration
Since personalized medicine works with highly specific and
well characterized cohorts, national and international cooper-
ation between biobanks as repositories of patient samples and
data is key to their optimal utilization. The European
Commission strongly supports biobanking as part of the
Horizon 2020 research projects and encourages international
collaboration and coordination [6, 7].
The BRoTHER (Biobank Research on Telemedical
Approaches for Human Biobanks in a European Region)
project is a bilateral, cross border collaboration between
two regions: German-Bavaria and the Czech Republic.
The project is supported by a grant from the Bavarian-
Czech University Agency (BTHA) with funding coming
from the Bavarian State Ministry of Finance. The aim of
the project is to define and analyze the obstacles that must
be overcome in order for two clinically related biobanks
from two different national health care systems to set up
collaboration. The BRoTHER consortium consists of four
partners: two in Germany—the Institute of Pathology of
the University of Regensburg and the Institute of
Pathology at Munich’s Technical University, and two in
t h e C z e c h R e p u b l i c— t h e D e p a r t m e n t o f
Immunochemistry at the Faculty Hospital in Pilsen and
the Masaryk Memorial Cancer Institute of Masaryk
University in Brno (Fig. 1).
Fig. 1 The BRoTHER logo
Innovation
Biobanks use modern and innovative tools and technologies
to make personalized medicine possible. Digitalization is a
progressive technological tool and is an important issue in
the cooperation between various biobanks. Therefore, whole
slide imaging (WSI) and virtual microscopy (VM)
technologies are being developed alongside modern
immunoanalytical techniques for personalized medicine,
cryotechnology and robotics. They will also help resolve IT-
related issues in biobanking [8]. The interaction of biobanks
from different regions and health care systems is a cornerstone
of the acceleration of biomedical research. Despite the harmo-
nizing process in biobanking within the European Union, spe-
cial challenges remain that must be overcome to facilitate
effective and fruitful international collaboration [9].
Education
Biobanking as a science is interdisciplinary due to its dual
nature involving both biological samples and data. Educated
medical staff, specialists for data management and other sup-
port services are all cooperating as a consortium with a full
range of expertise required for biobanking. There is, as yet, no
comprehensive education or training for new biobank staff in
Europe and this is urgently needed [10].
Two initiatives were set up for the education of future gener-
ations of students: A “Summer School” and an “Intensive
course in immunochemistry, biobanking and personalized
medicine, students learnt the practical work behind different
aspects of biobanking such as cryotechnology, immunochem-
istry, data-management, WSI, VW and pre-analytics as well
as ethical, legal, social issues (ELSI). The lessons were con-
ducted in English with the participation of students from both
Germany and the Czech Republic. These two courses are the
basis for the preparation of common curricula in the future.
Conclusions and PPPM-related expert recommendations:
& Biobanking is a pillar of personalized medicine and con-
tributes to the preventive, predictive and personalized
medicine (PPPM) paradigm.
& The BRoTHER project supports education and the dis-
semination of the ideas behind biobanks to the public, as
well as the education of young professionals in the field of
biobanking in order to train both current and future
biobank staff.
& A new generation of well-educated biobankers is promis-
ing for the future development of quality assurance in
biobanking. A better quality of biobanks means a better
quality of samples as well as the speeding up of biobanks’
operations and an improvement in the standards of subse-
quent research.
& BRoTHER represents an innovative example of how a
young generation of professionals could be systematically
acquainted with the principles of PPPM through the plat-
form of biobanks.
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Introduction
During the past three decades biobanking has grown dra-
matically and has become an important source for bio-
medical research. Biobanks are considered one of the
pillars of personalized medicine. Biobanks are special
facilities containing biological samples - usually - human
samples and related data and information [1]. Samples
stored in biobanks serve researchers all over the world,
helping solve both local and widely international health
problems. As some diseases (cancers, cardiovascular dis-
eases, diabetes, neurodegenerative, etc.) have a global
dimension, biobanking - the cornerstone for biomarker
discovery, has gained validation and is being used in
prevention, prediction, diagnosis and therapy as part of
a personalized approach to the patient [2]. International
collaboration and communication between biobanks
worldwide is one of the basic characteristics of
biobanking.
Biobanking: European and global strategies
Biobanking is strongly supported by the European
Commission and by a wide range of research and collab-
orative projects that are part of the biggest EU research
and innovation program ever, Horizon 2020 [3]. The
societal challenge of Horizon 2020 is ‘Health, demo-
graphic change and wellbeing (SC1)’. It is a call for -
better Health and care, economic growth and sustainable
health systems, with one of the priorities being ‘person-
alized medicine’ [4, 5, 6]. As biomedical research moves
forward, there is a paradigm shift in medicine from a
reactive to a proactive approach that is predictive, pre-
ventive, personalized and participatory [7]. Biobanking
and major chronic illnesses have a global dimension.
Globalization raises new ethical, legal and social
(ELSI) questions as well as regulatory, technical and
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managerial questions [2, 3]. Currently, two international
biobank entit ies: BBMRI-ERIC (Biobanking and
BioMolecular resource Research Infrastructure -
European Research Infrastructure Consortium) and
ISBER (International Society for Biological and
Environmental Repositories) are leading bodies in
biobanking.
BBMRI-ERIC
BBMRI is a European research infrastructure for
biobanking, whose purpose is to pool all the main actors
in biobanking in order to boost biomedical research.
BBMRI provides support and assistance for quality man-
agement services, ethical, legal and social issues. IT on-
line tools to facilitate the exchange of samples, mainly in
Europe. BBMRI-ERIC currently includes 20 countries,
as well as one international organization, making it one
of the largest European research infrastructures. BBMRI-
ERIC was initiated by the European Commission as a
research infrastructure in 2007–2013. During its prepa-
ratory phase (2008–2011), possible members - European
biobanks - were identified, and in 2013 BBMRI-ERIC
became an EU infrastructure. Current hot topics in the
European biobank infrastructure are GDPR (General
Data Protection Regulation) and its implementation via
Code of Conduct, as well as two supportive IT tools:
sample/data negotiator and sample/data locator. The
Negotiator enables users to negotiate access to samples
and datasets in biobanks. The Negotiator focuses on
making communication between a high number of re-
questers and biobanks as efficient as possible. The
Locator helps locate samples and datasets hosted by
biobanks that are of interest to the requesters and will
allow for detailed, privacy-preserving, multi-criteria
search of samples and datasets, while also respecting
the degree of control required by the biobank infrastruc-
ture operators [8]. The current goal of BBMRI-ERIC is
to make the new treatment possible.
ISBER
ISBER is a global biobanking organization which creates
opportunities for networking, education, and innovations
and harmonizes approaches to evolving challenges in
biological and environmental repositories. ISBER fosters
collaboration; creates education and training opportuni-
ties; provides a forum for the dissemination of state-of-
the-art policies, processes, and research findings; and
provides an international showcase for innovative
technologies, products, and services. Together, these ac-
tivities promote the best practices that cut across the
broad range of repositories that ISBER serves [9].
ISBER was initially planned in 1999, and the first regu-
lar annual meeting took place in 2001. ISBER provides
services around the world and has four domains:
Americas, Europe, Middle East and Africa, Indo-
Pacific, and China. In comparison to BBMRI-ERIC,
ISBER is global; reflecting a wider range of repository
types and trying to formulate future trends and chal-
lenges in biobanking. Notwithstanding, human biobanks
are the core of ISBER activities. The newly published
Best Practices in 2018, 4th edition [10] pays special at-
tention to the ELSI, thus bringing medicine closer to a
patient-focused approach and promoting a personalized
approach. BBMRI-ERIC on the other hand is mainly a
European entity with a focus on enabling samples and
data exchange between European BBMRI-ERIC
partners.
Conclusions and PPPM-related expert recommendations
& Biobanking is a cornerstone of personalized medicine;
samples and related data are of eminent importance in
predictive diagnostics and targeted prevention. The main
actors in the field of biobanking are BBMRI-ERIC, the
biggest European Research Infrastructure, and ISBER.
They determine the future developments in the field.
& Horizon 2020 and Horizon Europe are EU tools that re-
flect the current needs in personalized medicine and
biobanking. EPMA, BBMRI-ERIC, and ISBER, all main
actors in biobanking, have to contribute to identifying the
optimal solutions for future research in order to reach full
compliance with PPPM standards.
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